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Colorectal	  cancer	   is	   the	   third	  ranking	  cancer	   type	  worldwide	  with	   increasing	   incidences	   in	  
developed	   countries.	   Progression	   of	   the	   disease	   takes	   several	   years	   and	   early	   detection	   and	  
diagnosis	   following	  population	  based	  screenings	  has	   increased	  survival	   rate	  considerably.	  The	  
screening	  methods	  in	  clinical	  application	  such	  as	  faecal	  occult	  blood	  test	  (FOBT)	  lack	  sensitivity	  
and	  colonoscopy	  is	  unpleasant	  and	  invasive.	  Therefore,	  serum	  based	  minimal	  invasive	  methods	  
are	  in	  great	  demand.	  
The	  concepts	  of	  specific	  molecular	  signatures	  in	  the	  different	  stages	  of	  tumorigenesis,	  and	  
from	   there	   generation	   of	   tumor-­‐associated	   antigens	   are	   highly	   anticipated	   as	   biomarkers	   for	  
applications	   in	  diagnostics.	  Tumor	  associated	  antigens	  such	  as	  CEA	  and	  CA	  19.9	  are	   in	  clinical	  
applications,	  but	  exhibit	  low	  sensitivity	  and	  specificity.	  Moreover,	  many	  studies	  have	  presented	  
that	  panel	  of	  tumor	  biomarkers	  show	  higher	  sensitivity	  and	  specificity	  in	  detecting	  cancer	  than	  
individual	  biomarkers.	  	  
It	  is	  recognized	  that	  abnormal	  expression	  of	  proteins	  in	  tumors	  exhibits	  antigenic	  ability	  and	  
are	   recognized	   by	   the	   immune	   system,	   consequently	   producing	   tumor	   autoantibodies	   (TAA).	  
TAAs	   in	  combination	  with	  protein	  microarray	   technology	  are	  a	  promising	  approach	   for	   tumor	  
biomarker	   discovery.	   However,	   due	   to	   the	   complex	   nature	   of	   proteins,	   protein	   microarray	  
experiments	  have	  low	  reproducibility	  and	  require	  careful	  optimization.	  
This	  thesis	  presents	  screening	  for	  tumor	  autoantibodies	  using	  colon	  cancer	  plasma	  samples	  
of	   healthy	   controls,	   low	   risk	   polyps,	   high	   risk	   polyps	   and	   colon	   carcinoma	   groups	   utilizing	  
protein	  microarrays	   containing	   several	   thousand	   proteins,	   aiming	   at	   identifying	   specific	   TAAs	  
for	  generating	  a	  candidate	  marker	  array	  for	  subsequent	  validation	  in	  larger	  sample	  set.	  Due	  to	  
the	  low	  performance	  of	  conventional	  assay	  protocols,	  several	  optimizations	  were	  carried	  out	  to	  
establish	  a	  standard	  operating	  procedure	  for	  the	  particular	  type	  of	  protein	  microarray.	  Several	  
aspects	   important	   for	   protein	   microarray	   processing	   were	   addressed	   and	   tested	   for	   the	  
possible	  alternatives,	   such	  as	  protein	  microarray	  surfaces,	  blocking	  and	  buffer	  chemistries,	  as	  
well	  as	  reaction	  conditions	  of	  the	  assays.	  Most	  importantly,	  the	  possibility	  of	  using	  purified	  IgG	  




As	  a	  result,	  several	  changes	  to	  the	  protocol	  were	  made:	  probing	  in	  rotating	  chambers	  rather	  
than	  horizontal	  humidity	   chambers,	  extension	  of	   sample	   incubation	   from	  2	  hours	   to	  4	  hours,	  
addition	   of	   milk	   powder	   to	   samples,	   and	   optimization	   of	   detection	   antibody	   dilutions,	  
replacement	  of	   the	  detergent	  Tween20	  with	  Triton	  X-­‐100	   in	  buffers	  and	  using	  purified	   IgG	  of	  
samples	   rather	   than	   serum.	   	   Tumor	   autoantibody	   candidate	   marker	   screening	   performance	  
could	   be	   significantly	   improved	   from	   previous	   screening,	   with	   respect	   to	   sensitivities	   and	  
specificities,	   increasing	   from	  ~54%	  to	  97%	  for	  distinguishing	  patients	  versus	  controls	  using	  25	  
greedy-­‐pairs	  gene	  selection	  criteria	  for	  class	  prediction.	  
With	   this	   improved	   protocol,	   632	   classifier	   clones	   representing	   593	   genes	  were	   deduced	  
from	   class	   prediction	   analyses	   as	   the	   most	   predictive	   TAAs.	   Additionally,	   100	   genes	   were	  
selected	  from	  published	   literature	  on	  screening	  for	  tumor	  autoantibodies	   in	  colorectal	  cancer	  
using	   protein	   microarray	   technology.	   This	   total	   of	   732	   clones	   will	   comprise	   the	   candidate	  
marker	  array	  and	  will	  be	  applied	  in	  future	  studies	  for	  validation	  with	  384	  samples	  of	  4	  sample	  
groups:	  healthy	  controls,	  low	  risk	  polyps,	  high	  risk	  polyps	  and	  colon	  carcinoma.	  	  
The	   current	   Master’s	   thesis	   was	   carried	   out	   under	   the	   supervision	   of	   Dr.Andreas	  
Weinhäusel,	   at	   AIT,	  Molecular	   Diagnostics	  within	   the	   research	   project	   “Evaluation	   of	   Serum-­‐
Autoantibody-­‐Biomarkers	  for	  early	  diagnostic	  testing	  of	  Colon	  and	  Prostate	  Cancers”	  funded	  by	  












Dickdarmkrebs	   ist	   die	   dritthäufigste	   Krebserkrankung	   weltweit,	   mit	   zunehmender	  
Häufigkeit	  an	  Neuerkrankungen	   in	   Industrieländern.	  Die	  Progression	  der	  Erkrankung	  erstreckt	  
sich	   über	   mehrere	   Jahre,	   Früherkennung	   und	   Diagnose	   innerhalb	   eines	   bevölkerungsweiten	  
Screenings	   haben	   die	   Überlebensrate	   beträchtlich	   gesteigert.	   Da	   die	   üblichen	   klinischen	  
Screening-­‐Verfahren	  wie	   fäkaler	   okkulter	   Bluttest	   (FOBT)	   geringe	   Sensitivität	   aufweisen	   bzw.	  
Koloskopie	   eine	   invasive	   und	   für	   den	   Patient	   unangenehme	   Methode	   darstellen,	   ist	   die	  
Entwicklung	  von	  serumbasierten	  minimal	  invasiven	  Methoden	  von	  hohem	  Interesse.	  	  
Das	   Konzept	   von	   spezifischen	   molekularen	   Signaturen	   in	   unterschiedlichen	   Phasen	   der	  
Tumorgenese	   und	   die	   sich	   daraus	   ergebenden	   tumorassoziierten	   Antigenen	   können	  
voraussichtlich	  als	  Biomarker	  in	  der	  Krebsdiagnose	  fungieren.	  	  	  	  	  	  
Tumorassoziierte	  Antigene	  wie	   z.B.:	   CEA	   und	   CA	   19.9	   finden	   schon	   klinische	  Anwendung,	  
zeigen	  jedoch	  niedrige	  Sensitivität	  und	  Spezifität.	  Außerdem	  zeigen	  Studien,	  dass	  die	  Detektion	  
von	   Krebserkrankungen	   mit	   Hilfe	   eines	   Tumorbiomarkerpanels	   höhere	   Sensitivität	   und	  
Selektivität	  zeigt	  als	  bei	  Verwendung	  einzelner	  individueller	  Biomarker.	  
Es	  ist	  bekannt,	  dass	  abnorme	  Expression	  von	  Proteinen	  innerhalb	  von	  Tumoren	  antigenische	  
Eigenschaften	   aufweist.	   Diese	   werden	   durch	   das	   Immunsystem	   erkannt	   und	   draus	   folgend	  
Tumorautoantikörper	  (TAA)	  gebildet.	  In	  Kombination	  mit	  	  Protein-­‐Microarray	  Technologie	  sind	  
TAAs	   ein	   vielversprechender	   Ansatz	   für	   die	   Entdeckung	   von	   Tumorbiomarkern.	   Jedoch	   auf	  
Grund	  der	  komplexen	  Natur	   von	  Proteinen,	   zeigen	  Experimente	  mit	  Protein-­‐Microarrays	  eine	  
niedrige	  Reproduzierbarkeit,	  verglichen	  mit	  DNA-­‐Microoarrays,	  und	  bedürfen	  daher	  sorgfältiger	  
Optimierung.	  	  
Diese	   Arbeit	   präsentiert	   ein	   Tumor-­‐Autoantibody	   Screening	   von	   Dickdarmkrebsproben	  
(gesunder	  Kontrollgruppe,	  Darmpolypen	  mit	  niedrigem	  Risiko	  Darmpolypen,	  Darmpolypen	  	  mit	  
hohem	   Risiko	   und	   Dickdarmkarzinom)	   mittels	   Protein-­‐Microarrays	   bestehend	   aus	   mehreren	  
tausend	  Proteinen.	  Ziel	  ist	  es	  spezifische	  TAAs	  zu	  identifizieren,	  um	  ein	  Kandidatenmarker-­‐Array	  




Effizienz	   des	   konventionellen	   Assay-­‐Protokolls	   wurden	   einige	   Optimierungen	   vorgenommen,	  
um	   so	   eine	   standardisierte	   Arbeitsvorschrift	   für	   den	   Umgang	   mit	   den	   vorliegenden	   Protein-­‐
Microarrays	   zu	   erstellen.	   Wichtige	   Aspekte	   bei	   der	   Prozessierung	   der	   Protein-­‐Microarrays	  
wurden	   berücksichtigt	   und	   auf	   mögliche	   Alternativen	   getestet,	   wie	   beispielsweise	   Protein-­‐
Microarray	   Oberflächen,	   Blockier-­‐	   und	   Puffer	   chemikalien	   und	   experimentelle	   Bedingungen.	  
Am	   wichtigsten	   war	   es,	   die	   Verwendbarkeit	   von	   aufgereinigtem	   IgG	   für	   das	  
Tumorautiantikörper	  Screening	  zu	  testen.	  
Letztendlich	  wurden	  einige	  Veränderungen	  des	  Protokolls	  vorgenommen:	  Probentestung	  in	  
rotierenden	  Kammern	  bevorzugt	  gegenüber	  statischer	  Feuchtigkeitskammer,	  Verlängerung	  der	  
Probentestzeit	  von	  zwei	  auf	  vier	  Stunden,	  Zusatz	  von	  Milchpulver	  zu	  den	  Proben,	  Optimierung	  
der	  Verdünnung	  des	  Detektions-­‐Antikörpers,	  Ersetzen	  des	  Detergenz	  Tween20	  mit	  Triton	  X-­‐100	  
im	   Puffer	   und	   Verwendung	   von	   aufgereinigtem	   IgG	   besser	   als	   Serum.	   Die	   Leistung	   des	  
Tumorantikörper-­‐Kandidatscreenings	   konnte	   signifikant,	   im	   Bezug	   auf	   	   Sensitivitäten	   und	  
Spezifizitäten,	  	  gegenüber	  früheren	  Screenings	  verbessert	  werden.	  Eine	  Steigerung	  von	  ca.	  54%	  
auf	   97%	   für	   die	   Unterscheidung	   zwischen	   Patienten	   gegen	   Kontrollen	   wurde	   unter	   der	  
Verwendung	  von	  25	  greedy-­‐pairs	  gene	  selection	  für	  statistische	  Klassenvorhersage	  erreicht.	  	  	  
Mit	   diesem	   verbesserten	   Protokoll	   wurden	   mittels	   class	   prediction	   analyses	   632	  
Klassifikatorklone,	  welche	   593	  Gene	   repräsentieren,	   als	   die	   am	   besten	   vorhersagenden	   TAAs	  
ausgewählt.	  Zusätzlich	  wurden	  weitere	  100	  Gene	  aus	  publizierten	  Tumor-­‐Antikörper	  Screenings	  
mittel	   Protein-­‐Microarrays	   in	  Dickdarmkrebs	  herangezogen.	  Die	   insgesamt	  732	  Klone	  werden	  
auf	   einem	   Kandidatenmarker-­‐Array	   zusammengefasst	   und	   in	   der	   Zukunft	   für	   eine	  
Leistungsvalidierung	  des	  Arrays	  mit	  384	  Proben	  (unterteilt	  in	  4	  Probengruppen)	  verwendet.	  
Die	   vorliegende	   Masterarbeit	   wurde	   von	   PD	   Dr.	   Andreas	   Weinhäusel,	   am	   AIT	   in	   der	  
Forschungsgruppe	   „Molecular	   Diagnostics“,	   	   im	   Zuge	   des	   Forschungsprojekts	   „Evaluation	   of	  
Serum-­‐Autoantibody-­‐Biomarkers	   for	   early	   diagnostic	   testing	   of	   Colon	   and	   Prostate	   Cancers“,	  	  
finanziert	  durch	  “Life	  Science	  Krems”,	  betreut.	  	  





3.1 Colon	  Cancer	  
3.1.1 Cancer	  epidemiology	  
In	   2008,	   the	   World	   Health	   Organization	   reported	   that	   cancer	   accounted	   for	   13%	   or	   7.6	  
million	  of	  deaths	  worldwide	  annually,	  making	  it	  a	  leading	  cause	  of	  death.	  This	  figure	  is	  expected	  
to	   rise	   to	   about	  13	  million	  by	  2030	   (Ferlay	   J,	   2010).	   The	   top	  most	   common	  cancer	   types	   are	  
breast,	  lung,	  colon,	  prostate	  and	  cervical	  cancers,	  but	  differ	  among	  gender	  and	  socio-­‐economic	  
status	  (Figure	  1).	  
	  
Figure	   1.	   Estimated	   age-­‐standardized	   incidence	   and	  mortality	   rates	   for	   cancer.	   Adapted	   from	  
GLOBOCAN	  2008	  (Ferlay	  J,	  2010).	  
According	  to	  the	  Jahrbuch	  der	  Gesundheitsstatistik	  2010,	  Statistik	  Austria,	  in	  the	  year	  2009	  
328,000	   cancer	   patients	   in	   total	   were	   reported	   in	   Austria,	   with	   37,039	   incidences.	   19,757	  
cancer	  deaths	  were	  registered	  in	  the	  same	  year	  and	  comprised	  a	  quarter	  of	  the	  total	  deaths.	  In	  
Austria,	   following	   prostate	   and	   lung	   cancers,	   colon	   cancer	   is	   the	   third	  most	   frequent	   cancer	  
among	  men	  with	  13.6%	  incidence	  and	  7.2%	  mortality	  rates.	  Colon	  cancer	  is	  also	  the	  third	  most	  




1999,	   incidences	   of	   colon	   cancer	   among	   men	   and	   women	   declined	   by	   14.4%	   and	   22.1%,	  
mortality	  by	  30.8%	  and	  38.1%.	  Incidence	  and	  mortality	  rise	  significantly	  around	  the	  age	  of	  50,	  
incidence	  is	  highest	  around	  60	  and	  mortality	  around	  80	  years	  (Figure	  3,	  Statistik	  Austria,	  Cancer	  
incidence	  and	  mortality	  in	  Austria,	  2010).	  
	  
Figure	   2.	   Common	   cancer	   prevalence	   by	   gender	   in	   Austria.	   (Statistik	   Austria,	   Health	   statistics	  
yearbook,	  2010)	  	  
	  
Figure	   3.	   	   Age-­‐	   and	   gender-­‐standardized	   Incidence	   and	   Mortality	   of	   Colon	   Cancer	   in	   Austria	  




3.1.2 Multiple	  step	  carcinogenesis	  
Cancer	   is	   an	   aberrant	   and	   uncontrolled	   growth	   of	   cells,	   also	   referred	   to	   as	   neoplastic	  
diseases,	  as	  a	   result	  of	  malfunctioning	  of	   the	  controls	  governing	  normal	  cell	  proliferation	  and	  
homeostasis.	   Classification	   and	   naming	   of	   cancers	   depend	   on	   their	   origin,	   with	   four	   main	  
groups,	   epithelial,	   mesenchymal,	   hematopoietic	   and	   neuroectodermal.	   Carcinomas	   are	   the	  
most	   common	   type	   of	   cancer	   and	   originate	   from	   the	   epithelium.	   Tumors	   can	   localize	   to	   the	  
tissue	   and	   be	   non-­‐invasive	   or	   metastatic	   and	   invasive,	   termed	   benign	   and	   malignant,	  
respectively.	  The	  transition	  between	  non-­‐invasive	  to	  invasive	  tumors	  arises	  due	  to	  traveling	  of	  
some	   cancer	   cells	   from	   the	   primary	   tumor	   site	   to	   other	   tissues	   via	   the	   blood	   and	   lymphatic	  
vessels.	  These	  kinds	  of	  metastatic	  or	  secondary	  tumors	  cause	  90%	  of	  cancer	  deaths	  (Weinberg,	  
2007).	   In	  principle,	  carcinogenesis	  occurs	  through	  a	  three-­‐stage	  process:	   initiation,	  promotion	  
and	   progression.	   An	   irreversible	   damage	   to	   the	   DNA	   initiates	   neoplastic	   transformation	  
followed	   by	   the	   expression	   of	   the	   mutant	   product	   mediating	   promotion.	   In	   the	   last	   stage,	  
progression,	   cells	   are	   irreversibly	   transformed	   into	   malignant	   growing	   cells	   (Henry	   C.	   Pitot,	  
1993).	  It	  is	  suggested	  that	  for	  above	  stages	  to	  progress,	  cells	  need	  to	  require	  self	  sufficiency	  in	  
growth	   signals,	   insensitivity	   to	   growth-­‐inhibitory	   signals,	   evasion	   of	   apoptosis,	   limitless	  
replicative	  potential,	  sustained	  angiogenesis	  and	  tissue	  evasion	  and	  metastasis,	  as	  depicted	  in	  
Figure	   4.	   These	   capabilities	   are	   mainly	   acquired	   through	   gain	   of	   function	   mutations	   of	  
oncogenes	  and	   loss	  of	   function	  mutations	  of	   tumor	   suppressor	  genes	   (Hanahan	  &	  Weinberg,	  
2000).	  
Normal	  cells	  of	  eukaryotes	  have	  several	  mechanisms	  to	  prevent	  aberrant	  growth	  of	  cells,	  by	  
mechanisms	  that	  are	  controlled	  through	  the	  products	  of	  tumor	  suppressor	  genes	  and	  evading	  
activation	  of	  possible	  oncogenes.	  Tumor	  suppressor	  genes	  (TGS)	  encode	  proteins	  that	  regulate	  
normal	   cellular	   activities	   like	   cell	   cycle	   checkpoint	   control,	   transcriptional	   signaling,	   DNA	  
damage	  and	  other	  stress	  responses.	  The	  main	  processes	  are	  apoptosis	  and	  cell	  cycle	  arrest	  or	  
senescence.	  Majority	  of	  determined	  tumor	  suppressor	  genes	  are	  recessive	  and	  obey	  Knudson’s	  
“two-­‐hit”	   hypothesis,	   meaning	   both	   gene	   copies	   must	   undergo	   mutation	   to	   suppress	   their	  




mutation	  in	  only	  one	  copy.	  Aside	  from	  the	  famously	  studied	  p53,	  there	  are	  several	  other	  TSGs	  
that	  are	  found	  in	  general	  or	  are	  cancer	  specific	  (Sherr,	  2004).	  
	  
Figure	   4.	   Capabilities	   acquired	   by	   cells	   for	   neoplastic	   transformation	   (Hanahan	   &	   Weinberg,	  
2000).	  	  
Oncogenes,	   on	   the	   other	   hand,	   function	   through	   activation	   or	   overexpression	   of	   their	  
protein	   products,	   involved	   in	   cell	   proliferation	   and	   apoptosis.	  Mechanisms	   that	   are	   activated	  
include	   mutations,	   fusion	   with	   other	   genes,	   translocation	   of	   enhancer	   elements	   and	   by	  
amplification.	   Products	   of	   such	   genes	   range	   from	   transcription	   factors,	   signal	   transducers,	  
growth	   factors	   and	   their	   receptors	   to	   apoptosis	   regulators	   and	   chromatin	   remodelers.	   There	  
are	   several	   therapeutic	   approaches	   that	   target	   oncogenes,	   with	   some	   clinically	   approved	  
products	  (Croce,	  2008).	  
3.1.3 Colon	  Carcinogenesis	  
Colorectal	   cancer	   is	   the	   result	  of	  uncontrolled	  growth	  of	   a	   cell	   of	   the	   colon	  and/or	   rectal	  
epithelial	   layer.	  This	   single	   layer	   cells	   form	   the	   so-­‐called	  crypt	   structure	  along	   the	  connective	  




neoplastic	  conversion	  due	  to	  a	  series	  of	  successive	  mutations	  (Figures	  5	  and	  6)	  (Humphries	  &	  
Wright,	  2008).	  
	  
Figure	   5.	   An	   illustration	  of	   the	   colonic	   crypt.	  Differentiation	  of	   stem	   cells	   is	   directed	  upwards	  
from	  the	  base	  bordering	  the	  pericryptal	  myofibroblasts.	  Two	  intermediate	  cell	  stages:	  transient	  
amplifying	  and	  committed	  progenitor	  cells	  (Humphries	  &	  Wright,	  2008).	  	  
	  
Figure	  6.	   	  Clonal	   conversion	  with	  niche	  succession	  demonstrated	  on	   frozen	  section	   stained	  by	  
double-­‐enzyme	   histochemistry	   for	   cytochrome	   c	   oxidase	   (COX;	   brown)	   and	   for	   succinic	  
dehydrogenase	   (SDH;	  blue),	  as	  a.	  wild	   type,	  b.	  mutant	  clones	  appear	   (blue)	  and	  c.	   the	  mutant	  
clone	  successes	  throughout	  the	  crypt	  (Humphries	  &	  Wright,	  2008).	  	  
In	  hyperplastic	  growth	  of	  cancerous	  cells,	  histology	  appears	  normal,	  however,	  epithelial	  cell	  
division	   is	   faster	   and	   the	   tissue	   is	   slightly	   thicker.	   As	   a	   result	   of	   dysplastic	   growth,	   normal	  
colonic	  mucosal	  cell	  layers	  are	  altered	  and	  have	  slightly	  different	  cell	  morphology	  than	  normal	  




adenoma.	  Polyps	  that	  are	  attached	  to	  the	  colon	  wall	  are	  considered	  benign.	  A	  malignant	  polyp	  
occurs	  when	  attachment	  is	   lost	  and	  growth	  breaks	  through	  the	  basement	  membrane	  into	  the	  
stromal	   layers	   and	   smooth	   muscles.	   When	   the	   penetration	   is	   deep,	   cells	   migrate	   resulting	  
metastasis	  (Weinberg,	  2007).	  
Colon	  cancer	  carcinogenesis	  is	  one	  of	  the	  most	  studied	  in	  terms	  of	  the	  genetic	  events	  taking	  
place.	  A	  mathematical	  approach	  to	  determine	  the	  model	  for	  colon	  carcinogenesis	  found	  it	  may	  
have	  four	  stages	  (Figure	  7).	  Initial	  rare	  events	  that	  transform	  colonic	  crypt	  stem	  cells	  probably	  
involve	   mutations	   at	   the	   two	   APC	   (adenomatous	   polyposis	   coli)	   gene	   loci,	   override	   of	   the	  
asymmetric	   division	   of	   the	   stem	   cell	   and	   localization	   due	   to	   space	   limitations.	   The	   following	  
stage	   of	   initiated	   cell	   transformation	   into	   malignant	   cell	   was	   not	   described	   in	   detail,	  
nevertheless,	  TP53	  gene	  mutation	  and	  genomic	  instability	  are	  commonly	  observed	  (Luebeck	  &	  
Moolgavkar,	  2002).	  
Figure	  7.	   Four-­‐stage	  model	  of	  adenoma	  formation	   from	  normal	  crypt	   (Luebeck	  &	  Moolgavkar,	  
2002).	  	  	  
It	   can	   be	   summarized	   from	   the	   numerous	   studies	   on	   the	   molecular	   basis	   of	   colorectal	  
cancer,	   the	   concert	   of	   elements	   involved	   in	   genomic	   instability,	   tumor	   suppression	   gene	  
inactivation	   through	  mutations,	   oncogenic	   activations	   and	   growth	   factor	   pathway	   alterations	  
causing	   tumor	   progression.	   Aside	   from	   APC	   and	   P53	   genes,	   many	   other	   genes	   and	   growth	  
factors	   were	   found	   to	   be	   involved	   in	   the	   different	   stages	   of	   colon	   carcinogenesis	   (Figure	   8)	  




Figure	   8.	   Colon	   cancer	   carcinogenesis	   associated	   genes	   and	   growth	   factors	   (Markowitz	   &	  
Bertagnolli,	  2009).	  	  
3.1.4 Epidemiology,	  screening	  and	  treatment	  
	   Colon	   cancer	   is	   largely	   age	   dependent,	   as	   incidence	   rises	   dramatically	   for	   individuals	  
after	  50	  years	  of	  age	  with	  more	   tendencially	  men	  to	  be	  affected.	  Previous	  cases	  of	  polyps	  or	  
cancer	  and	  family	  history	  of	  the	  diseases	  are	  another	  important	  risk	  factor.	  Lifestyle	  factors	  of	  
the	   individual,	   such	   as	   diet,	   obesity,	   associated	   diseases	   like	   diabetes	  mellitus,	   smoking	   and	  
high	   alcohol	   consumption	   are	   equal	   contributors	   for	   colorectal	   cancer	   development	   (“CDC	   -­‐	  
Colorectal	  Cancer	  Risk	  Factors,”	  2012).	  
	   The	  reduction	  of	  colon	  cancer	  incidences	  and	  increased	  survival	   in	  recent	  years	  can	  be	  
attributed	  to	  diagnostic	  and	  treatment	   improvements.	  Around	  80%	  of	  cancers	  are	  thought	  to	  
arise	   from	  premalignant	  polyps	  or	   adenoma,	   therefore	  diagnosis	   during	   this	   stage	   is	   vital	   for	  
prevention	  of	  malignancy.	  Screening	  of	  colon	  cancer	  can	  decrease	  mortality	  although	  incidence	  
rates	  rise.	  The	  most	  commonly	  used	  method	  for	  screening	  is	  the	  faecal	  occult	  blood	  test	  (FOBT)	  
that	  has	  low	  sensitivity,	  but	  could	  reduce	  the	  mortality	  rate	  by	  16%	  if	  done	  every	  2	  years.	  The	  




from	   three	   successive	   stools,	  whereas	   for	   immunochemical	   test,	   one	  of	   two	   stool	   samples	   is	  
adequate.	   Immunochemical	   faecal	   test	   is	  not	  affected	  by	  animal	  blood	  from	  diet	  and	   is	  more	  
sensitive	  for	  detection	  of	  CRC	  and	  advanced	  adenomas	  (Cunningham	  et	  al.,	  2010).	  	  
	   Screening	   by	   rectal	   imaging	   involves	   colonoscopy	   and	   flexible	   sigmoidoscopy.	   Both	  
methods	   require	  bowel	  preparation	   through	  enema.	   Sigmoidoscopy	   is	   carried	  out	  with	  60cm	  
endoscope	  and	  can	  examine	  the	  sigmoid	  colon	  and	  rectum	  where	  most	  adenomas	  are	  found.	  
Simple	   bowel	   preparation	   with	   self-­‐administered	   enema	   is	   sufficient	   for	   sigmoidoscopy.	   The	  
method	   is	   recommended	   every	   5	   years	   and	   can	   reduce	   incidence	   and	   mortality	   of	   CRC	   by	  
around	   60	   to	   80%.	   If	   small	   polyps	   are	   observed	   during	   the	   procedure,	   they	   are	   removed,	  
however	   in	   the	   case	   of	   more	   or	   advanced	   polyps,	   colonoscopy	   is	   recommended.	   Important	  
disadvantages	  associated	  with	  colonoscopy	  are	  risk	  of	  complications,	  requirement	  for	  sedation	  
and	   complicated	   bowel	   preparation.	   Colonoscopy	   is	   recommended	   every	   10	   years.	   An	  
alternative	   to	   the	   invasive	   imaging	  approaches,	  CT	   colonography,	   is	   comparable	   in	   sensitivity	  
for	   cancer	   detection,	   however	   colonoscopy	   is	   required	   for	   confirmation	   (Cunningham	   et	   al.,	  
2010).	  	  
	   Diagnosis	  of	  CRC	  is	  made	  based	  on	  the	  histopathological	  examination	  on	  biopsy	  sample	  
obtained	  during	  colonoscopy	  or	  sigmoidoscopy.	  Localization	  of	  the	  tumor	  can	  be	  achieved	  with	  
CT	   colonography	   or	   MRI,	   with	   MRI	   having	   advantage	   of	   measuring	   the	   extent.	   Diagnosis	  
through	  histology	  or	  other	  methods	  are	  used	  to	  stage	  the	  tumor	  with	  the	  TNM	  (tumor,	  node	  





Figure	  9:	  Colon	  Cancer	  TNM	  Staging:	  Tumor	  Size,	  Invasion	  and	  Spread	  (Cunningham	  et	  al.,	  2010).	  
Significant	  efforts	  into	  improving	  performance	  of	  such	  methods	  have	  been	  made	  with	  major	  
emphasis	  on	   their	   cost	  effectiveness.	  New	  endoscopic	   technologies	  are	  being	  developed	   that	  
incorporate	   advances	   such	   as	  wider-­‐angle	   views,	   enhanced	   imaging	   and	   fluorescent	   imaging.	  
Aside	  from	  technological	  improvements,	  the	  strategies	  involved	  in	  population-­‐based	  screenings	  
are	  critical.	  With	  successful	  combination	  of	  strategies	  and	  technology,	   it	  would	  be	  possible	  to	  
reduce	   the	   burden	   of	   disease,	   incidence	   and	   mortality	   (Quintero,	   Hassan,	   Senore,	   &	   Saito,	  
2012).	  
An	   alternative	   possibly	   cost	   reducing	   and	   non-­‐invasive	   or	   less	   inconvenient	   method	   to	  
endoscopic	  and	  faecal	  screenings	   is	  biomarker	  screening	   in	  blood.	  Blood	  based	  methods	  have	  
the	   major	   advantage	   of	   minimal	   invasiveness	   and	   required	   samples.	   Due	   to	   the	   slow	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For colon cancer, total resection of the tumour should be 
done with adequate margins, and lymphadenectomy. 
Distal margins of 5 cm or more are recommended. At least 
12 lymph nodes should be taken and analysed to allow 
appropriate nodal staging;93–95 analysis of fewer than ten 
nodes might understage the tumour.12 En-bloc resection of 
invaded adjacent organs might be needed for T4 tumours 
to obtain R0 resection (no evidence of microscopic cancer 
at the margins). Surgical resection of the rectum for 
invasive rectal cancer should include total excision of the 
mesorectum (TME) with adequate circumferential and 
distal margins, and inferior mesenteric lymphadenectomy. 
TME is associated with a reduced risk of local recurrence 
whether or not combined with preoperative radiotherapy 
or chemo radiotherapy.96–98 Sphincter-saving surgery is 
feasible in most patients with mid and low rectal cancers if 
the distal margin is 1 cm or more. Intestinal continuity can 
be restored with colorectal or coloanal anastomosis 
according to the level of the tumour. For very low tumours, 
TME can be combined with resection of the internal 
sphincter of the anus without increasing the rate of local 
recurrence.99,100 Abdominoperineal resection is a valuab e 
alternative for very low tumours.101 Functional results after 
TME are associated with the level of the anastomosis. 
Risk of faecal incontinence is increased in patients 
with very low coloanal anastomosis, particularly after 
preoperative radiation.102,103
In patients with early rectal cancer, the choice of 
treatment is complete local excision or TME, and 
depends on the risk of lymph-node involvement, which 
is associated with the depth of invasion of the tumour in 
the rectal wall. Local excisi n—tr nsanal excision or 
endoscopic microsurgery for tumours in the upper-third 
layer of the submucosa (T1Sm1) and some in the middle 
layer (T1Sm2)—is valuable if excision is completed with 
adequate margins.104–106
Laparoscopic colectomy is safe for colon cancer, 
particularly left-sided cancer. The long-term oncological 
results of this surgery are similar to thos  of the open 
approach.107–110 Although laparoscopic colectomy is 
technically demanding, advantages are reduced pain, 
length of hospital stay, and duration of ileus.111 Comparison 
of laparoscopic  and open resection (with TME) of rectal 
cancer112 showed similar 3-year local recurrence rates and 
Panel 3: Advantages and limitations of MRI and endorectal 
ultrasound for staging of primary tumours (T) and regional 
lymph nodes (N) in rectal cancer
MRI
Advantages:
• Global staging of rectal tumour
• Circumferential resection margin assessment
• Assessment of extramural venous invasion
• Guide the indication for radiation treatment
• Few contraindications
• Assessment of pelvic spread of the tumour (iliac nodes)
Limitations:
• Node staging—MRI is more accurate than is endorectal 
ultrasound, but there are some limitations in correlation 
between radiological and pathological fi ndings
Endorectal ultrasound
Advantages:
• Measure of depth of invasion in the bowel wall
• Measurement of T staging
• Early rectal cancer
Limitations:
• Obstructing lesions
• User-dependent imaging modality
• Measurement of node staging
• Assessment of circumferential resection margin assessment 
and extramural venous invasion
Panel 4: TMN classifi cation of colon cancer91
T=primary tumour
TX=primary tumour cannot be assessed
T0=no evidence of primary tumour
Tis=carcinoma in situ: intraepithelial or invasion of lamina propria
T1=tumour invades submucosa
T2=tumour invades muscularis propria
T3=tumour invades through the muscularis propria into subserosa or into non-
peritonealised pericolic or perirectal tissues
T4a=tumour penetrates the surface of the visceral peritoneum
T4b=tumour directly invades or is histologically adherent to other organs or structures
N=regional lymph nodes
NX=regional lymph nodes cannot be assessed
N0=no regional lymph node metastasis
N1a=metastasis in one regional lymph node
N1b=metastasis in two to three regional lymph nodes
N2a=metastasis in four to six regional lymph nodes
N2b=metastasis in seven or more regional lymph nodes
M=distant metastasis
MX=distant metastasis cannot be assessed
M0=no distant metastasis
M1a=distant metastasis to one site
M1b=distant metastasis to more than one site
Surveillance, Epidemiology and End Results Program data for 5-year stage-specifi c relative 
survival rates in colon cancers:91,92
• Stage I (T1, T2, N0): 97·1%
• Stage IIA (T3, N0): 87·5%
• Stage IIB (T4, N0): 71·5%
• Stage IIIA (T1, T2, N1): 87·7%
• Stage IIIB (T1, T2, N2): 75·0%
• Stage IIIB (T3, N1): 68·7%
• Stage IIIC (T3, N2): 47·3%
• Stage IIIC (T4, N1): 50·5%
• Stage IIIC (T4, N2): 27·1%





progression	   and	   certain	   studied	   genetic,	   epigenetic,	   metabolic	   and	   protein	   biomarkers	  
associated	   with	   the	   different	   stages	   of	   disease	   progression,	   such	   biomarkers	   may	   serve	   as	  
prognostic	  and	  diagnostic	  tools.	  Genetic	  and	  epigenetic	  biomarkers	  associated	  with	  colorectal	  
cancer	  have	  been	  studied	  extensively,	  yet	  there	  are	  limited	  numbers	   in	  clinical	  application.	  At	  
present	   there	   are	   a	   few	  molecular	   biomarkers	   in	   clinical	   use,	   namely,	   faecal	   hemoglobin	   in	  
stool,	   protein	   CEA	   and	   carbohydrate	   CA	   19.9	   and	  methylated	   gene	   SEPT9	   (Lofton-­‐Day	   et	   al.,	  
2008)	   in	   serum	   or	   blood.	   Several	   other	   potential	   biomarkers	   are	   reported	   with	   promise	   to	  
improve	   and	   build	   on	   currently	   used	   biomarkers,	   but	   require	   large	   scale	   clinical	   studies	   to	  
validate	  their	  proposed	  performances	  (T.	  Tanaka,	  Tanaka,	  Tanaka,	  &	  Ishigamori,	  2010).	  
3.2 Tumor-­‐associated	  antigens	  
The	   human	   immune	   system	   protects	   “self”	   from	   infection	   by	   recognizing	   and	   removing	  
foreign	  agents.	  Cells	  of	  the	  immune	  system	  undergo	  maturations	  to	  omit	  those	  antibodies	  that	  
are	  reactive	  against	  self-­‐tissues	  and	  leaving	  the	  tolerant	  population,	  however	  a	  certain	  level	  of	  
autoimmunity	   is	   found.	   In	   the	  case	  of	  autoimmune	  diseases	   these	   tolerance	   is	  broken	  or	   the	  
naturally	   occurring	   autoimmunity	   is	   poorly	   controlled.	   Genetic	   (several	   genes)	   and	  
environmental	   factors	   contribute	   in	   combination	   to	   the	   development	   of	   autoimmunity.	   The	  
main	   mechanisms,	   from	   which	   autoimmune	   diseases	   arise	   are	   through	   exposure	   to	  
environmental	   factors	   that	   alter	   the	   innate	   immune	   response,	   overproduction	   of	  
proinflammatory	  cytokines	  and	  altering	  the	  regulations	  of	  inflammation	  (Fairweather,	  2007).	  
From	   the	   decades	   of	   research	   in	   the	   human	   immune	   system	   and	   malignancies,	   their	  
connection	   was	   seen	   through	   the	   presence	   of	   antigens	   against	   self,	   or	   autoantigens	   and	  
antibodies	  that	  are	  produced	  against	  them	  (autoantibodies).	  This	  association	  and	  concept	  was	  
demonstrated	   prominently	   by	   autoimmune	   diseases	   such	   as	   systemic	   lupus	   erythromatosus	  
(SLE)	  and	  scleroderma,	  other	  diseases	   like	   type	  1	  diabetes,	  gastrointenstinal	  and	  neurological	  
diseases	  (Eng	  M.	  Tan	  &	  Zhang,	  2008).	  	  
Earlier	   studies	   demonstrated	   several	   systemic	   autoimmune	   diseases	   having	   their	   unique	  
immune	  response	  by	  spontaneously	  producing	  autoantibodies	  reactive	  to	  intracellular	  proteins	  




by	  giving	  insights	  into	  intracellular	  mechanisms	  and	  processes	  of	  the	  diseases.	  In	  the	  1970s,	  two	  
nuclear	   antigens	   Smith	   antigen	   (Sm	   Ag)	   and	   nuclear	   ribonucleoprotein	   (HNRNP),	   both	   with	  
antibodies	  produced	  specifically	  by	  patients	  with	  SLE	  were	   identified	  and	  demonstrated	  to	  be	  
located	  closely	  within	  the	  nucleus.	  The	  combined	  role	  of	  these	  two	  to	  antigens	  were	  described	  
later	  to	  be	  associated	  with	  splicing	  of	  precursor	  mRNA	  (E	  M	  Tan,	  1989).	  	  
Alternatively,	   aberrantly	   expressed	   proteins	   or	   tumor-­‐associated	   antigens	   by	   tumor	   cells	  
were	  found	  to	  stimulate	  immune	  response	  through	  production	  of	  autoantibodies	  (Y.	  T.	  Chen	  et	  
al.,	  1997;	  Nelson,	  1977;	  Steiner,	  Klein,	  &	  Klein,	  1975;	  E.	  M.	  Tan	  &	  SHI,	  2003).	   	  The	  underlying	  
mechanisms	  of	  how	  tumor-­‐associated	  antigens	  are	  produced	  are	  not	  fully	  described,	  but	  quite	  
commonly	   mutations	   in	   the	   gene	   sequence	   can	   lead	   to	   mutated	   antigen	   product	  
(Somasundaram	   et	   al.,	   2006).	   Several	   other	   mechanisms	   including	   alternative	   splicing,	  
deregulated	   apoptotic	   or	   necrotic	   processes,	   post-­‐transcriptional	   modifications,	   single	  
nucleotide	   polymorphisms	   (SNPs)	   and	   overexpression	   can	   cause	   autoantigen	   production	   too	  
(Backes	  et	  al.,	  2011)(Utz	  &	  Anderson,	  1998).	  
Tumor-­‐associated	  antigens	  and	   corresponding	   tumor	  autoantibodies	  have	  been	  described	  
for	   a	   number	   of	   cancers	   such	   as	   breast,	   colon,	   lung,	   liver,	   prostate,	   ovarian,	   head	   and	   neck,	  
leukemia	  and	  lymphoma	  and	  their	  cancer	  specific	  nature	  has	  opened	  the	  possibility	  to	  serve	  as	  
prognostic	  or	  diagnostic	  biomarker	  (Anderson	  et	  al.,	  2008;	  Bauer	  et	  al.,	  2002;	  Chatterjee,	  2006;	  
Lin	  et	  al.,	  2007;	  Madrid	  et	  al.,	  2010;	  Massoner	  et	  al.,	  2012;	  Orchekowski	  et	  al.,	  2005;	  Perou	  et	  
al.,	  2000;	  Rapberger	  et	  al.,	  2008;	  Somers	  et	  al.,	  2002;	  Steiner	  et	  al.,	  1975;	  Wang	  et	  al.,	  2005;	  








3.3 Protein	  Microarray	  Technology	  
Protein	  microarrays	  offer	  a	  potent	  tool	  to	  study	  interactions	  between	  proteins	  and	  peptides	  
on	   a	   large	   scale.	   	   It	   is	   the	   advanced,	   high-­‐throughput	   form	   of	   immunoassays	   such	   as	  
Radioimmunoassay	   (RIA)	  described	  by	  Yarlow	  et	  al.	   (Yalow	  &	  Berson,	  1959)	  and	   the	  enzyme-­‐
linked	   immunosorbant	   assay	   (ELISA)	   by	   Engvall	   et	   al.	   (Engvall,	   Jonsson,	   &	   Perlmann,	   1971).	  	  
Initially,	  Ekins	  et	  al.	  (Ekins,	  Chu,	  &	  Biggart,	  1990)	  proposed	  that	  a-­‐few-­‐micron	  scale	  solid	  support	  
antibody	   assays	   could	   yield	   high	   sensitivity	   comparable	   to	   that	   of	  macroarrays.	   Advances	   in	  
studies	  on	  DNA	  microarray	  technology,	  such	  as	  spotting	  machinery,	  support	  surface	  chemistries	  
and	   detection	  methods	   and	   principles,	   have	   been	   successfully	   applied	   to	   protein	  microarray	  
technology.	  One	   of	   the	   earliest	   examples	   of	   implementation	   of	  DNA	  microarray	   e	   to	   protein	  
arrays	   is	   the	   use	   of	   a	   standard	   inkjet	   printer	   to	   apply	   200μm	  diameter	  monoclonal	   antibody	  
spots	   onto	   polystyrene	   film.	   Silzel	   and	   coworkers	   were	   able	   to	   reduce	   reagents,	   capture	  
antibody,	  analyte	  molecule	  per	  zone	  with	  equal	  sensitivity	  and	  specificity	  as	  that	  of	  ELISA	  (Silzel,	  
Cercek,	  Dodson,	  Tsay,	  &	  Obremski,	  1998).	  	  
At	  present	  protein	  microarrays	  utilize	  recombinant-­‐,	  fractions-­‐	  or	  puriﬁed	  proteins,	  as	  well	  
as	  synthetic	  peptides,	  for	  immobilization	  onto	  a	  microscope	  slide	  coated	  with	  various	  surfaces	  
in	  a	  planar	  or	  3D	  platform	  or	  are	  captured	  by	  affinity	  beads	  in	  a	  micro-­‐well	  plate	  setting.	  Planar	  
surface	  coating	  chemistries	  are	  categorized	  into	  4	  main	  groups	  based	  on	  the	  binding	  principle:	  
non-­‐specific-­‐	   noncovalent	   and	   covalent,	   specific-­‐	   noncovalent	   and	   covalent.	   The	   first	   group	  
includes	   nitrocellulose	   and	   poly(L-­‐lysine),	   the	   second,	   aldehyde	   and	   epoxy,	   the	   third,	   certain	  
affinity	   interaction	  molecules	   like	   streptavidin–biotin,	   His-­‐tag–nickel-­‐chelates,	   and	   the	   fourth	  
self-­‐assembly	  monolayers	  (SAMs)	  on	  gold	  coated	  surfaces	  (Tomizaki,	  Usui,	  &	  Mihara,	  2005).	  	  
Coating	   chemistries	   are	   vital	   in	   the	   overall	   performance	   of	   the	   protein	   microarray	   and	  
should	   offer	   low	   background,	   maintain	   proper	   orientation	   and	   reduce	   the	   effect	   on	   the	  
sensitive	   3-­‐D	   structure	   of	   the	   proteins	   (Predki,	   2007).	   The	   most	   commonly	   used	   surface	  
chemistries	   in	   antibody	  microarrays	   are	   nitrocellulose,	   amines,	   aldehyde	   or	   epoxy.	   However,	  




far	  (Fici	  et	  al.,	  2010;	  Huang,	  Huang,	  Fan,	  &	  Lin,	  2001;	  Lee,	  Kim,	  Choi,	  Shin,	  &	  Kim,	  2011;	  Nam	  et	  
al.,	  2003;	  Olle	  et	  al.,	  2005;	  Tomizaki	  et	  al.,	  2005).	  
Due	   to	   the	   highly	   complex	   nature	   of	   protein	   interactions,	   new	   technologies	   to	   improve	  
performance	  of	  protein	  microarrays	  have	  been	  developed,	  like	  the	  so-­‐called	  3D	  surface	  setups:	  
agarose,	  hydrogel	  and	  more	  recently	  nanoparticles	  and	  beads	  in	  microwell	  plate	  formats.	  These	  
approaches	   aim	   to	   overcome	   the	   difficulty	   of	   limited	   spot	   density,	   detecting	   low	   abundance	  
proteins,	   increased	   signal	   to	   noise	   ratio,	   decreased	   non-­‐specific	   binding	   and	   avoiding	   cross-­‐
reactivity	   	   (Chandra,	  Reddy,	  &	  Srivastava,	  2011;	  H.	  Chen	  et	  al.,	  2009;	  Guilleaume	  et	  al.,	  2005;	  
Kang,	   Trofin,	  Mota,	   &	  Martin,	   2005;	   Lee	   et	   al.,	   2011;	   H.	   Tanaka	   et	   al.,	   2009;	   Tsarfati-­‐Barad,	  
Sauer,	  Preininger,	  &	  Gheber,	  2011;	  Zubtsov	  et	  al.,	  2007).	  	  
Spotted	   protein	   arrays	   are	   processed	   with	   cancer	   patients’	   or	   control	   individuals’	   serum	  
samples	  and	  binding	  of	  proteins	  are	  detected	  using	  methods	  that	  avoid	  cross-­‐reactivity,	  enable	  
high-­‐resolution	   signals	   in	   high	   throughput	   format	   with	   good	   reproducibility	   and	   are	   cost	  
effective	   (Tomizaki	   et	   al.,	   2005).	   The	   same	   strategies	   as	   in	   immunoassays,	   like	   sandwich,	  
antigen	  capture	  and	  direct,	  do	  also	  apply	   to	  protein	  microarrays	   (Carlsson	  et	  al.,	  2011;	  Haab,	  
Dunham,	   &	   Brown,	   2001;	   Nolen	   et	   al.,	   2008;	   Pla-­‐Roca	   et	   al.,	   2012;	   Schweitzer	   et	   al.,	   2002;	  
Sreekumar	  et	  al.,	  2001).	  
3.4 Protein	  microarray	  application	  for	  TAA	  discovery	  
Different	   approaches	   to	  produce	   the	  protein	   analytes	   for	   tumor	  biomarker	  discovery	   and	  
validation	  exist,	  ranging	  from	  recombinant	  proteins	  to	  tumor	  tissues	  fractions.	  	  TAA	  biomarker	  
discovery	  initially	  begins	  with	  screening	  on	  a	  proteomic	  scale,	  subsequently	  narrowing	  down	  to	  
sets	   of	   proteins	   that	   best	   distinguish	   the	   tumor	   type	   under	   analysis.	   Several	   studies	   have	  
demonstrated	   the	  use	  of	   different	   liquid	   chromatography	   fractioning	  of	   proteins	   from	   tumor	  
(Bouwman	   et	   al.,	   2003;	   Yan	   et	   al.,	   2003)	   or	   tumor	   derived	   cell	   lines	   (Madoz-­‐Gúrpide,	   Kuick,	  
Wang,	  Misek,	  &	  Hanash,	  2008;	  Nam	  et	  al.,	  2003;	  Pereira-­‐Faca	  et	  al.,	  2007;	  Qiu	  et	  al.,	  2004)	   in	  
large	   scale.	   Using	   such	   native	   proteins	   for	   functional	   analysis	   are	   advantageous	   in	   having	  




manifold	  proteins	  present	   in	   the	  spots,	  as	  well	  as	   the	  dependence	  on	   the	   tissue	  sample	   they	  
originate	  from	  (Lu,	  Goodell,	  &	  Disis,	  2008;	  Qiu	  et	  al.,	  2004).	  
Recombinant	   proteins	   from	   cDNA	   libraries	   can	   be	   expressed	   via	   bacterial,	   insect	   or	  
mammalian	   expression	   systems.	   With	   the	   so-­‐called	   SEREX	   technology,	   high-­‐throughput	  
expression	   of	   libraries	   consisting	   of	   thousands	   of	   clones	   is	   effectively	   produced	   by	   bacterial	  
expression	   systems.	   Mammalian	   cells	   are	   the	   most	   suitable	   expression	   system	   for	   human	  
proteins	   (specifically	   with	   respect	   to	   post-­‐translational	   modifications),	   in	   regard	   to	   correct	  
folding,	   using	  many	   viral	   vectors	   such	   as	   adenovirus	   and	   retrovirus.	   However,	   the	   technique	  
lacks	   in	   ability	   to	   scale	   up,	   providing	   sufficient	   yield,	   being	   consequently	   not	   time	   and	   cost	  
effective	  (Schena,	  2005).	  	  
Several	  studies	  have	  addressed	  TAA	  discovery	  as	  a	  diagnostic	  biomarker	  using	  the	  protein	  
microarray	   approach	   (Table	   1).	   For	   instance	   in	   colon	   cancer,	   Nam	   et	   al.	   (Nam	   et	   al.,	   2003)	  
identified	   an	   antigenic	   target	   of	   colon	   cancer	   by	   using	   a	   protein	  microarray	   containing	   1760	  
solubilized	  protein	  fractions	  obtained	  from	  a	  human	  colorectal	  adenocarcinoma	  cell	  line	  LoVo.	  
Proteins	   were	   immobilized	   on	   nitrocellulose-­‐coated	   slides	   and	   hybridized	   with	   15	   plasma	  
samples	   each	   from	   colon	   and	   lung	   cancers	   and	   healthy	   controls.	   From	   the	   total	   of	   1760	  
fraction,	  39	  exhibited	  higher	  reactivity	  to	  colon	  cancer	  samples.	  One	  fraction	  reactive	  to	  9/15	  
colon	   cancer	   sera	   was	   identified	   with	   mass	   spectrometry	   as	   ubiquitin	   C-­‐terminal	   hydrolase	  
isozyme	  3	   (UCH-­‐L3).	  Antibody	   to	  UCH-­‐L3	   could	  be	  detected	   in	  19/43	   sera	   from	  patients	  with	  
colon	  cancer,	  but	  none	  of	  the	  54	  sera	  of	  lung	  cancer,	  colon	  adenoma	  or	  healthy	  subjects.	  	  
By	   using	   commercial	   protein	   microarrays	   containing	   8000	   human	   proteins,	   Babel	   et	   al.	  	  
(Babel	   et	   al.,	   2009)	   screened	   sera	   from	  colorectal	   cancer	   (CRC)	  patients	   and	  healthy	   subjects	  
and	  were	  able	  to	  identify	  43	  proteins	  that	  were	  recognized	  by	  tumoral	  sera	  but	  not	  the	  control	  
sera.	   From	   these	   43	   proteins,	   5	   immunoreactive	   antigens,	   PIM1,	  MAPKAPK3,	   STK4,	   SRC,	   and	  
FGFR4	   were	   shown	   to	   be	   highly	   prevalent	   in	   cancer	   samples.	   By	   using	   an	   ELISA	   with	   PIM1,	  
MAPKAPK3,	  and	  ACVR2B	  they	  showed	  specificity	  and	  sensitivity	  values	  of	  73.9	  and	  83.3%	  (area	  




From	  a	  37,830	  clone	  recombinant	  human	  protein	  array,	  Kijanka	  et	  al.	  (Kijanka	  et	  al.,	  2010)	  
could	   identify	   22	   antigens	   able	   to	   distinguish	   between	   colorectal	   cancer	   and	   non	   cancer	  
patients.	  18	  antigens	  are	   specific	   for	  cancer	  and	  4	  are	   for	  control.	  Expression	  of	   the	  antigens	  
(p53,	  high	  mobility	  group	  B1	  (HMGB1),	  TCF3,	  tripartite	  motif-­‐containing	  28	  (TRIM28),	  longevity	  
assurance	  gene	  homologue	  5	  (LASS5)	  and	  zinc	  finger	  protein	  346	  (ZNF346))	  using	  quantitative	  
reverse	  transcription	  PCR	  (Q-­‐PCR)	  and	  tissue	  microarray	  immunohistochemistry	  involvement	  in	  
various	  cellular	  processes.	  



















ZNF346 and 6 
other antigens 
CRC High density protein array NA Serum 
Training set: 20 
patients and 20 
controls. 


































Koc, p53 and 
c-myc 
CRC Recombinant proteins  ELISA Serum 46 60.9 89.7 
56.8 
(Patients) 
(Liu et al., 
2009) 
MAPKAPK3 
















CRC Recombinant proteins  ELISA Serum 
94 CRC patients 
and 54 control 77.6 58.5 
64 
(Patients)  
(Chan et al., 
2010) 
	  
Table	  1.	  Examples	  of	  screening	  and	  validation	  studies	  on	  TAA	  biomarker	  panels	  using	  clinical	  
samples	  of	  Colorectal	  Cancer	  patients	  and	  healthy	  controls.	  Single	  biomarker,	  CEA	  can	  be	  seen	  
to	  lack	  sensitivity	  and	  conversely,	  panels	  of	  different	  TAA	  biomarkers	  are	  able	  to	  classify	  disease	  





Tumors	  are	  found	  to	  evoke	  the	  immune	  system	  and	  stimulate	  the	  production	  of	  tumor	  
autoantibodies	  (TAAs),	  that	  consequently	  are	  a	  promising	  serological	  tool	  for	  minimal	  invasive	  
diagnosis	  of	  colon	  and	  other	  cancers	  (E.	  M.	  Tan	  &	  SHI,	  2003).	  Protein	  microarrays	  are	  an	  ideal	  
approach	  to	  identify	  and	  develop	  TAA	  tests	  (Anderson	  et	  al.,	  2008;	  Kijanka	  et	  al.,	  2010;	  
Massoner	  et	  al.,	  2012).	  However,	  the	  complex	  nature	  of	  proteins	  and	  variability	  of	  protocols	  
applied	  in	  different	  research	  settings	  make	  it	  difficult	  to	  produce	  highly	  reproducible	  results	  and	  
therefore	  an	  optimal	  protein	  microarray	  processing	  protocol	  is	  in	  demand.	  	  	  
The	  presented	  thesis	  was	  aimed	  at	  evaluating	  the	  protocol	  previously	  applied	  for	  protein	  
microarray	  experiments	  in	  the	  context	  of	  TAA	  candidate	  marker	  screening	  using	  high-­‐density	  
protein	  microarrays.	  Clinical	  samples	  from	  different	  colon	  disease	  stages	  (prior	  to	  and	  
established	  diagnosis	  of	  colon	  cancer)	  and	  healthy	  controls	  were	  used	  to	  perform	  the	  screening	  
experiments.	  The	  shortcomings	  of	  the	  protocol	  were	  addressed	  from	  an	  initial	  screening	  
experiment	  that	  was	  performed	  using	  100	  clinical	  samples	  belonging	  to	  four	  sample	  groups:	  
healthy	  control,	  low	  risk	  polyp,	  high	  risk	  polyps	  and	  colon	  carcinoma,	  respectively.	  As	  the	  
performance	  of	  the	  pilot	  screening	  had	  failed	  to	  produce	  a	  panel	  of	  classifiers	  with	  adequate	  
ability	  to	  classify	  disease	  and	  healthy	  groups,	  several	  technical	  issues	  were	  addressed	  that	  may	  
be	  important	  in	  protein	  microarray	  assays.	  The	  following	  goals	  had	  been	  set	  to	  improve	  the	  
protocol	  and	  the	  reproducibility	  of	  protein	  microarray	  experiments:	  
• Selecting	  the	  ideal	  slide	  surface	  to	  produce	  protein	  microarrays	  
• Choosing	  an	  efficient	  blocking	  buffer	  to	  reduce	  background	  
• Setting	  an	  optimal	  sample	  incubation	  time-­‐point	  to	  obtain	  sufficient	  specific	  bindings	  	  
• Setting	  an	  optimal	  experimental	  condition	  to	  ensure	  sample	  distribution	  over	  the	  
arrays	  




Upon	  optimizing	  the	  protocol,	  a	  TAA	  candidate	  biomarker	  screening	  experiment	  is	  to	  be	  
performed	  to	  elucidate	  a	  panel	  of	  the	  best	  classifiers	  of	  the	  four	  different	  sample	  groups.	  The	  
models	  for	  utilizing	  protein	  expression	  profile	  to	  predict	  the	  classes	  of	  future	  samples	  are	  
developed	  based	  on	  the	  Compound	  Covariate	  Predictor,	  Diagonal	  Linier	  Discriminant	  Analysis,	  
Nearest	  Neighbor	  Classification	  and	  Support	  Vector	  Machines	  with	  linear	  kernel.	  Genes	  
differentially	  expressed	  at	  the	  specified	  significance	  level	  or	  a	  defined	  number	  of	  greedy-­‐pairs	  
genes	  are	  incorporated	  into	  the	  models.	  The	  prediction	  error	  of	  each	  model	  will	  be	  estimated	  
using	  leave-­‐one-­‐out	  cross-­‐validation	  (LOOCV).	  	  	  





5.1 Chemicals	  	  
5.1.1 Sample	  preparation	  
-­‐ Serum	  Clot	  Activator	  9ml	  Vacuette,	  Greiner	  Bio-­‐GmbH	  (Cat#	  455092)	  
-­‐ MelonTM	  Gel	  Spin	  Plate	  Kit	  for	  IgG	  Screening,	  Thermo	  Scientific	  (Cat#	  45208)	  
-­‐ MelonTM	  Gel	  Purification	  Buffer	  (100	  ml),	  Thermo	  Scientific	  (Cat#	  1859376)	  
-­‐ 96	  well	  Spin	  Plate	  (Cat#	  1825285)	  
-­‐ Wash	  Plate	  (Cat#	  1860083)	  
-­‐ Collection	  Plate	  (Cat#	  1860082)	  
-­‐ NuPAGE®	  MOPS	  SDS	  Running	  Buffer	  (20x),	  Invitrogen	  (Cat#	  NP0001)	  
-­‐ NuPAGE®	  4-­‐12	  %	  Bis	  Tris	  Gel,	  1.0	  mm	  x	  17	  well,	  Invitrogen	  (Cat#	  NP0329BOX)	  
-­‐ NuPAGE®	  LDS	  Sample	  Buffer	  (4x),	  Invitrogen	  (Cat#	  NP0007)	  
-­‐ NuPAGE®	  Reducing	  Agent	  (10X),	  Invitrogen	  (Cat#	  NP0004)	  
-­‐ NuPAGE®	  Antioxidant,	  Invitrogen	  (Cat#	  NP0005)	  
-­‐ Ladder:	  SeeBlue®	  Plus	  2	  Prestained	  Standard	  (Cat#:	  LC5925)	  
-­‐ Roti®-­‐Blue	  (5x),	  ROTH®	  ®	  (Cat#:	  A152.1)	  
5.1.2 Protein	  expression	  and	  purification	  
-­‐ UniPEx	  human	  cDNA	  library	  (human	  fetal	  brain,	  T-­‐cells,	  lung),	  imaGenes	  GmbH	  (IMA-­‐
PROT-­‐ARR)	  
-­‐ Glycerol	  minimum	  99%	  GC,	  Sigma	  (Cat#	  200-­‐289-­‐5)	  
-­‐ D-­‐(+)-­‐Glucose,	  Sigma	  (Cat#	  G6152)	  
-­‐ Α-­‐Lactose-­‐Monohydrate,	  Sigma	  (Cat#	  L2643)	  
-­‐ Na2HPO4-­‐	  di-­‐sodium	  hydrogen	  phosphate,	  anhydrous	  GR	  for	  analysis,	  MERCK	  (Cat#	  
106586)	  
-­‐ KH2PO4-­‐	  potassium	  dihydrogen	  phosphate,	  GR	  for	  analysis,	  MERCK	  (Cat#	  104873)	  
-­‐ (NH4)2SO4-­‐	  ammonium	  sulfate	  GR	  for	  analysis,	  MERCK	  (Cat#	  101217)	  
-­‐ MgSO4-­‐	  magnesium	  sulfate,	  dried,	  ROTH	  (Cat#	  0261.1)	  




-­‐ Yeast	  extract,	  Fluka	  (Cat#	  70161)	  
-­‐ Ampicillin	  sodium	  salt,	  Sigma	  (Cat#	  A9518)	  
-­‐ Kanamycin	  sulfate,	  Applichem	  (Cat#	  A1493)	  
-­‐ Tris-­‐HCl	  Trizma®	  hydrochloride,	  Sigma	  (Cat#	  T5941)	  
-­‐ rLysozyme,	  Novagen	  (Cat#	  71110)	  
-­‐ Benzonase	  nuclease	  >99%	  pure,	  Novagen	  (Cat#	  70664)	  
-­‐ PMSF	  Phenylmethanesulfonyl	  fluoride,	  Sigma	  (Cat#	  P7626)	  
-­‐ MgCl2	  hexahydrate,	  GR	  for	  analysis,	  MERCK	  (Cat#	  105833)	  
-­‐ Urea,	  PlusOne™	  Urea,	  GE	  Healthcare	  (Cat#	  171319-­‐01)	  
-­‐ NaH2PO4	  Sodium	  dihydrogen	  phosphate,	  GR	  for	  analysis,	  MERCK	  (Cat#	  104873)	  
-­‐ Imidazole,	  Fluka	  (Cat#	  56748)	  
-­‐ SDS	  solution,	  Fluka	  (Cat#	  5030)	  
-­‐ NaCl,	  Sigma	  (Cat#	  S3014)	  
-­‐ NaN3	  Sodium	  azide	  extra	  pure,	  MERCK	  (Cat#	  106688)	  
-­‐ Coomassie	  (Bradford)	  Protein	  Assay	  Kit,	  Thermo	  Scientific	  (Cat#	  23200)	  
5.1.3 Protein	  array	  spotting	  and	  probing	  
-­‐ SU8	  epoxide	  coated	  glass	  slides,	  TOP	  Oberflächen	  GmbH	  
-­‐ Micro	  Cleaning	  solution,	  Telechem	  (Cat#	  MCS)	  
-­‐ MilliQ	  purified	  water	  
-­‐ 16K	  protein	  microarrays	  representing	  15,770	  UniPEx	  library	  clones	  
-­‐ 642	  arrays	  
-­‐ 642+H	  arrays	  
-­‐ DIG	  Easy	  Hyb	  (500	  ml),	  Roche	  (Cat#:	  70013-­‐016)	  
-­‐ GIBCO®	  PBS	  pH	  7.2,	  Phosphate	  Buffered	  Saline	  (10x),	  Invitrogen	  (Cat#	  70013-­‐065)	  
-­‐ TWEEN®	  20,	  SIGMA®	  (Cat#	  P1379-­‐100ML)	  
-­‐ TritonTM	  X-­‐100,	  SIGMA®	  (Cat#	  T9284)	  
-­‐ Milk	  powder:	  sofortlösliches	  Magermilch-­‐Pulver,	  Fixmilch	  instant	  
-­‐ Goat	  anti-­‐human	  IgG	  (H+L)	  Alexa	  Fluor®	  647,	  Invitrogen	  (Cat#	  A-­‐21445)	  




-­‐ Microscope	  coverslips	  
-­‐ Humidity	  chamber	  
5.1.4 Instruments	  
-­‐ Hard-­‐Shell®	  Thin-­‐Wall	  96-­‐Well	  Skirted	  PCR	  Plates,	  Bio-­‐Rad	  (Cat#	  HSP-­‐9611)	  
-­‐ 96-­‐Well	  Filter	  plates,	  Porvair	  Sciences	  (Cat#	  360112)	  
-­‐ Pipetboy:	  BIOHIT,	  Midi	  Plus	  
-­‐ Analytical	  Balance:	  PioneerTM	  PA1	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
14CM,	  OHAUS®	  
-­‐ Balance:	  PioneerTM	  PA2102,	  OHAUS®	  
-­‐ Magnetic	  stirrer:	  Variomag	  poly,	  Thermo	  Scientific	  
-­‐ Magnetic	  stirring	  hotplate:	  MR3002	  S8,	  Heidolph	  
-­‐ Centrifuge	  5415D,	  Eppendorf	  
-­‐ Shaker:	  MS	  2	  Minishaker,	  IKA®	  
-­‐ Platform	  shaker:	  Titramax	  1000,	  Heidolph	  
-­‐ Arium®	  p50	  UV,	  Sartorius	  stedium	  biotech	  
-­‐ Heraeus	  Multifuge	  3S-­‐R,	  Thermo	  Electron	  Corporation	  
-­‐ EpochTM	  Microplate	  Spectrophotometer,	  BioTek®	  
-­‐ Take3TM	  Micro-­‐Volume	  Plate,	  BioTek®	  
-­‐ Hybridisation	  oven:	  Model,	  SHEL	  LAB	  
-­‐ Agilent	  G2534-­‐60005	  Hybridization	  Gasket	  Slide	  -­‐	  1	  microarray	  per	  slide	  format,	  Agilent	  
Technologies	  
-­‐ Agilent	  G2534A	  Microarray	  Hybridization	  Chamber,	  Agilent	  Technologies	  
-­‐ DNA	  Microarray	  Scanner	  with	  “Surescan	  high-­‐Resolution	  Technology”,	  Agilent	  
Technologies	  
-­‐ ZebaTM	  96-­‐well	  Desalt	  Spin	  Plate,	  PIERCE	  
-­‐ GeneAmp®	  PCR	  System	  2700,	  Applied	  BiosystemsTM	  
-­‐ Freezer:	  5812,	  Thermo	  Scientific	  
-­‐ OmniGrid	  100,	  GeneMachines	  




-­‐ XCell	  SureLock™	  Mini	  Electrophoresis	  Cell,	  Invitrogen™	  
-­‐ PowerEase®	  500	  Power	  Supply	  
	  
	  





6.1 Clinical	  samples	  and	  IgG	  purification	  
6.1.1 Clinical	  samples	  
Plasma	   samples	   were	   collected	   within	   the	   ongoing	   “Molecular	   Epidemiology	   Colorectal	  
Cancer	   Study	   of	   Austria”	   (CORSA)	   conducted	   at	   the	   Institute	   of	   Cancer	   Research,	   Medical	  
University	  of	  Vienna	  (P.	  Hofer	  et	  al.,	  2011;	  P.	  Hofer	  et	  al.,	  2012).	  In	  the	  CORSA	  study	  more	  than	  
6,000	   Caucasian	   participants	   were	   recruited	   since	   May	   2002	   within	   a	   large,	   province-­‐wide	  
screening	  project	   in	   the	  province	  Burgenland,	  Austria.	   This	  CRC	   screening	  program	  uses	   fecal	  
occult	  blood	   tests	   (FOBT)	  and	  all	  habitants	  of	  Burgenland	  aged	  between	  40	  and	  80	  years	  are	  
invited	   annually	   to	   take	   part	   in	   the	   screening.	   Positively	   tested	   participants	   receive	   further	  
diagnostic	  workup	   including	   colonoscopy	   and	   are	   asked	   to	   take	   part	   in	   the	   CORSA	   study.	   All	  
participants	   (100%)	   had	   a	   positive	   FOBT	   and	   underwent	   complete	   colonoscopy	   up	   to	   the	  
cecum.	   Together	   with	   a	   whole	   blood	   sample,	   a	   short	   questionnaire	   on	   demographic	   and	  
anthropometric	   factors,	   dietary	   and	   smoking	   status	   was	   obtained.	   Heparinized	   plasma	   was	  
immediately	   centrifuged	   at	   2000	   g	   for	   10	  minutes	   and	   stored	   at	   -­‐80°C.	   All	   participants	   gave	  
written	   informed	   consent	   and	   the	   study	   was	   approved	   by	   the	   institutional	   review	   board	  
“Ethikkommission	  Burgenland”.	  
	  	  	  	  	  CRC	  cases	  were	  patients	  with	  histologically	  confirmed,	  previously	  untreated	  CRC,	  newly	  
diagnosed	  within	  this	  screening	  program.	  For	  statistical	  analysis	  the	  polyp	  group	  was	  classified	  
by	   their	   histopathology	   as	   high-­‐risk	   and	   low-­‐risk	   polyps	   according	   to	   the	   amount	   of	   villous	  
elements.	   Adenomatous	   villous,	   adenomatous	   tubulovillous,	   and	   co-­‐occurrence	   of	  
adenomatous	   tubular	   with	   tubulovillous	   polyps	   were	   classified	   as	   high-­‐risk	   polyps	   while	  
hyperplastic	  polyps	  and	  adenomatous	  tubular	  polyps	  were	  assigned	  to	  the	  low-­‐risk	  group.	  The	  
control	  group	  comprised	  individuals	  with	  positive	  FOBT	  who	  underwent	  complete	  colonoscopy	  
to	   the	   cecum	   and	   exhibited	   no	   pathological	   findings.	   Participants	   with	   serious	   medical	  




For	   this	   project,	   512	   plasma	   samples	   of	   the	   CORSA	   cohort	   were	   provided,	   in	   a	   test	   set	  
(n=128)	   and	   a	   validation	   set	   (n=384).	   Test	   set	   and	   validation	   set	   comprised	   of	   four	   groups,	  
based	  on	  histology	  (CRC,	  high-­‐risk	  polyp,	  low-­‐risk	  polyp	  and	  control).	  The	  four	  groups	  comprised	  
32	  samples	  each	  (test	  set)	  and	  96	  samples	  each	  (validation	  set),	  respectively.	  	  
For	   optimization	   experiments,	   serum	   samples	   from	   6	   healthy	   volunteers	   from	   the	  
laboratory	  were	  collected	  in	  Vacuette®	  serum	  clot	  activator	  containing	  collection	  tubes	  (Greiner	  
Bio-­‐One,	  Austria).	  After	  collection,	  blood	  was	  incubated	  at	  room	  temperature	  for	  30-­‐45	  minutes	  
to	  allow	  clotting.	  Serum	  was	  obtained	  by	  centrifugation	  of	  samples	  for	  15	  minutes	  at	  2000rcf,	  
aliquoted	  in	  cryovials	  and	  stored	  at	  -­‐80°C	  until	  use.	  	  
6.1.2 IgG	  purification	  
6.1.2.1 Principle	  
Human	   immunoglobulin	   or	   antibodies	   are	   glycoproteins	  with	   akin	   structure	   and	   function	  
with	  around	  90%	  protein	  and	  10%	  carbohydrate	  content.	  The	  five	  classes	  of	   immunoglobulin,	  
IgG,	  IgM,	  IgA,	  IgD	  and	  IgE	  together	  represent	  the	  humoral	  immunity	  in	  humans.	  They	  consist	  of	  
two	  identical	  copies	  of	  each	  “L”	  light	  and	  “H”	  heavy	  polypeptide	  chains	  that	  are	  held	  together	  
by	  noncovalent	  and	  covalent	  disulfide	  bonds	  forming	  a	  bilaterally	  symmetric	  structure.	  The	  type	  
of	  heavy	  chain	  determines	  the	  Ig	  class	  and	  L	  and	  H	  chains	  each	  contain	  a	  “V”	  variable	  domain	  
having	   highly	   conserved	   amino	   acid	   composition	   that	   comprise	   the	   antigen	   binding	   sites	   or	  
epitopes	  (Figure	  10).	  	  
The	   immunoglobulin	  G	  or	   IgG	  having	  Gamma	  heavy	   chains	   is	   the	  most	   abundant	   class	  of	  
antibody	  in	  human	  serum	  comprising	  75%	  of	  total	  Igs	  with	  a	  concentration	  of	  approximately	  10-­‐
16mg/ml.	   IgG	   acts	   predominantly	   in	   the	   secondary	   immune	   response	   and	   can	   cross	   the	  
placenta,	  unlike	  the	  other	  classes	  of	   Ig	   in	  humans,	  and	  is	  responsible	  for	   long-­‐term	  immunity,	  
memory	   antibodies,	   neutralization,	   agglutination,	   opsonization	   and	   complement	   fixation.	   The	  





Figure	   10.	   Structure	   of	   IgG	   in	   3D	   (left)	   and	   schematic	   representation	   (right).	   Symmetrical	  
structure	   formation	   of	   two	   heavy	   and	   two	   light	   chains	   and	   terminal	   ends	   containing	   antigen	  
binding	  site	  (“Western	  Blotting,”	  2012).	  
The	   three	   main	   methods	   for	   purifying	   antibodies	   involve	   physicochemical	   fractionation,	  
class-­‐specific	   affinity	   and	   antigen-­‐specific	   affinity.	   The	   MelonTM	   Gel	   systems	   by	   Thermo	  
Scientific	  uses	  physicochemical	  fractioning	  with	  resins	  that	  binds	  to	  non-­‐IgG	  proteins	  present	  in	  
serum	   and	   other	   sources,	   resulting	   in	   selective	   IgG	   fractionation	   in	   the	   flow-­‐through.	   It	   also	  
allows	  removal	  of	  interfering	  proteins	  such	  as	  BSA	  from	  the	  sample	  (Meulenbroek,	  2002;	  “The	  
human	  IgG	  subclasses,”	  n.d.;	  Thermo	  Scientific,	  2010a).	  
6.1.2.2 Procedure	  
IgG	  from	  the	  samples	  were	  purified	  using	  the	  MelonTM	  Gel	  Spin	  Plate	  Kit	  for	  IgG	  Screening	  
(Cat#45206,	   Thermo	   Scientific)	   according	   to	   the	   manufacturer’s	   protocol.	   The	   factory	   seals	  
from	  the	  MelonTM	  Gel	  Spin	  Plate	  are	  removed,	  the	  plate	  is	  placed	  on	  a	  white	  wash	  plate	  and	  the	  
entire	   assembly	   is	   centrifuged	   to	   remove	   the	   storage	   buffer.	   Afterwards,	   the	   Spin	   plate	   is	  
positioned	   on	   the	   blue	   Collection	   plate	   and	   100ul	   of	   plasma	   samples	   diluted	   1:10	   in	   the	  
MelonTM	  Gel	   Purification	  Buffer	   is	   applied	   to	   a	  well	   in	   the	  MelonTM	  Gel	   Spin	   Plate.	   To	  obtain	  
enough	   IgG	   for	   each	   sample,	   a	   total	   of	   300ul	   of	   the	   1:10	   diluted	   sample	   was	   prepared	   and	  
applied	  to	  3	  wells	  on	  the	  spin	  plate.	  Samples	  are	  incubated	  in	  the	  spin	  plate	  for	  5	  minutes	  on	  an	  




assembly	  at	  1,000xg	  for	  2	  minutes.	  The	  IgG	  solution	  from	  each	  sample	  is	  pooled	  and	  stored	  at	  
4°C	  until	  use	  in	  protein	  microarray	  experiment	  and	  at	  -­‐80°C	  for	  longer	  storage.	  	  
6.1.3 Protein	  expression	  and	  purification	  
6.1.3.1 Principle	  
The	  UniPEx	  library	  (purchased	  from	  ImaGenes,	  Source	  Bio-­‐Science)	  applied	  in	  this	  study	  is	  a	  
protein	  expression	  library	  consisting	  of	  clones	  in	  two	  differently	  modified	  pQE	  (Qiagen)	  vectors.	  
The	   library	   contains	   15,456	   in-­‐frame	  ORF	   clones	   representing	   7,390	   human	   genes	   that	  were	  
deduced	   from	   100,000	   sequenced	   clones	   of	   human	   fetal	   brain,	   T-­‐cells	   and	   lung	   protein	  
expression	   libraries.	  The	  UniPEx-­‐1	   clones	   (n=7560)	  are	   inserted	   into	  pQE30NST	  vector	   (Figure	  
11)	  that	  allows	  auto-­‐inducible	  expression	  of	  His6-­‐tagged	  fusion	  proteins	  and	  contain	  Ampicillin	  
and	   Kanamycin	   resistances.	   UniPEx-­‐2	   clones	   (n=7896)	   are	   inserted	   into	   pQE80LSN	   vector	  
(Figure	   12)	   that	   allows	   IPTG-­‐inducible	   expression	   of	   His6-­‐tagged	   fusion	   proteins	   and	   contain	  
Ampicillin	   resistance	   gene	   (Source	   BioScience	   imaGenes,	   2012).	   The	   clones	   of	   the	   642	   and	  
642+H	  arrays	  were	   inserted	   into	  pQE30NST	  vector	  and	  auto-­‐induction	  strategy	  was	  optimized	  
as	  in	  (Stempfer	  et	  al.,	  2010;	  Syed,	  2012).	  	  
6xHis	  tags	  have	  affinity	  to	  Ni-­‐NTA	  and	  when	  expressed	  in	  fusion	  with	  the	  UniPEx	  proteins,	  
this	  property	  can	  be	  utilized	  to	  purify	  these	  proteins	  from	  the	  expression	  host.	  6xHis	  tags	  are	  
reported	   to	   be	   uncharged,	   non-­‐interfering	   to	   secretion,	   compartmentalization,	   folding	   of	   the	  
fusion	  proteins	   in	   the	  cell,	   structure	  and	  function	  of	   the	  purified	  proteins.	  Nitrilotriacetic	  acid	  
(NTA)	  is	  a	  tetradentate	  chelating	  absorbent	  that	  binds	  to	  four	  ligand-­‐binding	  sites	  of	  the	  nickel	  
ion	   that	   leaves	   two	   sites	   for	   6xHis	   tag	   to	   interact	   as	   shown	   in	   Figure	   13.	   The	   6xHis	   tagged	  
proteins	   are	   bound	   to	   Ni-­‐NTA	   coupled	   to	   Sepharose®	   CL-­‐6B	   resin	   (Qiagen)	   that	   have	   the	  





Figure	  11.	  Vector	  pQE30NST	  with	  an	  N	  terminus	  6xHis	  tag	  (“www.imagenes-­‐bio.de,”	  2012).	  
Denaturing	  of	  the	  proteins	  prior	  to	  applying	  onto	  Ni-­‐NTA	  would	  solubilize	  the	  proteins	  and	  
completely	  reveal	  the	  6xHis	  tag	  making	  binding	  more	  efficient.	  After	  several	  rounds	  of	  washing,	  
the	   expression	   host	   cell	   debris	   and	   non-­‐specific	   protein	   products	   are	   excluded,	   leaving	   only	  
6xHis	   tagged	   proteins.	   With	   low	   10-­‐20mM	   concentrations	   of	   imidazole	   in	   washing	   buffers	  
prevents	   the	   possibility	   of	   low	   affinity	   binding	   of	   non-­‐tagged	   endogenous	   proteins	   with	  
histidine	   clusters.	   A	   higher	   concentration	   of	   imidazole	   (>100mM)	   competes	   with	   6xHis	   tag	  





Figure	   12.	   pQE80LSN	   vector	   containing	   an	   N	   terminal	   6xHis	   tag	   and	   a	   lacq	   gene	  





Figure	   13.	   Polyhistidine	   tag	   (blue)	   and	   Ni-­‐NTA	   (red)	   interaction	   through	   2	   free	   sites	   (2	   black	  
dashed	   lines	   on	   the	   left	   side	   of	   Ni2+)	   on	   the	  Ni2+	   ion.	   	   The	  Ni-­‐NTA	   is	   attached	   to	   the	   agarose	  
beads	  (black).	  (Qiagen,	  2003).	  
6.1.3.2 Recombinant	  protein	  expression	  and	  purification	  
For	  use	   in	  expressing	   the	  UniPEx-­‐1	  and	   the	  642	   (Syed,	  2012)	  and	  642+H	   (Stempfer	  et	   al.,	  
2010)	  clones,	  the	  Auto-­‐induction	  medium	  was	  prepared	  and	  autoclaved	  as	  follows:	  solution	  1:	  
50X	   consisting	   of	   25%	   Glycerol,	   2.5%	   Glucose	   and	   10%	   α-­‐Lactose,	   solution	   2:	   20X	   with	   1M	  
Na2HPO4,	  1M	  KH2PO4	  and	  0.5M	  (NH4)2SO4,	  solution	  3:	  1000X	  with	  1M	  MgSO4	  and	  TB	  medium	  
with	  12g	  Tryptone,	  24g	  Yeast	  extract,	  4ml	  Glycerol	  with	  pH	  adjusted	  to	  7.5.	  All	  three	  solutions	  
1,	  2	  and	  3	  and	  TB	  medium	  are	  autoclaved	  prior	  to	  use.	  The	  final	  medium	  consisted	  of	  100µg/ml	  
Ampicillin	  and	  15µg/ml	  Kanamycin	  added,	  after	  filtration	  through	  0.2μm	  syringe	  filter	  (Thermo	  
Scientific,	   Cat#	   190-­‐2520),	   to	   20ml	   solution	   1,	   50ml	   solution	   2,	   1ml	   solution	   3	   and	   929ml	   TB	  
medium.	  	  
The	   IPTG-­‐induction	   medium,	   for	   expressing	   UniPEx-­‐2	   clones	   contained	   solution	   1:	   50X	  
consisting	  of	  25%	  Glycerol,	   2.5%	  Glucose	  and,	   solution	  2:	   20X	  with	  1M	  Na2HPO4,	   1M	  KH2PO4	  
and	  0.5M	  (NH4)2SO4,	  solution	  3:	  1000X	  with	  1M	  MgSO4	  and	  TB	  medium	  with	  12g	  Tryptone,	  24g	  
Yeast	   extract,	   4ml	   Glycerol	   pH=7.5.	   All	   three	   solutions	   1,	   2	   and	   3	   and	   TB	   medium	   were	  




through	  0.2μm	  syringe	  filter	  (Thermo	  Scientific,	  Cat#	  190-­‐2520)	  added	  into	  to	  20ml	  solution	  1,	  
50ml	  solution	  2,	  1ml	  solution	  3	  and	  929ml	  TB	  medium.	  
1.2ml	  of	   induction	  medium	  was	  pipetted	   into	  pre-­‐weighed	  deep	  96-­‐well	  microtiter	  plates	  
and	   3µl	   of	   E.	   coli	   glycerol	   stock	   was	   inoculated.	   The	   inoculated	   plates	   were	   sealed	   with	  
AirPore™	  permeable	  sheets	   (Qiagen,	  Cat#	  19571)	  and	   incubated	  at	  37°C	  for	  8	  hours,	   then	  for	  
auto-­‐induction	   16	   hours	   at	   30°C	   shaking	   at	   1000rpm,	   for	   IPTG	   induction	   30°C	   for	   12	   hours	  
shaking	  at	  1000rpm,	  and	  later	  were	  added	  90ul	  of	  100mM	  IPTG	  solution	  and	  incubated	  4	  more	  
hours	   at	   37°C.	   The	   induced	   cultures	   were	   centrifuged	   at	   3500rpm	   for	   10	   minutes	   and	   the	  
supernatant	  was	  discarded.	  The	  wet	  biomasses	  of	  the	  cultures	  are	  determined	  by	  weighing	  the	  
plate	  and	  subtracting	  the	  mass	  of	  the	  empty	  plate	  weighed	  earlier.	  	  
For	  protein	  purification	  from	  cultures,	  the	  bacterial	  pellets	  are	  added	  90	  µL	  of	  50	  mM	  Tris-­‐
HCl	  pH=7.5,	  with	  a	  multi-­‐channel	  pipette,	  for	  lysis	  and	  resuspended	  by	  vortexing	  10	  seconds	  at	  
high	  speed.	  The	  plates	  were	  rapidly	  frozen	  by	  putting	  in	  liquid	  nitrogen	  for	  10-­‐15	  seconds	  and	  
thawed	   in	   cold	   water.	   Then,	   10	   µL	   Enzyme-­‐Mix	   (30KU/µl	   rLysozyme,	   25U/µl	   Benzonase	  
Nuclease,	  1mM	  PMSF	  and	  2mM	  MgCl2)	  in	  50mM	  Tris-­‐HCl	  pH=7.5	  was	  added	  and	  shaken	  for	  30	  
min	  at	  37°C	  1000rpm.	  In	  between	  the	  plates	  were	  sonicated	  3	  times	  for	  1	  min	  each	  with	  100%	  
ultrasonic.	  Plates	  were	  rapidly	  frozen	  in	  liquid	  nitrogen	  and	  thawed	  by	  sonicating	  with	  100%	  for	  
3	  minutes;	  freeze	  thaw	  was	  repeated	  twice.	  Afterwards,	  20μl	  1M	  NaOH	  was	  added	  in	  each	  well	  
and	  shaken	  for	  10	  minutes	  at	  1000rpm,	  and	  added	  400μl	  Denaturation	  buffer,	  pH=7	  (8M	  Urea,	  
50mM	   pH=7.12	   Na-­‐P-­‐Buffer,	   20mM	   Imidazole	   and	   0.01%	   SDS).	   The	   solution	   was	   mixed	   by	  
shaking	  for	  30	  minutes	  at	  1000rpm.	  Plates	  were	  centrifuged	  for	  45	  minutes	  at	  4600rpm	  at	  20°C	  
to	   separate	  proteins	   from	  cell	  debris	   and	   transfer	   supernatant	   containing	  protein	   into	  empty	  
deep	   96-­‐well	   plate.	   In	   the	  meanwhile,	  Ni-­‐NTA	   agarose	   beads	  were	   equilibrated	   by	   preparing	  
10ml	   beads	   per	   50ml	   Falcon	   tubes,	   washing	   with	   3X	   volume	  Wash	   buffer	   and	   adding	  Wash	  
buffer	   until	   25%	   slurry	   (10ml	   light	   blue	   colored	   Ni-­‐NTA	   beads	   and	   30ml	   Wash	   buffer)	   was	  
obtained.	   After	   equilibration,	   200μl	   25%	   Ni-­‐NTA-­‐agarose	   was	   added	   into	   each	   well,	   while	  
constantly	  mixing	  Ni-­‐NTA	  agarose	   in	  between.	  Suspension	  was	  shaken	  for	  1	  hour	  at	  1000rpm	  




were	  washed	   three	   times	  with	  400μl	  wash	  buffer	   (pH=7,	  6M	  Urea,	  50mM	  pH=7.12	  Na2HPO4,	  
0.3M	  NaCl	   and	   20mM	   Imidazole)	   and	   centrifuged	   each	   time	   for	   2	  minutes	   at	   500	   xg.	   Finally	  
filter	   plates	   were	   placed	   onto	   collection	   plates,	   75μl	   elution	   buffer,	   pH=7	   (50mM	   pH=7.12	  
Na2HPO4,	  0.3M	  NaCl,	  500mM	  Imidazole,	  0.01%	  SDS	  and	  0.01%	  NaN3)	  was	  added	  to	  each	  well	  
and	  centrifuged	  for	  2	  minutes	  at	  500	  xg	  to	  collect	  protein	  eluates.	  The	  purified	  protein	  eluates	  
were	   stored	  at	  +4°C	  until	   determining	  protein	   concentration	  and	  at	   -­‐20°C	   for	   longer	   storage.	  
Pipetting	  during	  protein	  purification	  has	  been	  carried	  out	  with	  multi-­‐channel	  pipettors.	  	  
The	  Na-­‐P-­‐Buffer	  was	  prepared	  by	  titrating	  1M	  Na2HPO4	  with	  1M	  NaH2PO4	  to	  obtain	  pH	  of	  
7.12.	  The	  0.01%	  SDS	  and	  0.01%	  NaN3	  was	  added	  to	  Denaturation	  buffer	  or	  Elution	  buffer	  after	  
filtration	   through	   0.2μm	   syringe	   filter	   (Thermo	   Scientific,	   Cat#	   190-­‐2520).	   The	   Denaturation	  
buffer,	  Wash	   buffer	   and	   Elution	   buffers	  were	   filtered	  with	   0.22µm	  Nitrocellulose	  membrane	  
(Millipore,	  Cat#	  R0HA46038)	  before	  use.	  	  
6.1.4 Protein	  quantification	  	  
Concentration	  of	  purified	  IgG’s	  was	  measured	  with	  the	  Protein	  A280	  protocol	  of	  the	  Take	  3	  
Session	  on	  the	  Epoch	  Microplate	  Spectrophotometer.	  2μl	  of	  protein	  elution	  buffer	  was	  read	  as	  
blank	   and	   2μl	   of	   protein	   sample	   was	   read	   twice.	   The	   concentration	   values	   obtained	   from	  
reading	  were	  corrected,	  as	  the	  human	  IgG	  absorbance	  relative	  to	  BSA	  standard	  has	  a	  ratio	  of	  
0.6	  (Thermo	  Scientific,	  2010b,	  p.	  9).	  	  
The	   purified	   recombinant	   protein	   concentrations	   for	   protein	   microarray	   printing	   were	  
measured	   with	   the	   Coomassie	   (Bradford)	   Protein	   Assay	   Kit	   (Thermo	   Scientific,	   Cat#	   23200).	  
Bradford	   Assay	   standards	   (Thermo	   Scientific,	   Cat#	   23209)	  were	   serially	   diluted	   to	   125μg/ml,	  
250μg/ml,	   500μg/ml,	   750μg/ml,	   1000μg/ml,	   1500μg/ml	   and	   2000μg/ml	   concentrations	   and	  
measured	   in	   triplicates.	  5μl	  of	   the	  calibrated	  standard	  solutions	  or	  5μl	  of	   the	  purified	  protein	  
eluates	   was	   added	   into	   150μl	   Coomassie	   (Bradford)	   reagent	   in	   flat	   bottom	   96-­‐well	   ELISA	  
microplates	   (Greiner	   Bio-­‐one,	   Cat#	   655001)	   and	   mixed	   shortly	   by	   vortex	   at	   500rpm.	   The	  
solutions	  were	   incubated	  at	  room	  temperature	  for	  10	  minutes	  and	  absorbances	  were	  read	  at	  
595nm	  with	  the	  Protein	  A280	  Microplate	  protocol	  on	  the	  Epoch	  Microplate	  Spectrophotometer.	  




for	  each	  BSA	  standard	  against	  its	  concentration	  in	  μg/ml.	  	  A	  liner	  regression	  was	  plotted	  for	  the	  
entire	   set	   of	   standards	   and	   the	   linear	   fit	   equation	   was	   used	   for	   calculation	   of	   protein	  
concentration	  from	  their	  absorbances.	  	  
6.1.5 SDS-­‐PAGE	  
As	   quality	   control	   for	   purified	   IgGs,	   NuPAGE®	  Novex	   4-­‐12%	   Bis-­‐Tris	   1.0mm,	   17	  well	   SDS-­‐
PAGE	  was	  performed.	  Samples	  contained	  2μg	  of	  IgG,	  2.5μl	  NuPAGE®	  LDS	  buffer	  (4X)	  and	  dH2O	  
upto	  10μl	  total	  volume.	  IgG’s	  were	  denatured	  at	  70°C	  for	  10	  minutes	  and	  loaded	  onto	  gel	  wells.	  
PAGE	  was	  assembled	  in	  Vertical	  Mini-­‐Gel	  Electrophoresis	  chamber	  and	  filled	  with	  1X	  NuPAGE®	  
MOPS	   SDS	   Running	   buffer	   (1X).	   10μl	   of	   SeeBlue®	   Plus2	   pre-­‐stained	   standard	   was	   used	   as	  
protein	  size	   ladder.	  Electrophoresis	  was	  performed	   for	  50	  minutes,	  125mA	  per	  gel	  with	  200V	  
constant.	  The	  gels	  were	  stained	  with	  1X	  Roti®-­‐Blue	  staining	  solution	  (1X	  Methanol	  and	  3X	  dH2O)	  
overnight	   shaking	   at	   500rpm	   and	   destained	  with	   dH2O	   three	   times	  washing	   for	   1	   hour	   each	  
while	  shaking	  at	  500rpm.	  	  
To	  verify	  recombinant	  protein	  purification,	  NuPAGE®	  Novex	  4-­‐12%	  Bis-­‐Tris	  1.0mm,	  17	  well	  
SDS-­‐PAGE	  was	  performed	  with	  additional	  reagents	  such	  as	  NuPAGE®	  Reducing	  agent	  in	  sample	  
loading	   solution	   and	   NuPAGE®	   Antioxidant	   in	   gel	   running	   buffer.	   Samples	   contained	   5μl	   of	  
protein	  eluate,	  2.5μl	  NuPAGE®	  LDS	  buffer	   (4X),	  1μl	  NuPAGE®	  Reducing	  agent	   (10X)	  and	  1.5μl	  
dH2O.	   The	   sample	   preparations	  were	   denatured	   at	   70°C	   for	   10	  minutes	   and	   loaded	  onto	   gel	  
wells.	   PAGE	   is	   assembled	   in	   a	   Vertical	   Mini-­‐Gel	   Electrophoresis	   chamber,	   filled	   with	   1X	  
NuPAGE®	   MOPS	   SDS	   Running	   buffer	   (1X)	   and	   added	   500μl	   NuPAGE®	   Antioxidant.	  
Electrophoresis,	   gel	   staining	   and	   destaining	   procedures	   were	   done	   according	   to	   procedures	  
mentioned	  above	  for	  IgG	  protein	  quality	  control	  with	  SDS-­‐PAGE.	  
6.1.6 Protein	  microarray	  production	  
6.1.6.1 Principle	  
Microarrays	   that	   contain	   thousands	   of	   immobilized	   proteins	   offer	   the	   possibility	   to	   study	  
aspects	   such	   as	   expression,	   binding,	   interactions,	   folding	   and	   specificity	   in	   a	   highly	   parallel,	  
miniaturized	   and	   automated	   manner.	   As	   proteins	   are	   more	   complex	   than	   DNA	   by	   having	  




surface	  chemistry	  they	  are	  spotted	  onto,	  unfold	  and	  lose	  their	  activity,	  or	  lose	  binding	  ability	  to	  
the	  partner	  molecules.	  The	   type	  of	   surface	   to	  use	   for	  protein	  microarray	  experiments	   should	  
fulfill	   the	   following	   criteria:	   high	   binding	   capacity,	   retain	   ability	   of	   protein,	   low	   variability	  
between	  slides,	  high	  signal-­‐to-­‐noise	  ratio	  and	  long	  shelf	  life.	  	  
Covalent	  binding	  of	  proteins	  to	  functional	  groups	  on	  array	  surface	  allows	  strong,	  permanent	  
binding	   and	   will	   be	   persistent	   during	   stringent	   washing	   conditions.	   The	   most	   common	  
functional	  groups	  used	   for	  protein	  microarray	   immobilization	  are	  epoxides,	  aldehydes	  and	  N-­‐
hydroxy	   succinimidyl	   esters	   (NHS	   esters)	   that	   allow	   for	   random	   covalent	   binding	   through	  
reactive	   groups	   (Kusnezow	   &	   Hoheisel,	   2003;	   Seurynck-­‐Servoss,	   Baird,	   Rodland,	   &	   Zangar,	  
2007).	  Epoxy-­‐coated	  slides	  are	  derivatized	  from	  epoxysilane	  and	  proteins	  bind	  to	  the	  epoxide	  
ring	  with	  their	  amine,	  hydroxyl	  and	  thiol	  groups	  (Figure	  14)	  (Arrayit,	  2012).	  Several	  studies	  have	  
reported	  epoxy	  surfaces	  to	  posses	  lower	  background	  and	  high	  signals	  with	  low	  spotted	  proteins	  
and	  higher	  sensitivity	  compared	  to	  other	  covalent	  binding	  reactive	  group	  surfaces	  (Kusnezow	  &	  
Hoheisel,	  2003;	  Li	  &	  Reichert,	  2002;	  Seong,	  2002).	  The	  current	  study	  employed	  ARChip-­‐Epoxy	  
(Preininger,	  Bodrossy,	  Sauer,	  Pichler,	  &	  Weilharter,	  2004),	  an	  epoxy	  based	  photoresist,	   that	   is	  
ideal	   for	  microarray	   surface	   application	  due	   to	   advantages	   such	   as	   high	   stability	   in	   chemical,	  
thermal	  and	  radiation	  exposures,	  biocompatibility,	  rigidness	  and	  inexpensiveness	  (Deepu,	  Sai,	  &	  





Figure	   14.	   Proteins	   binding	   covalently	   to	   epoxide	   groups	   on	   the	   SuperEpoxy	   surface	   from	  
ArrayIt®	   (Arrayit,	   2012)	   through	   amine-­‐	   (top),	   hydroxyl-­‐	   (middle)	   and	   thiol-­‐	   (bottom)	   groups.	  
These	  reactive	  groups	  approach	  the	  epoxy	  group	  as	  a	  nucleophile,	  resulting	  in	  covalent	  coupling	  
of	  the	  protein	  to	  surface.	  	  
Protein	   spotting	   technique	   is	   another	   vital	   factor	   in	   the	   final	   performance	   of	   protein	  
microarrays.	  Two	  main	  approaches	  exist	   to	  deposit	   the	  proteins	  onto	  arrays:	   contact	  printing	  
with	   pins	   that	   touch	   the	   surface	   and	   Piezo-­‐electric	   non-­‐contact	   printing.	   Among	   contact	  




compared	  to	  solid	  tip	  pins	  (Figure	  15	  Hook	  et	  al.,	  2010;	  Kambhampati,	  2004,	  p.	  169).	  Flat	  tipped	  
split	  pins	  exist	  that	  can	  prevent	  damage	  to	  slide	  surface	  by	  reducing	  the	  contact	  force.	  Protein	  
spotting	  is	  carried	  out	  in	  humidity	  and	  temperature	  controlled,	  dust-­‐free	  condition.	  	  
	  
Figure	  15.	  Microarray	  printing	  scheme	  from	  spotting	  or	  source	  plate	  via	  solid,	  quilled/split	  pins	  
or	  ink-­‐jet	  Peizo-­‐electric	  tips	  onto	  the	  slide	  (Hook	  et	  al.,	  2010).	  	  
6.1.6.2 Procedure	  
16K	  microarrays,	  containing	  the	  expressed	  proteins	  from	  UniPEx	  library	  15,770	  clones,	  were	  
printed	  with	   48	  946MP2	  pins	   (ArrayIt®)	   in	   a	   contact	   printer	   the	  NanoPrint™	   LM210	  Platform	  
(Telechem)	  with	   relative	   humidity	   set	   at	   45%,	   as	   provided	   by	  Michael	   Stierschneider	   at	   AIT,	  
Tulln,	  Austria.	  An	  array	  consisted	  of	  48	  subarrays,	  each	  containing	  384	  protein	  spots	  in	  source	  
position	  from	  384	  well	  spot-­‐plates	  (Biozym,	  Cat#	  621521),	  in	  4	  by	  12	  format,	  each	  protein	  being	  
printed	  in	  duplicates	  of	  60μm	  diameter	  spots.	  Slides	  were	  scanned	  immediately	  after	  printing,	  
using	   the	   Tecan	   laserscanner	   LS200	  with	   full	   PMT	   at	   532nm	  excitation	   for	   auto-­‐fluorescence	  




The	  642	  (Syed,	  2012)	  and	  642+H	  (Stempfer	  et	  al.,	  2010)	  designated	  arrays	  are	  printed	  with	  8	  
SMP3	  pins	  in	  OmniGrid	  ™	  100,	  GeneMachines	  by	  Ronald	  Kulovics	  at	  AIT,	  Muthgasse	  11,	  Vienna,	  
Austria.	   The	   642	   arrays	   consist	   of	   642	   sero-­‐reactive	   clones	   deduced	   by	   candidate	   marker	  
screening	   experiment	   on	   macroarrays	   containing	   38,016	   human	   proteins,	   derived	   from	   a	  
human	   fetal	   brain	   library	   (Büssow,	  Nordhoff,	   Lübbert,	   Lehrach,	  &	  Walter,	   2000),	  with	   breast	  
cancer	  and	  healthy	   control	   sera	  pools.	   The	  642+H	  arrays	   in	  addition	   to	   the	  642	  array	   clones,	  
contain	   76	   potential	   tumor	   associated	   antigens	   derived	   from	   candidate	   marker	   SEREX	  
(serological	  identification	  of	  antigens	  by	  recombinant	  expression	  cloning)	  and	  fetal	  brain	  cDNA	  
expression	   library	  screenings	  of	  brain	  and	   lung	  cancer	  serum	  samples.	   	  642	  and	  642+H	  arrays	  
were	  in	  spotted	  4	  identical	  subarrays,	  with	  each	  spots	  printed	  in	  duplicates.	  Spot	  positions	  on	  
each	  subarrays	  are	  consistent	  with	  the	  protein	  source	  position	  on	  the	  384	  well	  spotting	  plate	  
(Biozym,	   Cat#	   621521).	   All	   arrays	   were	   spotted	   onto	   ARChip	   epoxy	   (Preininger	   et	   al.,	   2004)	  
coated	  slides	  (T_O_P	  Oberflaechen	  GmbH)	  at	  55%	  relative	  humidity.	  
6.1.7 Protein	  microarray	  assay	  	  
6.1.7.1 Principle	  
Protein	   microarray	   assay	   procedure	   follows	   the	   same	   principles	   as	   in	   conventional	  
immunoassays	   such	   as	   ELISA:	   prior	   to	   applying	   the	   sample,	   the	   arrays	   are	  blocked	   to	   reduce	  
background	  and	  non-­‐specific	  binding	  to	  reactive	  surfaces	  around	  the	  spots.	  Several	  wash	  steps	  
using	   buffer	   solutions	   to	   eliminate	   unbound	   blocking	   buffer	   content,	   without	   disturbing	   the	  
spotted	  proteins.	   Protein	   interaction	   can	  be	  monitored	  by	  direct	   detection	  or	   via	   chemically,	  
radioisotopically	   or	   fluorescently	   labeled	   proteins.	   Direct	   detection	   methods	   include	   mass	  
spectrometry	   (MS),	   surface	   Plasmon	   resonance	   (SPR)	   and	   grating-­‐coupled	   surface	   Plasmon	  
resonance	  (GC-­‐SPR),	  atomic	  force	  microscopy	  (AFM),	  micro-­‐electromechanical	  systems	  (MEMS)	  
cantilevers	  and	  quartz-­‐crystal	  microbalance	  analysis	   (QCM).	   Labeled	  proteins	  are	  detected	  by	  
direct,	   indirect	   or	   in	   sandwich	   assay	   approaches	   (Figure	   16).	   The	   most	   commonly	   applied	  
approach	  is	  sandwich	  assay,	  where	  samples	  containing	  target	  proteins	  are	  applied	  onto	  arrays	  
allowing	   for	   binding	   with	   probe	   on	   arrays	   to	   occur.	   A	   secondary	   labeled	   detection	   antibody	  




labeling	  is	  frequently	  applied	  for	  protein	  microarray	  readout	  and	  is	  now	  the	  method	  of	  choice	  
and	  among	  the	  different	   fluorophores	  Cy3	   (green,	  532nm	  excitation	  maximum)	  and	  Cy5	   (red,	  
635	  excitation	  maximum)	  are	  popular	  (Cretich,	  Damin,	  Pirri,	  &	  Chiari,	  2006).	  	  
	  
Figure	  16.	  Labeled-­‐probe	  protein	  microarray	  detection	  approaches	  (Cretich	  et	  al.,	  2006).	  
6.1.7.2 Procedure	  
Protocol	  1.	  Protein	  microarray	  assays	  were	  performed	  with	  a	  static	  condition	  in	  a	  humidity	  
chamber	  with	   the	   coverslip	  approach	   (the	  microarray	   slides	  were	   covered	  with	  a	  microscope	  
glass	   coverslip	   (Paul	   Marienfeld,	   Cat#	   0101242)	   after	   applying	   serum	   sample	   or	   detection	  
antibody	  and	  put	  in	  a	  humid	  horizontal	  chamber).	  The	  protein	  microarrays	  were	  blocked	  using	  
DIG	  Easy	  Hyb	  (Roche)	  blocking	  solution	  for	  30	  minutes,	  then	  washed	  three	  times	  for	  5	  minutes	  
each	  with	  PBSTw	  (1X	  PBS,	  0.01%	  Tween20)	  and	  rinsed	  once	  with	  dH2O.	  Slides	  were	  spin	  dried	  
for	  2	  minutes	  at	  900rpm	  centrifugation.	  Serum	  or	  plasma	  samples	  were	  diluted	  1:10	  in	  PBSTw	  
and	   75μl	   is	   applied	   onto	   arrays	   and	   covered	   with	   microscope	   slide	   coverslips.	   Samples	   are	  
incubated	   2	   hours	   in	   horizontal	   humidity	   chamber	   and	   slides	   then	  washed	   three	   times	   for	   5	  
minutes	  each	  with	  PBSTw	  and	  rinsed	  once	  with	  dH2O.	  Slides	  were	  spin	  dried	  for	  2	  minutes	  at	  




IgG	   Alexa	   Fluor®	   647	   (Invitrogen,	   Cat#	   A-­‐21445)	   diluted	   1:5000	   in	   PBSTw	   for	   1	   hour	   in	   the	  
humidity	   chamber.	   After	   wash,	   rinse	   and	   drying	   procedures	   as	   mentioned	   above,	   the	   slides	  
were	  scanned	  using	  Agilent	  high-­‐resolution	  microarray	  scanner	  with	  Red	  channel	  (Helium-­‐Neon	  
laser	  at	  633nm)	  at	  10-­‐micron	  resolution.	  	  Scanned	  images	  are	  saved	  in	  TIFF	  (Tagged	  Image	  File	  
Format)	  image	  format.	  	  
Protocol	  2.	  Protein	  microarray	  assays	  were	  performed	  using	  Agilent	  Hybridization	  chamber	  
and	   gasket	   slides.	   Each	   purified	   IgG	   samples	   from	   patient	   plasma	  were	   prepared	   to	   contain	  
0.3μg/μl	   protein	   concentration	   in	   PBSTx	   (1X	   PBS,	   0.01%	   TritonX-­‐100)	   with	   3%	   milk	   powder	  
(PBSTx+MP3%)	   and	   500μl	   (0.3μg/μl	   IgG)	   of	   sample	   was	   applied	   onto	   gasket	   slide	   (Agilent	  
Technologies,	   Cat#	   G2534-­‐60005),	   the	   protein	  microarray	   was	   placed	   facing	   the	   sample	   and	  
hybridization	   chamber	   (Agilent	   Technologies,	   Cat#	  G2534A)	  was	   assembled	   tightly.	   Assembly	  
was	   checked	   for	   bubbles	   and	   rotated	   to	   ensure	   only	   a	   single	   bubble	  moves	   freely	   along	   the	  
sample.	   After	   4	   hours	   of	   sample	   incubation	   at	   12rpm	   at	   25°C	   in	   hybridization	   oven	   (Agilent	  
Technologies,	   Cat#	   G2545A),	   the	   assembly	   was	   taken	   apart,	   microarray	   slides	   were	   washed	  
with	  PBSTx	  3	   times	   for	  5	  minutes	  each	  and	  rinsed	  with	  dH2O.	  Microarray	  slides	  are	  then	  spin	  
dried	   for	   2	   minutes	   at	   900rpm	   centrifugation.	   Goat	   anti-­‐human	   IgG	   Alexa	   Fluor®	   647	  
(Invitrogen,	  Cat#	  A-­‐21445)	  was	  diluted	  1:20,000	  in	  PBSTx+MP3%	  and	  500μl	  was	  applied	  to	  each	  
microarray	  slides.	  Fluorescent	  labeling	  was	  done	  for	  1	  hour	  at	  12rpm	  at	  25°C	  and	  arrays	  were	  
washed	  with	  PBSTx	  3	   times	   for	  5	  minutes	  each	  and	  rinsed	  with	  dH2O.	  Microarray	  slides	  were	  
then	  spin	  dried	  for	  2	  minutes	  at	  900rpm	  centrifugation	  and	  were	  scanned	  using	  Agilent	  high-­‐
resolution	  microarray	   scanner	   with	   Red	   channel	   (Helium-­‐Neon	   laser	   at	   633nm)	   at	   10-­‐micron	  
resolution.	  	  Scanned	  images	  are	  saved	  in	  TIFF	  (Tagged	  Image	  File	  Format)	  image	  format.	  	  
6.1.8 Image	  processing	  and	  data	  analysis	  
6.1.8.1 Principle	  
The	   scanned	   slide	   image	   obtained	   from	   protein	  microarray	   experiment	   is	   used	   to	   obtain	  
intensity	  values	  corresponding	  to	  each	  feature	  on	  the	  array.	  This	  is	  achieved	  by	  using	  gridding	  
files	  in	  .GAL	  file	  format	  generated	  during	  in-­‐house	  printing	  or	  provided	  from	  the	  manufacturer	  




determined	   followed	   by	   subtraction	   of	   the	   background	   intensity	   value	   from	   the	   median	  
intensity	  value	  or	  the	  total	  intensity	  value	  of	  features.	  
The	   final	   intensity	   values	   then	   undergo	   transformation	   by	   the	   inverse/reciprocal	  method	  
that	   transforms	   expression	   values	   into	   fold-­‐change	   or	   logarithmic	   transformations	   that	   takes	  
logarithm	   base	   2	   values.	   Both	   methods	   are	   appropriate	   to	   map	   up-­‐	   or	   down-­‐regulation	   of	  
proteins,	   however,	   the	   following	   analyses	   for	   identifying	   differentially	   abundant	   proteins	   are	  
problematic.	   Subsequently	   the	   transformed	   data	   are	   normalized	   due	   to	   variations	   in	   the	  
experiments	   that	   may	   arise	   during	   microarray	   experiment	   procedures	   (Babu,	   2004).	  
Normalization	   methods	   range	   from	   centering	   all	   arrays	   at	   the	   median	   to	   Quantiles	  
normalization	   that	   distributes	   all	   intensity	   values	   equally.	   Quantiles	   normalization	   reduces	  
variability	   of	   arrays	   while	   retaining	   reproducibility	   among	   same	   conditions.	   Final	   step	   in	   the	  
processing	   of	   microarray	   screening	   experiment	   data	   is	   to	   perform	   class	   classification	   or	  
prediction	   analyses	   according	   to	   the	   class	   of	   samples,	   for	   example	   tumor	   vs	   non-­‐tumor,	   and	  
result	  in	  a	  group	  of	  features	  being	  differentially	  abundant	  among	  classes	  (Sánchez-­‐Cabo,	  Rainer,	  
Dopazo,	  Trajanoski,	  &	  Hackl,	  2011).	  	  
Class	   comparison	   analysis	   is	   applied	   for	   comparing	   two	   or	   more	   predefined	   classes	   by	  
determining	   the	   significance	   of	   individual	   proteins	   with	   univariate	   permutation	   tests.	   The	  
univariate	   permutation	   test	   computes	   a	   t-­‐test	   (two	   classes)	   or	   F-­‐test	   (multiple	   classes)	  
separately	  for	  each	  protein	  using	  the	  normalized	  log-­‐intensities	  of	  the	  microarrays.	  The	  t-­‐test	  is	  
based	   on	   comparing	   the	   differences	   in	   mean	   log-­‐intensities	   between	   classes	   relative	   to	   the	  
variation	  expected	  in	  the	  mean	  differences	  and	  the	  variation	  is	  calculated	  assuming	  that	  all	  the	  
samples	  are	  independent	  (Wright	  &	  Simon,	  2003).	  	  	  	  
The	  aim	  of	  class	  prediction	  analysis	  is	  to	  develop	  models	  for	  utilizing	  gene	  expression	  profile	  
to	   predict	   the	   class	   of	   future	   samples.	   The	   gene	   expression	   profile	   or	   predictors	   includes	  
proteins	   that	   are	   differentially	   expressed	   between	   the	   predefined	   classes	   at	   the	   univariate	  
parametric	  significance	   level	   less	   than	  the	  specified	  threshold.	  The	  proteins	  are	  ranked	  based	  
on	   the	   extent	   to	   which	   they	   are	   individually	   differentially	   expressed	   among	   the	   classes	   and	  




greedy-­‐pairs	  method	  described	  by	  Bo	  and	  Jonassen	  (Bo	  &	  Jonassen,	  2002).	  This	  approach	  ranks	  
proteins	   based	   on	   their	   individual	   t-­‐scores	   on	   the	   training	   set	   and	   selects	   the	   best	   ranked	  
protein	  and	   finds	   the	  one	  other	  protein	   that	   in	   combination	  provides	   the	  best	  discrimination	  
using	  as	  a	  measure	   the	  distance	  between	  of	   the	   two	  classes	  with	   regard	   to	   the	   two	  proteins	  
when	  projected	  to	  the	  diagonal	  linear	  discriminant	  axis.	  The	  two	  selected	  proteins	  are	  removed	  
from	   the	   protein	   set	   and	   the	   procedure	   is	   repeated	   on	   the	   remaining	   set	   until	   the	   specified	  
numbers	  of	  proteins	  have	  been	  selected.	  In	  another	  approach,	  namely	  Support	  Vector	  Machine	  
Recursive	  Feature	  Elimination	  (SVM	  RFE)	  that	  uses	  an	  SVM	  classifier	  trained	  on	  the	  data	  to	  rank	  
proteins	   according	   to	   their	   contribution	   to	   the	  prediction	  performance.	   It	   utilizes	   a	  weighted	  
linear	  combination	  of	  the	  protein	  expressions	  as	  a	  discriminator	  between	  the	  two	  classes	  and	  
this	   is	  selected	  to	  maximize	  the	  margin,	  or	  the	  distance	  between	  the	  worst	  classified	  samples	  
and	  the	  discriminant	  plane.	  After	  removing	  proteins	  having	  low	  absolute	  value	  of	  weight	  in	  the	  
linear	  combination,	  a	  new	  SMV	  classifier	  is	  developed	  using	  the	  remaining	  proteins,	  then	  a	  new	  
linear	  discriminant	   is	   found	  and	  the	  process	  continues	   iteratively	  until	   the	  desired	  number	  of	  
protein	  is	  left	  (R.	  M.	  Simon,	  2003).	  	  
The	   multivariate	   predictor	   for	   determining	   to	   which	   of	   the	   two	   classes	   a	   given	   sample	  
belongs	   is	   achieved	   by	   several	  methods:	   the	  Compound	   Covariate	   Predictor,	  Diagonal	   Linear	  
Discriminant	   Analysis,	   Nearest	   Neighbor	   Predictor,	   Nearest	   centroid	   Predictor	   and	   Support	  
Vector	  Machine	  Predictor.	  The	  Compound	  Covariate	  Predictor	  is	  a	  weighted	  linear	  combination	  
of	   log	   intensities	   for	   proteins	   that	   are	   univariately	   significant	   at	   the	   specified	   level	   and	   at	   a	  
stringent	   significance	   level,	   proteins	   reduced	   in	   the	   multivariate	   predictor.	   The	   univariate	   t-­‐
statistics	  for	  comparing	  the	  classes	  are	  used	  as	  weights	  that	  are	  determined	  by	  the	  large	  values	  
of	   log-­‐intensities	   pre-­‐disposing	   to	   one	   class	   (Radmacher,	   McShane,	   &	   Simon,	   2002).	   The	  
Diagonal	  Linear	  Discriminant	  Analysis	  differs	  from	  Compound	  Covariate	  Predictor	  as	   it	   ignores	  
correlations	  among	  the	  proteins	   in	  order	  to	  avoid	  over-­‐fitting	  the	  data.	  The	  Nearest	  Neighbor	  
Predictor	  uses	  Euclidean	  distance	  as	  the	  distance	  metric	  and	  the	  vector	  of	  log-­‐intensities	  as	  the	  
expression	  profile.	  The	  nearest	  neighbor	   in	   the	  training	  set	  of	   the	  test	  samples	   is	  determined	  
and	   the	   class	   of	   that	   nearest	   neighbor	   (with	   a	   similar	   expression	   profile)	   is	   taken	   as	   the	  




the	  Nearest	  Centroid	  Predictor,	  the	  centroid	  of	  each	  training	  samples	  belonging	  to	  two	  classes	  
are	   determined.	   The	   centroid	   is	   a	   vector	   containing	   mean	   log-­‐intensities	   of	   the	   training	  
samples.	  The	  distance	  of	  the	  expression	  profile	  for	  the	  test	  sample	  to	  each	  of	  the	  two	  centroids	  
is	   measured	   and	   the	   test	   sample	   is	   predicted	   to	   belong	   to	   the	   class	   corresponding	   to	   the	  
nearest	  centroid	  (R.	  M.	  Simon,	  2003).	  
The	  Bayesian	  Compound	  Covariate	  Predictor	  selects	  the	  differentially	  expressed	  proteins	  for	  
distinguishing	  two	  classes	  in	  a	  cross-­‐validated	  training	  set,	  the	  compound	  covariate	  is	  computed	  
which	   is	   the	  weighted	  average	  of	   the	   log	  expression	  values	  of	   the	  selected	  proteins,	  with	  the	  
weights	  being	  the	  t-­‐statistics	  of	  the	  differential	  expression	  in	  that	  training	  set.	  The	  means	  of	  the	  
Gaussian	  distributions	  of	  the	  compound	  covariate	  scores	  of	  samples	  in	  each	  class	  in	  the	  training	  
set	  differ	  among	  classes	  but	   the	  variances	  are	  assumed	  to	  be	  equal	  and	  a	  pooled	  estimate	   is	  
used.	   The	   cross-­‐validated	   misclassification	   rates	   of	   the	   multivariate	   class	   predictor	   are	  
computed	  using	  Leave-­‐one-­‐out	  cross-­‐validation	  (LOOCV)	  that	  omits	  one	  sample	  at	  a	  time	  and	  
with	   each	   samples	   omitted,	   the	   entire	   analysis	   is	   carried	   out	   from	   the	   beginning.	   A	   list	  
containing	  genes	  that	  are	  univariately	  significant	  on	  the	  reduced	  training	  sample	  is	  constructed	  
and	  the	  accuracy	  of	  the	  prediction	  is	  recorded	  (R.	  M.	  Simon,	  2003).	  
For	   more	   than	   two	   classes,	   Binary	   Tree	   Prediction	   is	   applied	   that	   combines	   the	   above	  
mentioned	  prediction	  methods	  as	   the	   foundation.	  At	  each	  node	  of	  a	  binary	   tree	   the	  samples	  
are	   classified	   into	   two	   subsets	   of	   classes	  with	   the	   possibility	   of	   one	   or	   both	   having	  multiple	  
subclasses.	   The	   splitting	   of	   classes	   is	   accomplished	   with	   the	   fewest	   cross-­‐validated	  
misclassification	   errors	   and	   all	   the	   possibilities	   are	   tested	   to	   choose	   the	   best	   one	   that	   is	  
accepted	  as	  a	  node	  of	  the	  binary	  tree.	  The	  resulting	  groups	  undergo	  the	  same	  procedure	  again	  
until	  each	  group	  contains	  only	  one	  class	  (R.	  M.	  Simon,	  2003).	  
6.1.8.2 Procedure	  
Scanned	  microarray	   TIFF	   image	  were	   loaded	  onto	  GenePix®	   Pro	  Microarray	  Acquisition	  &	  
Analysis	   Software	  version	  6.0.	   Images	  were	  viewed	   in	   red	  channel	  at	  635nm	   laser	   range.	  The	  
GAL	   file	   produced	   during	   printing	   of	   microarray	   slides	   was	   used	   to	   navigate	   the	   blocks	   and	  




slides	  were	  analyzed	  and	  the	  results	  containing	   fluorescence	   intensity	  values	  were	  saved	   in	  a	  
GPR	   file	   format.	   Fluorescence	   intensity-­‐medians	   after	   subtraction	   of	   local	   background	   were	  
obtained	  from	  the	  scanned	  array	  images	  and	  used	  for	  the	  data	  analysis.	  
Statistical	  analysis	  of	  the	  microarray	  experiments	  was	  performed	  using	  the	  BRB-­‐	  ArrayTools	  
software	   3.8.1	   [http://linus.nci.nih.gov/	   BRB-­‐ArrayTools.html]	   developed	   by	   Dr.	   R	   Simon	   and	  
Amy	   Peng	   Lam	   (R.	   Simon	   et	   al.,	   2007).	   Prior	   to	   analysis,	   data	   was	   normalized	   by	  Quantiles	  
normalization	   and	   intensity	   values	   are	   Log2	   transformed.	   Classifier	  models	   for	   discriminating	  
patient	   groups	   were	   built	   using	   class	   prediction	   analysis	   with	   seven	   methods:	   Compound	  
Covariate	  Predictor,	  Diagonal	  Linear	  Discriminant	  Analysis,	  k-­‐Nearest	  Neighbor	   (using	  k=1	  and	  
3),	   Nearest	   Centroid,	   Support	   Vector	  Machines	   and	   Bayesian	   Compound	   Covariate	   Predictor.	  
LOOCV	   receiver	   operating	   curve	   (ROC)	   analyses	   from	   the	   Bayesian	   Compound	   Covariate	  







7.1 Tumor	  autoantibody	  candidate	  marker	  screening	  using	  Protocol	  1	  
The	   current	   thesis	   commenced	   with	   tumor	   autoantibody	   candidate	  marker	   screening	   by	  
utilizing	  the	  16K	  protein	  microarray	  and	  the	  assay	  was	  performed	  according	  to	  the	  Protocol	  1	  
procedures	  described	   in	  Methods	   section	  6.1.7.2,	  with	  122	   samples	  belonging	   to	   four	   clinical	  
samples	  groups:	  Colon	  carcinoma	   (n=31),	  High	   risk	  polyps	   (n=31),	   Low	   risk	  polyps	   (n=30)	  and	  
Healthy	   controls	   (n=28).	   The	   16K	   protein	   microarrays	   were	   produced	   previously	   from	   the	  
UniPEx	   library	   (purchased	   from	   ImaGenes,	   Source	  Bio-­‐Science)	   containing	   15,456	   clones.	   The	  
recombinant	  proteins	  encoded	  by	  each	  clones	  were	  expressed	  and	  purified	  according	  to	  section	  
6.1.3.2	  and	  printing	  of	  the	  16K	  protein	  microarray	  was	  carried	  out	  with	  settings	  given	  in	  section	  
6.1.6.2.	   The	   plasma	   samples	   were	   diluted	   in	   a	   1:30	   ratio	   and	   applied	   onto	   the	   16K	   protein	  
microarrays	   by	   covering	   with	   a	   glass	   microscope	   coverslip	   to	   distribute	   samples.	   Detection	  
antibody	  goat	  anti-­‐human	  IgG	  Alexa	  Fluor®	  647	  (Invitrogen,	  Cat#	  A-­‐21445)	  was	  used	  to	  detect	  
protein	  binding	  and	  slide	  images	  were	  obtained	  by	  a	  fluorescent	  microarray	  slide	  scanner.	  The	  
resulting	   values	   from	   foreground	   median	   intensity	   with	   background	   intensity	   subtracted,	  
obtained	  after	  image	  analysis	  were	  used	  for	  statistical	  analyses.	  Data	  were	  normalized	  over	  the	  
median	  of	  the	  reference	  array.	  	  
The	  order	  of	  the	  total	  122	  samples	  was	  randomized	  and	  processed	  in	  3	  runs	  on	  3	  different	  
days,	  with	  48	  samples	  in	  each	  of	  the	  first	  two	  runs	  and	  27	  samples	  within	  the	  third	  run.	  Samples	  
are	   displayed	   according	   to	   the	   experimental	   run	   to	   check	   for	   homogeneity	   using	  
multidimensional	   scaling	   with	   Euclidean	   Distance.	   Samples	   are	   found	   to	   be	   moderately	  
homogeneous	   as	   can	  be	   seen	   from	   figure	   17,	  where	  overall	   clustering	  of	   samples	  within	   the	  






Figure	   17.	   Multidimensional	   scaling	   of	   the	   three	   runs	   of	   the	   candidate	   marker	   screening	  
experiment	   using	   median	   over	   reference	   array	   normalized	   intensity	   data.	   Clustering	   in	   122	  
samples	  based	  on	  15053	  genes,	  using	  the	   first	  3	  components	   (covering	  45%	  of	   total	  variation)	  
obtained	  using	  the	  Euclidean	  distance	  metric.	  Blue-­‐	  Run	  1,	  Pink-­‐	  Run	  2	  and	  Green-­‐	  Run	  3.	  	  
Diagonal	  Linear	  Discriminant	  Analysis	  Classifier	  
	  
3-­‐Nearest	  Neighbor-­‐Classifier	  
	   	  Class	   Sensitivity	   Specificity	   PPV	   NPV	  
	  
Class	   Sensitivity	   Specificity	   PPV	   NPV	  
Control	   0.2	   0.87	   0.333	   0.769	  
	  
Control	   0.133	   0.609	   0.1	   0.683	  
High	  risk	  	   0.29	   0.846	   0.391	   0.778	  
	  
High	  risk	  	   0.226	   0.484	   0.13	   0.647	  
Carcinoma	   0.129	   0.593	   0.098	   0.667	  
	  
Carcinoma	   0.129	   0.418	   0.07	   0.585	  
Low	  risk	   0.267	   0.652	   0.2	   0.732	  
	  
Low	  risk	   0.133	   0.533	   0.085	   0.653	  
	   	   	   	   	   	   	   	   	   	   	  1-­‐Nearest	  Neighbor-­‐Classifier	  
	   	   	  
Nearest	  Centroid	  Classifier	  
	   	  Class	   Sensitivity	   Specificity	   PPV	   NPV	  
	  
Class	   Sensitivity	   Specificity	   PPV	   NPV	  
Control	   0.267	   0.804	   0.308	   0.771	  
	  
Control	   0.2	   0.848	   0.3	   0.765	  
High	  risk	  	   0.258	   0.758	   0.267	   0.75	  
	  
High	  risk	  	   0.387	   0.813	   0.414	   0.796	  
Carcinoma	   0.194	   0.637	   0.154	   0.699	  
	  
Carcinoma	   0.129	   0.626	   0.105	   0.679	  
Low	  risk	   0.2	   0.772	   0.222	   0.747	  
	  
Low	  risk	   0.267	   0.707	   0.229	   0.747	  
Table	  2.	  Performance	  of	  classifiers	  between	  the	  Colon	  cancer	  test	  set	  groups	  with	  4	  prediction	  




Class	  prediction	  analysis	  was	  carried	  out	  to	   identify	  classifiers	  able	  to	  distinguish	  between	  
the	  4	  groups	  of	  clinical	  samples,	  using	  multiple	  methods:	  Nearest	  Centroid	  Predictor,	  Diagonal	  
Linear	   Discriminant	   Analysis	   and	   K	   nearest	   neighbor	   analysis	   with	   K=1	   and	   3.	   Genes	   were	  
selected	  based	  on	  a	  significance	  level	  of	  p<0.001.	  The	  mean	  correct	  classification	  rate	  of	  the	  6	  
classifiers	   comparing	   all	   methods	   was	   22-­‐25%	   after	   LOOCV.	   Sensitivity	   and	   specificity	   values	  
ranged	  from	  13-­‐38%	  and	  48-­‐87%,	  respectively	  (Table	  2).	  	  At	  p<0.05	  significance	  threshold,	  639	  
classifiers	  were	  deduced	  with	  22-­‐30%	  correct	  classification	  rate,	  6-­‐43%	  sensitivity	  and	  53-­‐81%	  
specificity.	  
Class	   prediction	   analysis	   between	   colon	   carcinoma	  and	  healthy	   control	   groups	  was	  made	  
with	   three	   additional	  methods,	  Compound	  Covariate	   Predictor,	  Support	  Vector	  Machines	   and	  
Bayesian	  Compound	  Covariate	  Predictor,	  a	  total	  of	  7	  methods.	  Significance	  levels	  of	  classifiers	  
were	   set	   at	   p<0.001	   and	   only	   1	   feature	   had	   passed	   this	   criterion.	  With	   significance	   level	   of	  
p<0.05,	  404	  classifiers	  were	  elucidated	  that	  had	  correct	  classification	  rate	  of	  32-­‐51%	  among	  all	  
7	  methods,	  with	   10-­‐60%	   sensitivity	   and	   specificity	   (Table	   3).	   Low	  performance	  was	   apparent	  
with	  AUC	  of	  0.295	  after	  cross-­‐validation	  from	  Bayesian	  Compound	  Covariate	  Predictor	  analysis,	  
as	  can	  been	  seen	  from	  the	  ROC	  curve	  in	  Figure	  18.	  	  
	  
Figure	  18.	  ROC	  curve	  of	  cross	  validation	  with	  Bayesian	  Compound	  Covariate	  Predictor	  analysis	  




Compound	  Covariate	  Predictor	  
	   	   	  
Diagonal	  Linear	  Discriminant	  Analysis	  Classifier	  
Class	   Sensitivity	   Specificity	   PPV	   NPV	  	  
	  
Class	   Sensitivity	   Specificity	   PPV	   NPV	  	  
Control	   0.367	   0.387	   0.367	   0.387	  
	  
Control	   0.367	   0.387	   0.367	   0.387	  
Carcinoma	   0.387	   0.367	   0.387	   0.367	  
	  
Carcinoma	   0.387	   0.367	   0.387	   0.367	  
	   	   	   	   	   	   	   	   	   	   	  1-­‐Nearest	  Neighbor	  Classifier	  
	   	   	  
3-­‐Nearest	  Neighbors	  Classifier	  
	   	  Class	   Sensitivity	   Specificity	   PPV	   NPV	  	  
	  
Class	   Sensitivity	   Specificity	   PPV	   NPV	  	  
Control	   0.6	   0.419	   0.5	   0.52	  
	  
Control	   0.5	   0.355	   0.429	   0.423	  
Carcinoma	   0.419	   0.6	   0.52	   0.5	  
	  
Carcinoma	   0.355	   0.5	   0.423	   0.429	  
	   	   	   	   	   	   	   	   	   	   	  Nearest	  Centroid	  Classifier	  
	   	   	  
Support	  Vector	  Machine	  Classifier	  
	   	  Class	   Sensitivity	   Specificity	   PPV	   NPV	  	  
	  
Class	   Sensitivity	   Specificity	   PPV	   NPV	  	  
Control	   0.267	   0.355	   0.286	   0.333	  
	  
Control	   0.333	   0.516	   0.4	   0.444	  
Carcinoma	   0.355	   0.267	   0.333	   0.286	  
	  
Carcinoma	   0.516	   0.333	   0.444	   0.4	  
	   	   	   	   	   	   	   	   	   	   	  Bayesian	  Compound	  Covariate	  Classifier	  
	   	   	   	   	   	   	  Class	   Sensitivity	   Specificity	   PPV	   NPV	  	  
	   	   	   	   	   	  Control	   0.133	   0.258	   0.148	   0.235	  
	   	   	   	   	   	  Carcinoma	   0.258	   0.133	   0.235	   0.148	  
	   	   	   	   	   	  
Table	  3.	  Performance	  of	  classifiers	  between	  the	  Carcinoma	  and	  Healthy	  control	  groups	  with	  7	  
prediction	  analysis	  methods	  at	  p<0.05	  significance	  level.	  
By	   taking	   the	   Colon	   carcinoma	   group	   as	   one	   cancer	   class	   and	   combining	   all	   other	   three	  
groups	   as	   non-­‐cancer	   class,	   prediction	   analysis	   was	   done	  with	   the	   all	   7	  methods	  mentioned	  
above.	  When	  feature	  selection	  criteria	  were	  set	  to	  P<0.001,	  15	  reactive	  proteins	  (features)	  had	  
fulfilled	   the	   criteria	   and	   their	   correct	   classification	   rate	   ranged	   from	   58-­‐67%;	   sensitivity	   and	  
specificity	   ranged	   from	   12-­‐83%	   (Table	   4)	   with	   an	   AUC	   of	   0.525	   indicating	   the	   failure	   of	  
classification	  of	  all	  the	  samples	  (Figure	  19).	  	  	  
At	   P<0.05	   significance	   level,	   class	   prediction	   analyses	   yielded	   752	   proteins	   that	   correctly	  
classified	  66-­‐72%	  of	  samples	  into	  the	  two	  groups,	  with	  3-­‐95%	  sensitivity	  and	  specificity	  (Table	  5)	  
and	   AUC	   of	   0.513	   (Figure	   20).	   The	   95%	   sensitivity	   was	   obtained	   by	   3-­‐Nearest	   Neighbors	  






Figure	  19.	  ROC	  curve	  of	  cross	  validation	  with	  Bayesian	  Compound	  Covariate	  Predictor	  analysis	  
for	  Colon	  carcinoma	  group	  vs	  Healthy	  Control,	  High	  and	  Low	  risk	  polyps	  groups	  at	  significance	  
level	  of	  p<0.001.	  AUC=0.525.	  
Compound	  Covariate	  Predictor	  
	   	   	  
Diagonal	  Linear	  Discriminant	  Analysis	  Classifier	  
Class	   Sensitivity	   Specificity	   PPV	   NPV	  	  
	  
Class	   Sensitivity	   Specificity	   PPV	   NPV	  	  
HR	  LR	  
Control	   0.692	   0.323	   0.75	   0.263	  
	  
HR	  LR	  
Control	   0.681	   0.29	   0.738	   0.237	  
Carcinoma	   0.323	   0.692	   0.263	   0.75	  
	  
Carcinoma	   0.29	   0.681	   0.237	   0.738	  
	   	   	   	   	   	   	   	   	   	   	  1-­‐Nearest	  Neighbor	  Classifier	  
	   	   	  
3-­‐Nearest	  Neighbors	  Classifier	  
	   	  Class	   Sensitivity	   Specificity	   PPV	   NPV	  	  
	  
Class	   Sensitivity	   Specificity	   PPV	   NPV	  	  
HR	  LR	  
Control	   0.725	   0.29	   0.75	   0.265	  
	  
HR	  LR	  
Control	   0.824	   0.226	   0.758	   0.304	  
Carcinoma	   0.29	   0.725	   0.265	   0.75	  
	  
Carcinoma	   0.226	   0.824	   0.304	   0.758	  
	   	   	   	   	   	   	   	   	   	   	  Nearest	  Centroid	  Classifier	  
	   	   	  
Support	  Vector	  Machine	  Classifier	  
	   	  Class	   Sensitivity	   Specificity	   PPV	   NPV	  	  
	  
Class	   Sensitivity	   Specificity	   PPV	   NPV	  	  
HR	  LR	  
Control	   0.692	   0.323	   0.75	   0.263	  
	  
HR	  LR	  
Control	   0.835	   0.194	   0.752	   0.286	  
Carcinoma	   0.323	   0.692	   0.263	   0.75	  
	  
Carcinoma	   0.194	   0.835	   0.286	   0.752	  
	   	   	   	   	   	   	   	   	   	   	  Bayesian	  Compound	  Covariate	  Classifier	  
	   	   	   	   	   	   	  Class	   Sensitivity	   Specificity	   PPV	   NPV	  	  
	   	   	   	   	   	  HR	  LR	  
Control	   0.363	   0.129	   0.55	   0.065	  
	   	   	   	   	   	  Carcinoma	   0.129	   0.363	   0.065	   0.55	  
	   	   	   	   	   	  
Table	   4.	  Performance	   of	   classifiers	   between	   the	   Carcinoma	   as	   one	   class	   and	  Healthy	   control,	  






Figure	  20.	  ROC	  curve	  of	  cross	  validation	  with	  Bayesian	  Compound	  Covariate	  Predictor	  analysis	  
for	  Colon	  carcinoma	  group	  vs	  Healthy	  control,	  High	  and	  Low	  risk	  polyps	  groups	  at	  significance	  
level	  of	  p<0.05.	  AUC=0.513.	  
Compound	  Covariate	  Predictor	  
	   	   	  
Diagonal	  Linear	  Discriminant	  Analysis	  Classifier	  
Class	   Sensitivity	   Specificity	   PPV	   NPV	  	  
	  
Class	   Sensitivity	   Specificity	   PPV	   NPV	  	  
HR	  LR	  
Control	   0.835	   0.258	   0.768	   0.348	  
	  
HR	  LR	  
Control	   0.813	   0.258	   0.763	   0.32	  
Carcinoma	   0.258	   0.835	   0.348	   0.768	  
	  
Carcinoma	   0.258	   0.813	   0.32	   0.763	  
	   	   	   	   	   	   	   	   	   	   	  1-­‐Nearest	  Neighbor	  Classifier	  
	   	   	  
3-­‐Nearest	  Neighbors	  Classifier	  
	   	  Class	   Sensitivity	   Specificity	   PPV	   NPV	  	  
	  
Class	   Sensitivity	   Specificity	   PPV	   NPV	  	  
HR	  LR	  
Control	   0.857	   0.097	   0.736	   0.188	  
	  
HR	  LR	  
Control	   0.956	   0.032	   0.744	   0.2	  
Carcinoma	   0.097	   0.857	   0.188	   0.736	  
	  
Carcinoma	   0.032	   0.956	   0.2	   0.744	  
	   	   	   	   	   	   	   	   	   	   	  Nearest	  Centroid	  Classifier	  
	   	   	  
Support	  Vector	  Machine	  Classifier	  
	   	  Class	   Sensitivity	   Specificity	   PPV	   NPV	  	  
	  
Class	   Sensitivity	   Specificity	   PPV	   NPV	  	  
HR	  LR	  
Control	   0.835	   0.258	   0.768	   0.348	  
	  
HR	  LR	  
Control	   0.824	   0.258	   0.765	   0.333	  
Carcinoma	   0.258	   0.835	   0.348	   0.768	  
	  
Carcinoma	   0.258	   0.824	   0.333	   0.765	  
	   	   	   	   	   	   	   	   	   	   	  Bayesian	  Compound	  Covariate	  Classifier	  
	   	   	   	   	   	   	  Class	   Sensitivity	   Specificity	   PPV	   NPV	  	  
	   	   	   	   	   	  HR	  LR	  
Control	   0.549	   0.129	   0.649	   0.089	  
	   	   	   	   	   	  Carcinoma	   0.129	   0.549	   0.089	   0.649	  
	   	   	   	   	   	  
Table	   5.	  Performance	   of	   classifiers	   between	   the	   Carcinoma	   as	   one	   class	   and	  Healthy	   control,	  
High	  risk	  polyps	  and	  Low	  risk	  polyps	  groups	  as	  the	  other	  with	  7	  prediction	  analysis	  methods	  at	  




The	  above	  results	  are	  significantly	  poor	  and	  these	  failures	  were	  possibly	  due	  to	  the	  use	  of	  
total	   plasma	   that	   could	  have	  matrix	   effect	   or	   heterophile	   antibodies	   interfering	   in	   the	   assay,	  
which	  may	  be	  overcome	  by	  using	  purified	  IgG	  instead	  of	  total	  plasma.	  Several	  serious	  flaws	  and	  
defects	   in	   the	   screening	  experiment	   results	  and	  array	   images	  could	  be	  viewed	  as	  depicted	   in	  
Table	  6	  and	  Figure	  21.	  	  
№	   Type	  of	  defect	   Possible	  cause	  
1	   Low	  classification	  
performance	  in	  screening	  
experiment	  
Interference	  of	  plasma	  
matrix	  or	  heterophile	  
antibodies	  
2	   Uneven	  sample	  distribution	  
and	  smearing	  
Protein	  microarray	  assay	  
condition	  during	  sample	  
incubation	  
3	   Uneven	  spot	  morphology	  
Merging	  of	  spots	  
Microarray	  printing	  error	  
Table	   6.	   Type	   of	   defects	   on	   the	   processed	   arrays	   observed	   during	   the	   candidate	   marker	  
screening	  experiment	  with	  test	  set	  plasma	  samples	  and	  their	  possible	  causes.	  	  
1. 	   2.	   	  
3.	  	   	   4.	   	  
Figure	   21.	   The	   slide	   images	   displaying	   defects	   observed	   from	   candidate	   marker	   screening	  
experiment	   performed	   according	   to	   the	  Protocol	   1.	   Images	   1	   and	   2	   correspond	   to	   the	   defect	  




Due	  to	  these	  technical	  issues	  at	  hand,	  improvements	  in	  the	  Standard	  Operating	  Procedure	  
of	   protein	  microarray	   assays	  with	   clinical	   samples	   needed	   to	   be	   reviewed	   and	   optimized	   for	  
increasing	   quality	   and	   reproducibility	   of	   arrays	   and	   results.	   Taking	   into	   consideration,	   the	  





7.2 Protein	  microarray	  assay	  optimizations	  
7.2.1 Surface	  chemistries	  and	  blocking	  conditions	  
The	   foundation	   for	   any	  microarray	  experiment	   is	   the	   surface	   chemistry	   and	   for	   a	   reliable	  
and	  reproducible	  result	  it	  is	  vital	  to	  choose	  the	  correct	  one	  for	  the	  particular	  type	  of	  probe	  that	  
is	  used,	  the	  target	  to	  be	  captured	  and	  the	  detection	  methods	  applied.	  This	  holds	  true	  especially	  
in	   cases	   of	   high-­‐throughput	   experiments	   dealing	   with	   thousands	   of	   different	   probes,	   where	  
maximal	  compatibility	  of	  samples	  is	  intended.	  To	  address	  whether	  in	  our	  experiment,	  utilization	  
of	   an	   alternative	   surface	   could	   improve	   analyses,	   we	   tested	   several	   commercially	   available	  
slides	   in	   parallel	   to	   in-­‐house	   developed	   surface-­‐	   SU8	   epoxy	   along	   with	   4	   different	   blocking	  
conditions	  (Table	  7).	  Blocking	  conditions	  affect	  the	  specificity	  of	  binding	  and	  increase	  the	  true	  
signal	   intensities	  of	  the	  features	  by	  minimizing	  the	  background	  (unspecific	  bindings).	  With	  the	  
best	   combination	  of	   surface	  and	  blocking,	  we	  could	   significantly	   improve	   the	  performance	  of	  
our	  experiments.	  For	  each	  optimization	  experiments,	  642+H	  arrays	  were	  used.	  Protocol	  1	  was	  
used	   for	   this	   experiment	  with	   the	   above-­‐mentioned	   adjustments	   for	   blocking	   conditions	   and	  
instead	  employed	  serum	  sample.	  The	  serum	  samples	  and	  detection	  antibodies	  are	  applied	  onto	  
arrays	  under	  coverslips	  and	  incubation	  is	  carried	  out	  in	  horizontal	  humidity	  chamber	  that	   lack	  
mixing	  of	  samples	  over	  arrays.	  	  
No	   Slides	  
1	   NEXTERION®	  Slide	  E	  
2	   Corning®	  GAPS	  Amino-­‐silane	  
3	   PolyAn®	  3D-­‐Aldehyde	  
4	   PolyAn®	  3D-­‐Epoxy	  
5	   Corning®	  Epoxide	  
6	   NEXTERION®	  Slide	  A	  
7	   Anopoli®	  VEPO	  
8	   ArrayIt®	  Aldehyde	  
9	   SU8	  Epoxy	  
	   	  No	   Blocking	  reagents	  
1	   DIG	  Easy	  Hyb	  	  
2	   3M	  Urea+	  0.1%	  SDS	  
3	   PBSTw	  
4	   PBSTw+MP3%	  




Figure	  22.	  Representative	  Images	  of	  the	  nine	  different	  slides	  tested.	  Each	  subarray	  on	  the	  slides	  
is	  blocked	  with	  4	  different	  buffers.	  Aside	   from	  slides	  PolyAn®	  3D-­‐Epoxy	  and	  SU8	  Epoxy,	  other	  
eight	  tested	  slides	  are	  prone	  to	  smearing	  or	  have	  features	  with	  low	  intensities.	  	  
Slides	  are	  scanned	  with	  90%	  PMT	  (Photomultiplier	   tube)	   level	  and	  viewed	  using	  GenePix®	  
Pro	   Microarray	   Acquisition	   &	   Analysis	   Software	   version	   6.0	   with	   92%	   brightness	   and	   95%	  
contrast	   settings.	  With	   the	   current	  protocol,	   two	   types	  of	   epoxy	   surfaces,	   namely	  SU8	  epoxy	  
and	  PolyAn®	   3D-­‐Epoxy	   performed	   better	   compared	   to	   the	   other	   seven	   tested	   slides	   (Figures	  
22),	  with	  low	  background	  and	  high	  feature	  intensities.	  As	  with	  blocking	  reagents,	  DIG	  Easy	  Hyb	  
and	  PBSTw+MP3%	   (1X	  PBS,	   0.01%	  SDS,	   3%	  Milk	  powder)	  has	   less	   smearing	   compared	   to	  3M	  
Urea	  with	  0.1%	  SDS	  or	  PBSTween20	  without	  milk	  powder.	  	  
Surface	  SU8	  epoxy	  was	  taken	  further	  with	  the	  two	  types	  of	  blocking	  reagents	  to	  determine	  
the	  level	  of	  6xHis-­‐taged	  fusion	  proteins	  spotted	  on	  the	  642	  array	  using	  Penta-­‐His	  Alexa	  Fluor®	  










and	   PBSTw+MP3%)	   are	   quite	   comparable	   and	   from	   the	   green	   (532nm)	   foreground	   median	  
(F532	   Median)	   and	   background	   (B532)	   signal	   intensity	   values	   obtained	   from	   both	   blocking	  
conditions,	  DIG	  Easy	  Hyb	   shows	   less	  deviation	   in	   the	   foreground	  signal	  of	   features	   (Figure	  23	  
right).	   Average	   F532	  median	   intensity	   is	   increased	   by	   around	   1000	   in	   PBSTw+MP3%	  blocked	  
slides	  as	  well	  as	  the	  B532	  intensity	  by	  around	  400	  (Figure	  23	  right).	  	  
	  
Figure	  23.	  Left.	  Penta-­‐His	  Alexa	  Fluor®	  532	  (green)	  detection	  of	  6xHis	  tagged	  fusion	  proteins	  on	  
SU8	  642	  arrays	  blocked	  with	  DIG	  Easy	  Hyb	  and	  PBSTw+MP3%.	  Right.	  Average	  values	  of	  532nm	  
foreground	  median	  and	  background	  intensities	  of	  SU8	  642	  arrays	  blocked	  with	  DIG	  Easy	  Hyb	  and	  
PBSTw+MP3%.	  
It	  could	  be	  concluded	  from	  the	  above	  results	  shown	  in	  figures	  22	  and	  23	  that	  the	  utilization	  
of	  PolyAn®	  3D-­‐Epoxy	  or	  SU8	  epoxy	  surfaces	  for	  spotting	  our	  expressed	  proteins	  from	  the	  UniPEx	  
cDNA	   library	  would	  be	   feasible.	  Nonetheless,	  SU8	  epoxy	   slides	  are	  preferable	   since	   these	  are	  
cheaper	   in	   comparison	   to	   the	   commercial	   product	   PolyAn®	   3D-­‐Epoxy	   and	   the	   conditions	  
defined,	  could	  improve	  the	  performance	  of	  TAA	  detection.	  	  
7.2.2 Assay	  conditions	  
A	  very	   important	   factor	   in	  protein	  microarray	   is	   sample	  and	   reagent	  homogeneity	  on	   the	  
arrays,	   for	   reducing	  uneven	   fluorescence	  and	   smearing	  effects	  on	   the	   slides.	   Several	   systems	  
exist	  that	  allow	  for	  homogenous	  mixing,	  retain	  humidity	  and	  contamination	  of	  applied	  samples	  
during	  microarray	  probing	  procedure,	   such	   as	  OneArray®	  Microarray	  Hybridization	  Chambers	  




























Chamber	   Kits	   (Agilent®	   Technologies).	   The	   conventional	   method	   of	   probing	   in	   horizontal	  
humidity	  chamber	  may	  possibly	  be	  disadvantageous,	  as	  the	  samples	  cannot	  dispense	  over	  the	  
array,	   resulting	   in	   inhomogeneous	   distribution.	   The	   Microarray	   hybridization	   Chamber	   Kits	  
(microarray	  hybridization	  gasket	   slides	  and	  hybridization	  oven)	   from	  Agilent®	  Technologies	   in	  
comparison	  to	  horizontal	  humidity	  chamber	  were	  tested	  for	  sample	  homogeneity	  and	  binding.	  
Additionally	  sample	  incubation	  durations	  were	  tested	  to	  observe	  changes	  in	  protein	  binding	  on	  
microarrays.	  	  	  
The	   rotating	   (Agilent®	   microarray	   hybridization	   oven)	   and	   static	   (horizontal	   humidity	  
chamber)	   conditions	   were	   compared	   using	   test	   serum	   samples	   for	   durations	   of	   2,	   4	   and	   16	  
hours	  of	  sample	  incubation.	  The	  experiment	  was	  carried	  out	  according	  to	  Protocol	  1	  for	  static	  
condition	   and	   the	   Agilent	   Hybridization	   chamber	   and	   gasket	   slides	   were	   employed	   for	   the	  
rotating	   condition,	   using	   642+H	   arrays.	   Extending	   the	   duration	   of	   sample	   incubation	   could	  
potentially	   increase	  binding.	  Results	  suggest	   that	  under	  both	  static	  and	  rotating	  conditions	  of	  
sample	  incubation	  from	  2	  to	  4	  and	  16	  hours	  results	  in	  significant	  increase	  in	  signal	  intensities	  of	  
features	  (Figure	  24).	  However,	  under	  at	  4	  and	  16	  hours	  of	  incubation	  under	  rotating	  conditions,	  
several	  features	  are	  saturated,	  with	  start	  of	  saturation	  taking	  place	  between	  2	  to	  4	  hours	  and	  
clearly	   increasing	   at	   16	   hours	   incubation	   (Figure	   24	   Left.	   white	   features).	   This	   suggests	   that	  
sufficient	   binding	  of	   sample	   antibodies	  with	   capture	   antigens	   already	   takes	  place	   at	   4	   hours.	  
The	   rotating	   condition	   evidently	   yields	   more	   efficient	   binding	   of	   the	   sample	   proteins	  
(consequently	   detection	   antibodies)	   with	   the	   antigens	   on	   arrays.	   The	   scatter	   plot	   of	   log2	  
transformed	  signal	  intensities	  of	  arrays,	  processed	  under	  rotating	  and	  static	  conditions	  reveals	  
that	  under	  rotating	  conditions,	  majority	  of	  features	  have	  increased	  signal	  intensities	  (Figure	  25)	  
compared	  to	  static	  conditions.	  This	  is	  apparent	  by	  the	  higher	  density	  of	  the	  plots	  towards	  the	  x-­‐
axis	   representing	   the	   arrays	   of	   rotating	   condition.	   Therefore,	   protein	   microarray	   binding	  
experiment	   should	   be	   carried	   out	  with	   adequate	  mixing	   of	   samples	   to	   ensure	  movement	   of	  
target	  and	  capture	  proteins.	  	  
To	  test	  the	  reproducibility	  of	  the	  performance	  of	  the	  binding	  experiment	  carried	  under	  the	  




features	  on	  the	  arrays,	  for	  each	  of	  the	  4	  replicates	  of	  the	  test	  samples	  were	  computed	  with	  the	  
Pearson	   correlation	  method	   (Figure	   26).	   The	  mean	   correlation	   coefficient	   is	   calculated	   from	  
individual	  correlations	  among	  the	  sample	  replicates	  within	  each	  incubation	  time-­‐point	  groups.	  
With	  increased	  sample	  incubation	  time,	  correlations	  are	  slightly	  increasing:	  at	  2	  hours	  r=0.9,	  4	  
hours	  r=0.91	  and	  16	  hours	  r=0.915.	  Based	  on	  the	  visualization	  of	  arrays	  (Figure	  24),	  comparison	  
of	  signal	   intensities	   (Figure	  25)	  and	  reproducibility	  of	  experiments	  (Figure	  26),	   the	  decision	  to	  
modify	  the	  protein	  microarray	  binding	  experimental	  condition	  with	  rotating	  in	  the	  hybridization	  
oven	  and	  sample	  incubation	  for	  4	  hours	  was	  made.	  	  
	  
Figure	  24.	   Incubation	  of	  serum	  samples	  in	  static	  and	  rotating	  conditions	  for	  2,	  4	  and	  16	  hours.	  
The	  signal	  intensities	  of	  features	  are	  increasing	  as	  the	  sample	  incubation	  time	  increases	  from	  2	  
to	  4	  and	  16	  hours	   in	  both	  static	  and	  rotating	  conditions.	  After	  16	  hours	  of	   sample	   incubation,	  
several	  features	  are	  seen	  to	  be	  oversaturated	  (white	  features)	  for	  rotating	  condition.	  Saturation	  
level	   of	   highly	   reactive	   features	   initially	   appears	   at	   4	   hours	   of	   sample	   incubation	   in	   rotating	  
condition.	  	  


















Figure	   25.	   Scatter	   plot	   of	   Log2	   transformed	   intensity	   values	   from	   arrays	   processed	   under	  
rotating	  and	  static	  conditions,	  with	  all	   sample	   incubation	   time	  points	  combined.	  Overall	   signal	  
intensities	  are	  significantly	  increased	  in	  the	  rotating	  condition	  of	  microarray	  experiment.	  	  
	  
Figure	   26.	   Pairwise	   correlation	   plots	   and	  
corresponding	   Pearson	   correlation	   coefficients	  
of	  microarrays	  incubated	  with	  samples	  at	  three	  
time-­‐points	   (2,	   4	   and	   16	   hours),	   with	   4	  
replicates	   of	   samples	   under	   rotating	   condition.	  
Mean	   correlation	   coefficients	   are	   calculated	  
from	   correlation	   of	   all	   4	   replicates.	   The	  
correlation	   between	   replicates	   are	   consistent	  
with	  increase	  in	  sample	  incubation	  time.	  	  

















7.2.3 Blocking	  agent	  in	  sample	  and	  detection	  antibody	  dilutions	  
In	  several	  experiments,	  it	  was	  observed	  that	  using	  PBSTw	  (1X	  PBS,	  0.01%	  Tween20)	  buffer	  
as	  blank	  or	  negative	  control	  yielded	   fluorescent	   features	  on	  arrays	  with	  goat	  anti-­‐human	   IgG	  
Alexa	  Fluor®	  647	  detection.	  This	  was	  taken	  as	  an	  indication	  that	  samples	  or	  detection	  antibody	  
dilution	   conditions	   are	   lacking	   a	   blocking	   component,	   for	   example	   the	  most	   commonly	   used	  
BSA	   or	  Milk	   powder,	   that	   eliminate	   high	   background	   and	   unspecific	   binding	   by	   blocking	   the	  
reactive	  surface	  sites.	  As	  to	  compare	  with	  two	  different	  serum	  samples,	  PBST	  buffer	  was	  used	  
as	   blank	   or	   negative	   control	   and	   the	   probing	   was	   carried	   out	   as	   stated	   in	   Protocol	   1	   under	  
rotating	   condition,	   sample	   incubation	   4	   hours,	  with	   the	   inexpensive	   alternative	  milk	   powder	  
(3%)	   added	   to	   either	   sample	   or	   detection	   antibody	   dilution	   buffer	   or	   both.	   In	   addition	   to	  
detecting	   captured	   antibodies	   with	   goat	   anti-­‐human	   IgG	   Alexa	   Fluor®	   647	   antibody	   (diluted	  
1:5000),	  Penta-­‐His	  Alexa	  Fluor®	  532	  detection	  antibody	  (diluted	  1:500)	  was	  used	  to	  detect	  6xHis	  
tagged	  fusion	  proteins.	  The	  dual	  color	  (red-­‐	  human	  IgG;	  green-­‐	  6xHis-­‐tag)	  experiment	  will	  clarify	  
the	   performance	   of	   blocking	   effects	   of	   milk	   powder	   during	   probing	   with	   sample	   or	   blank	  
controls.	  	  
For	  serum	  samples	  diluted	  with	  PBSTw	  of	  detection	  antibodies	  goat	  anti-­‐human	  IgG	  Alexa	  
Fluor®	  647	  and	  Penta-­‐His	  Alexa	  Fluor®	  532,	  only	  captured	  IgG’s	  and	  not	  the	  6xHis-­‐tag	  of	  fusion	  
proteins	   was	   detected	   regardless	   of	   the	   sample	   dilution	   with	   PBSTw+MP3%	   (1X	   PBS,	   0.01%	  
Tween20,	  3%	  Milk	  powder)	  (Figure	  27	  A).	  Conversely,	  when	  detection	  antibodies	  were	  diluted	  
with	  PBSTw+MP3%,	  both	  IgG’s	  in	  samples	  and	  6xHis-­‐tag	  on	  arrays	  were	  detected,	  giving	  a	  dual-­‐
color	   fluorescence	  for	  samples	  diluted	   in	  both	  PBSTw	  and	  PBSTw+MP3%	   (Figure	  27	  B).	  Result	  
was	  consistent	  with	  buffer	  blanks,	  where	  addition	  of	  milk	  powder	  in	  detection	  antibody	  dilution	  
buffer	  was	  essential	  (Figure	  27	  C	  and	  D).	  It	  was	  concluded	  from	  figure	  29	  that	  milk	  powder	  is	  an	  
indispensable	  component	  in	  detection	  antibody	  dilution	  buffer.	  	  
As	   many	   studies	   utilized	   milk	   powder	   as	   a	   component	   in	   their	   sample	   dilution	   buffer	  
(Carlsson	  et	  al.,	  2011;	  Haab	  et	  al.,	  2001;	  Ingvarsson	  et	  al.,	  2007;	  Stempfer	  et	  al.,	  2010)	  and	  our	  
results	   are	   suggestive	   of	   the	   reduced	   number	   of	   fluorescent	   features	   (Figure	   27A),	   it	   was	  




Figure	  27.	  Effect	  of	  milk	  powder	  in	  buffer	  for	  dilutions	  of	  serum	  sample	  and	  detection	  antibodies	  
goat	   anti-­‐human	   IgG	   Alexa	   Fluor®	   647	   (Red)	   and	   Penta-­‐His	   Alexa	   Fluor®	   532	   (Green),	   with	  
incubation	  at	  rotating	  conditions.	  A.	  Serum	  sample	  diluted	   in	  buffer	  without	  (Top.	  PBSTw)	  and	  
with	  (Bottom.	  PBSTw+MP3%)	  milk	  powder	  and	  detection	  antibody	  diluted	  in	  PBSTw.	  B.	  .	  Serum	  
sample	  diluted	   in	  buffer	  without	   (Top.	  PBSTw)	   and	  with	   (Bottom.	  PBSTw+MP3%)	  milk	  powder	  
and	   detection	   antibody	   diluted	   in	   buffer	   PBSTw+MP3%.	   C.	   PBSTw	   (Top)	   or	   PBSTw+MP3%	  
(Bottom)	  buffers	   applied	   as	  blank	   control	   and	  detection	  antibody	  diluted	   in	  PBSTw.	  D.	  PBSTw	  
(Top)	  or	  PBSTw+MP3%	  (Bottom)	  buffers	  applied	  as	  blank	  control	  and	  detection	  antibody	  diluted	  
in	   PBSTw+MP3%.	   As	   seen	   in	   A	   and	   C,	   milk	   powder	   addition	   to	   samples	   reduces	   unspecific	  
binding.	   Comparing	   A	   with	   B	   and	   C	   with	   D,	   presence	   of	   milk	   powder	   in	   dilution	   buffer	   for	  
detection	   antibody	   enhances	   specific	   binding,	  making	   it	   possible	   for	   a	   dual	   color	   detection	   of	  
both	  bound	   IgG’s	   (Red)	   and	   the	   6XHis-­‐tagged	   recombinant	   proteins	   (Green)	   on	   arrays,	   that	   is	  




























7.2.4 Comparison	  of	  Buffer	  Detergents	  	  
Another	   feature	   within	   the	   protein	   microarray	   procedures	   is	   washing	   of	   slides	   between	  
different	   steps	   of	   incubation	   and	   the	   contents	   of	   these	   washing	   buffers.	   Wash	   buffers	   for	  
immunoassays	  or	  protein	  microarray	  experiments	  generally	  contain	  phosphate	  or	  Tris	  buffered	  
saline	  and	  detergent,	  most	  commonly	  used	  are	  PBS	  or	  TBS	  and	  nonionic	  surfactants	  like	  0.01%	  
Tween	   20.	   Tween	   20	   is	   a	   polyoxyethylene	   surfactant	   applied	   for	   protein	   immunoassays	   to	  
reduce	  surface	  tension.	  While	  Tween	  20	  is	  a	  relatively	  mild	  detergent,	  an	  alternative	  Triton	  X-­‐
100,	  a	  polyethylene	  oxide,	  is	  also	  used	  for	  protein	  and	  peptide	  microarray	  washing	  steps	  for	  its	  
ability	   to	   enhance	   penetration	   of	   spotted	   proteins.	   The	   Protocol	   1	   was	   used	   with	   several	  
modifications:	  The	  performances	  of	  these	  two	  detergents	  in	  wash	  buffer	  PBS	  at	  a	  concentration	  
of	   0.01%	   were	   tested	   and	   are	   designated	   PBSTx	   for	   Triton	   X-­‐100	   and	   PBSTw	   for	   Tween	   20	  
containing	   buffers.	   Serum	   samples	   and	   detection	   antibodies	   are	   diluted	   with	   buffers	   with	  
addition	   of	   3%	   milk	   powder	   (PBSTx+MP3%	   and	   PBSTw+MP3%).	   	   For	   each	   buffer	   type	   used	  
(PBSTx	  and	  PBSTw),	  2	  serum	  samples	  are	  used	  in	  4	  repeats.	  Samples	  are	  incubated	  for	  4	  hours	  
and	  the	  binding	  procedures	  are	  carried	  out	  at	  rotating	  condition.	  	  
	  
Figure	  28.	   Images	  of	   arrays	  processed	  with	  buffers	   containing	  detergents	   Tween20	  or	   TritonX	  
100.	   Increase	   in	   overall	   signal	   intensities	   are	   visually	   apparent	   for	   arrays	   washed	   with,	   and	  
incubated	   with	   samples	   and	   detection	   antibody	   diluted	   in	   PBS	   buffer	   containing	   TritonX	   100	  






Figure	  30.	  Pairwise	  correlation	  plots	  and	  corresponding	  Pearson	  correlation	  coefficients	  of	   the	  
replicates	   of	   each	  microarray	   experiment	   carried	   out	   with	   PBS	   buffer	   containing	   Tween20	   or	  
TritonX	  100.	  The	  mean	  correlation	  coefficient	  of	  the	  4	  replicates:	  Tween20	  R=0.91	  and	  TritonX	  




The	  signal	  intensities	  of	  features	  on	  arrays	  are	  higher	  for	  arrays	  processed	  with	  buffer	  PBSTx	  
than	  PBSTw	  (Figure	  28).	  In	  order	  to	  choose	  between	  TritonX	  100	  	  and	  Tween20	  	  as	  a	  detergent	  
in	   the	  PBS	  buffer	  used	   for	   sample	  dilution	  and	  microarray	  washing,	   the	  correlations	  between	  
sample	  replicates	  within	  the	  same	  experimental	  setting	  (PBSTx	  or	  PBSTw)	  was	  computed	  from	  
the	   log2	   transformed	   intensity	   values	   (Figure	   29)	   using	   the	   Pearson	   method.	   A	   higher	  
correlation	   coefficient,	   r=0.95,	   was	   achieved	   by	   samples	   processed	   with	   PBSTx	   buffers,	  
compared	  to	  PBSTw,	  r=0.91.	  The	  results	  suggest	  TritonX	  100	  detergent	  can	  be	  used	  for	  protein	  
microarray	   experiments	   yielding	   higher	   signal	   intensities	   on	   arrays	   and	   reproducibility	   for	  
sample	  replicates.	  	  
Aside	  from	  the	  results	  of	  experiments	  to	  observe	  usability	  of	  Triton	  X-­‐100	  in	  our	  protocol,	  it	  
was	   recommended	   by	   Prof.Franz	   Steindl	   (Institut	   für	   Angewandte	   Mikrobiologie,	   BOKU)	   for	  
immunoassays	  and	  protein	  microarray	  application.	  Tween	  20	  usage	  was	  replaced	  with	  Triton	  X-­‐
100	   as	   the	   component	   in	   PBS	  buffer	   for	  microarray	  washing,	   sample	   and	  detection	   antibody	  
dilutions.	  	  
7.2.5 Performance	  of	  serum	  vs	  plasma	  for	  autoantibody	  screening	  	  
As	  we	  are	  screening	  for	  potential	  tumor	  auto-­‐antibody	  biomarkers	  in	  colon	  cancer	  samples	  
and	  many	  studies	  conducted	  on	  the	  theme	  are	  primarily	  employing	  serum	  or	  plasma	  samples,	  it	  
is	  feasible	  to	  assume	  that	  the	  non-­‐IgG	  proteins	  in	  these	  samples	  could	  interfere	  with	  binding	  of	  
the	  antibodies	  to	  specific	  antigens	  present	  on	  protein	  microarrays.	  Based	  on	  this	  assumption,	  
the	  usability	  of	  IgG	  purified	  from	  patient	  plasma	  for	  profiling	  TAA	  in	  colon	  cancer	  samples	  was	  
pilot	   tested	   with	   642+H	   array.	   IgG	   was	   considered,	   as	   it	   is	   the	   prevalent	   subtype	   of	  
Immunoglobulin	  found	  in	  human	  sera,	  followed	  by	  IgA	  and	  IgM	  that	  are	  present	  in	  1:5	  ratio	  to	  
IgG.	  To	  compare	  IgG	  and	  serum	  performance	  on	  protein	  microarrays,	   IgG	  was	  purified	  from	  2	  
test	   serum	  samples	  with	  MelonTM	  Gel	   IgG	  Purification	   kit	   and	  diluted	  with	  PBSTw+MP3%	   to	  
contain	  0.3µg/µL	  of	  purified	   IgG	  and	   corresponding	   serum	  sample	  diluted	  1:30.	   Four	   replicas	  
per	  sample	  were	  incubated	  on	  the	  642+H	  	  arrays	  for	  4	  hours	  under	  rotating	  conditions	  and	  for	  1	  
hour	  with	   detection	   antibody	  goat	   anti-­‐human	   IgG	   Alexa	   Fluor®	   647	   (Red)	   diluted	   1:5000	   in	  




PBSTw	   buffer	  makes	   approximate	   concentration	   as	   0.3-­‐0.4	   µg/µL	   of	   IgG	   per	   sample.	   Sample	  
IgGs	  are	  diluted	   in	  PBSTw+MP3%	  buffer,	  whereas	  without	   the	  blocking	  effect	  of	  milk	  powder	  
very	  high	  number	  of	  unspecific	  binding	  could	  be	  observed.	  	  
Apparent	   from	  visual	   inspection	  of	   the	  processed	   slides	   in	   this	  experiment	   is	   that	   sample	  
serum	   has	   significantly	   higher	   number	   of	   reactive	   components	   to	   the	   proteins	   on	   642+H	  
microarray	  than	  sample	  IgGs	  (Figure	  30),	  suggesting	  the	  influence	  of	  non-­‐IgG	  serum	  proteins.	  
	   	  
Figure	  30.	  642+H	  array	  probed	  with	  sample	  1	  serum	  and	  IgG.	  Significant	  decrease	  in	  the	  number	  
of	   fluorescent	   features	  are	  observed	  with	  sample	   IgG,	  however	  with	  certain	  highly	   fluorescent	  
features	  consistent	  with	  both	  sample	  types.	  
	  
Figure	   31.	   Dendogram	   for	   clustering	   experiments	   using	   centered	   correlation	   and	   average	  
linkage.	   The	   correlation	   of	   sample	   replicates,	   of	   samples	   1	   and	   2,	   whether	   as	   serum	   or	   as	  




The	   dendogram	   (Figure	   31)	   for	   clustering	   experiments	   using	   centered	   correlation	   and	  
average	  linkage	  shows	  that	  reproducibility	  of	  protein	  microarray	  experiments	  utilizing	  serum	  or	  
IgG	  of	  samples	  are	  comparable	  with	  a	  mean	  correlation	  coefficient	  of	  0.85.	  	  
It	  can	  be	  viewed	  from	  figure	  32	  that	  the	  IgG	  or	  serum	  of	  the	  two	  samples	  were	  quite	  distinct	  
in	  reactivity	  over	  the	  642+H	  arrays.	  Class	  comparisons	  were	  performed	  between	  samples	  1	  and	  
2	  serum	  and	  IgG	  using	  features	  with	  a	  significance	  p	  value	  cut-­‐off	  <0.001.	  Serum	  samples	  class	  
comparison	  deduced	  73	  classifiers	  differentially	  expressed	  between	   the	   two	   samples	  and	   IgG	  
samples	   had	  49	   classifiers,	   however,	  when	   compared	   to	   serum	   sample	   classifiers	   there	  were	  
only	  13	  classifiers	  in	  common.	  	  
	  
Figure	  34.	  Left.	  Expression	  patterns	  of	  the	  first	  73	  (Serum)	  and	  47	  (IgG)	  reactive	  proteins	  with	  a	  
significance	  at	  the	  nominal	  0.001	  level	  of	  univariate	  testing	  among	  classes	  (samples	  1	  and	  2).	  	  
Right.	  Visualization	  of	  the	  samples	  distributions	  by	  Euclidean	  Distance	  multidimensional	  scaling	  
analysis.	  Sample	  serum	  (Red	  circled)	  and	   IgG	   (Purple	  circled)	  positioned	  significantly	  distant	   in	  
the	  matrix.	  	  
As	   the	   IgG	   and	   serum	   of	   the	   samples	   1	   and	   2	   are	   producing	  markedly	   separate	   clusters	  
(Figure	  31)	  and	  the	  low	  overlap	  of	  classifiers	  of	  class	  comparison	  between	  samples	  1	  and	  2,	  it	  is	  




than	   the	   serum	  would	   yield	   smaller	   number	   of	   differentially	   expressed	   genes	   on	   arrays	   that	  
have	   comparable	   performance	   of	   class	   prediction	   than	   those	   deduced	   from	   serum	   samples.	  
This	   could	   be	   due	  mainly	   to	   the	   elimination	   of	   non-­‐IgG	  proteins	   from	   the	   serum	   resulting	   in	  
possibly	   an	   enhanced	   specificity	   of	   autoantibody	   profile.	   With	   the	   above	   results	   in	  
consideration,	  purification	  of	  IgGs	  from	  sample	  serum	  or	  plasma	  was	  chosen	  to	  be	  incorporated	  







7.2.6 Summary	  of	  optimizations	  
Taking	  into	  consideration	  the	  trial	  experiments	  concerning	  aspects	  in	  different	  steps	  of	  protein	  
microarray	  processing,	  the	  following	  conclusion	  on	  the	  resulting	  protocol	  was	  made	  (Table	  8).	  
The	  protocol	  is	  designated	  Protocol	  2	  in	  the	  Methods	  section.	  	  
Conditions	  for	  
testing	  




• SU8	  epoxy	  
• PolyAn	  3D	  epoxy	  
• And	  8	  others	  
SU8	  epoxy	   SU8	  epoxy	   7.2.1	  
Blocking	   • DIG	  Easy	  Hyb	  
• PBST+Milk	  powder	  
3%	  
DIG	  Easy	  Hyb	   DIG	  Easy	  Hyb	   7.2.1	  
Effect	  of	  Milk	  
powder	  
• On	  serum	  dilution	  
• On	  purified	  IgG	  
dilution	  
• On	  Detection	  
antibody	  dilution	  


















• 2	  hours	  
• 4	  hours	  
2	  hours	   4	  hours	   7.2.2	  
Wash	  and	  
dilution	  buffer	  
• TritonX	  100	  	  
• Tween20	  
Tween	  20	   TritonX	  100	   7.2.4	  
Sample	  type	   • Serum	  
• Purified	  IgG	  
(MelonGel	  column)	  
Serum	   Purified	  IgG	   7.2.5	  
Table	  8.	  Summary	  of	  protein	  microarray	  protocol	  optimizations.	  The	  tested	  conditions	  are	  listed	  




7.3 Tumor	  autoantibody	  candidate	  marker	  screening	  using	  Protocol	  2	  
The	  tumor	  autoantibody	  candidate	  marker	  screening	  experiment	  was	  performed	  using	  the	  
newly	  established	  procedure	  designated	  Protocol	  2	  (Methods	  6.1.7.2)	  with	  the	  aim	  to	  deduce	  a	  
panel	   of	   significantly	   expressed	   features	   between	   the	   sample	   groups	   with	   an	   improved	  
significance	   and	   specificity	   as	   compared	   to	   the	   previous	   screening	   experiment	   described	   in	  
Section	   7.1.	   Due	   to	   the	   amount	   of	   analysis	   data	   and	   ongoing	   decisions	   on	   patenting	   results	  
(Intellectual	   Property	   Rights),	   the	   details	   on	   classifiers	   are	   not	   depicted	   but	   key	   findings	   are	  









Sample	  groups	  and	  number	  of	  samples	  
within	  each	  group	  
run	  1	   n=34	   Carcinoma	  n=17,	  Healthy	  Control	  n=17	  
run	  2	   n=30	   Carcinoma	  n=15,	  Healthy	  Control	  n=15	  
run	  3	   n=36	   Carcinoma	  n=9,	  	  High	  risk	  polyps	  n=9,	  	  	  Low	  risk	  polyps	  n=9,	  Healthy	  Control	  n=9	  
run	  4	   n=36	   Carcinoma	  n=9,	  	  High	  risk	  polyps	  n=9,	  	  	  Low	  risk	  polyps	  n=9,	  Healthy	  Control	  n=9	  
2	   Data	  transformation	  
Quantiles	  
Normalization	   	  
DWD	  
adjustment	   	  
3	   Class	  predictions	  
1	   Healthy	  Control	  vs	  Carcinoma	  
2	   Healthy	  Control	  and	  Low	  risk	  polyps	  vs	  High	  risk	  polyps	  and	  Carcinoma	  
3	   Healthy	  Control	  vs	  Low	  risk	  polyps,	  High	  risk	  polyps	  and	  Carcinoma	  
4	   Healthy	  Control	  vs	  Low	  risk	  polyps	  
5	   Low	  risk	  polyps	  vs	  High	  risk	  polyps	  
6	   High	  risk	  polyps	  vs	  Carcinoma.	  
Table	   9.	   The	   setup	   of	   the	   candidate	   marker	   screening	   experiment	   performed	   according	   to	  
Protocol	  2	  (Methods	  6.1.7.2).	  The	  first	  step	  in	  the	  setup	  shows	  the	  distribution	  of	  sample	  groups	  
and	  number	  of	  samples	  processed	  among	  different	  runs.	  The	  second	  step	   involves	  the	  type	  of	  
transformation	   or	   normalization	   applied	   to	   the	   background	   subtracted	   intensity	   values	   after	  
log2	   transformation.	   The	   final,	   third,	   step	   describes	   the	   classes	   that	  were	   defined	   to	   perform	  




IgGs	  were	  purified	   from	  a	   total	  of	  99	  plasma	  samples	  and	  used	   for	  4	   runs	  of	  16K	  protein	  
microarray	  experiments.	  Run	  1	  contained	  17	  samples	  each	  from	  control	  and	  carcinoma	  groups	  
and	  run	  2	  comprised	  15	  control	  and	  15	  carcinoma	  group	  samples.	  The	  following	  runs	  3	  and	  4	  
contained	  9	  samples	  from	  each	  of	  the	  4	  groups:	  control,	  high	  risk,	  low	  risk	  and	  carcinoma.	  Due	  
to	   the	   total	  number	  of	   test	   set	   samples	   in	  each	  group	   (n=32),	  28	   samples	  of	   the	  control	   and	  
carcinoma	  groups	  were	  reanalyzed	  in	  the	  3rd	  and	  4th	  runs	  along	  with	  high	  and	  low	  risk	  samples.	  
The	   background	   subtracted	   median	   intensity	   values	   were	   log2	   transformed	   (Figure	   33)	   and	  
subsequently	  were	  normalized	  with	  Quantiles	  normalization	  (Figure	  34)	  using	  BRB	  array	  tools.	  
For	   removing	   “batch	   effects”	   due	   to	   the	   different	   runs,	   intensity	   data	   were	   adjusted	   using	  
Distance	   Weighted	   Discrimination	   (DWD)	   method	   (Figure	   35).	   The	   Quantiles	   and	   DWD	  
normalized	  total	  intensity	  values	  of	  all	  arrays	  shown	  in	  figures	  34	  and	  35	  are	  seen	  to	  be	  equally	  
efficient	  in	  correcting	  deviations	  where	  medians	  of	  each	  arrays	  are	  centered	  evenly.	  The	  same	  
data	   are	   viewed	   by	   multidimensional	   scaling	   by	   Principle	   Component	   Analysis	   (PCA)	   using	  
Qlucore	   software,	   Figure	   36,	   in	  which	  Quantiles	  normalized	   expression	   data	   of	   the	   four	   runs	  
exhibited	   low	  unification,	  whereas	  DWD	  adjustment	   to	   the	  data	   resulted	   in	   fine	  clustering	  of	  
arrays.	  The	  features	  with	  intensity	  values	  having	  50th	  percentile	  lower	  than	  250	  were	  excluded	  
and	   10,172	   features	   remained	   for	   the	   analysis	   for	   Quantiles	   normalized	   	   data	   and	   10,597	  
features	  for	  DWD	  adjusted	  data.	  	  
	  






















Figure	   34.	   The	   distribution	   of	   log2	   transformed	   intensity	   values	   of	   all	   arrays	   after	  Quantiles	  
normalization.	  	  
	  














































Figure	  36.	  Multidimensional	   scaling	  of	   trends	  exhibited	  by	  expression	  data	   according	   to	   the	  4	  
processing	   runs.	   Visualization	   carried	   out	   by	   Principle	   Components	   Analysis	   using	   Qlucore	  
software.	   Top.	   Expression	   data	   before	   normalization.	   Bottom	   left.	   Expression	   data	   after	  
Quantiles	  normalization.	  Bottom	   right.	   Expression	   data	   after	   DWD	   adjustment.	   Color	   legends	  
and	   numbers	   represent	   the	   runs.	   Color	   coding	   of	   the	   screening	   runs:	   Red-­‐1,	   green-­‐2,	   blue-­‐3,	  
white-­‐4.	  	  
For	   further	   statistical	   analyses,	   both	  Quantiles	   normalized	   and	   DWD	   adjusted	   expression	  
data	  are	  used.	  Class	  prediction	  analyses	  were	  carried	  out	  with	  six	  different	  setups	  as	   listed	   in	  
Table	   89.	   In	   addition,	   binary	   tree	   prediction	   analysis	   was	   made	   between	   all	   4	   groups.	   The	  
methods	   applied	   for	   class	   predictions	   were:	   Nearest	   Centroid	   Predictor,	   Diagonal	   Linear	  
Discriminant	   Analysis,	   K	   nearest	   neighbor	   analysis	   with	   K=1	   and	   3,	   Compound	   Covariate	  




selection	  criteria	   set	  are:	  19-­‐40	  greedy-­‐pairs,	  40	   recursive	   features	  elimination,	  over	  a	  grid	  of	  
significance	   levels	   and	   those	   with	   fold-­‐ratio	   of	   geometric	   means	   between	   the	   two	   classes	  
exceeding	  1.25.	  	  
7.3.1 Control	  vs	  Carcinoma	  groups	  
The	  highest	  correct	  classification	  rate	  between	  healty	  control	  (n=49)	  and	  carcinoma	  (n=50)	  
groups	  for	  Quantiles	  normalized	  data	  was	  79%	  by	  using	  Support	  Vector	  Machines	  based	  on	  216	  
features	  with	  0.005	  significance	   threshold	  value	  and	  over	  1.25	   fold	  difference	  among	  classes.	  
Highest	   sensitivity	   and	   specificity	   values	   are	   achieved	   with	   Compound	   Covariate	   Predictor	  
method	  with	  81%	  and	  72%,	  respectively	  (Table	  10).	  The	  AUC	  obtained	  with	  Bayesian	  Compound	  
Covariate	  Predictor	  method	  was	  0.786	  (Figure	  37).	  	  
Compound	  Covariate	  Predictor	  
	   	   	  
Diagonal	  Linear	  Discriminant	  Analysis	  Classifier	  
Class	   Sensitivity	   Specificity	   PPV	   NPV	  	  
	  
Class	   Sensitivity	   Specificity	   PPV	   NPV	  	  
Carcinoma	   0.796	   0.7	   0.722	   0.778	  
	  
Carcinoma	   0.735	   0.74	   0.735	   0.74	  
Control	   0.7	   0.796	   0.778	   0.722	  
	  
Control	   0.74	   0.735	   0.74	   0.735	  
	   	   	   	   	   	   	   	   	   	   	  1-­‐Nearest	  Neighbor	  Classifier	  
	   	   	  
3-­‐Nearest	  Neighbors	  Classifier	  
	   	  Class	   Sensitivity	   Specificity	   PPV	   NPV	  	  
	  
Class	   Sensitivity	   Specificity	   PPV	   NPV	  	  
Carcinoma	   0.918	   0.56	   0.672	   0.875	  
	  
Carcinoma	   0.939	   0.56	   0.676	   0.903	  
Control	   0.56	   0.918	   0.875	   0.672	  
	  
Control	   0.56	   0.939	   0.903	   0.676	  
	   	   	   	   	   	   	   	   	   	   	  
Nearest	  Centroid	  Classifier	  
	   	   	  
Support	  Vector	  Machine	  
Classifier	  
	   	  Class	   Sensitivity	   Specificity	   PPV	   NPV	  	  
	  
Class	   Sensitivity	   Specificity	   PPV	   NPV	  	  
Carcinoma	   0.755	   0.7	   0.712	   0.745	  
	  
Carcinoma	   0.878	   0.7	   0.741	   0.854	  
Control	   0.7	   0.755	   0.745	   0.712	  
	  
Control	   0.7	   0.878	   0.854	   0.741	  
	   	   	   	   	   	   	   	   	   	   	  Bayesian	  Compound	  Covariate	  Classifier	  
	   	   	   	   	   	   	  Class	   Sensitivity	   Specificity	   PPV	   NPV	  	  
	   	   	   	   	   	  Carcinoma	   0.571	   0.52	   0.538	   0.553	  
	   	   	   	   	   	  Control	   0.52	   0.571	   0.553	   0.538	  
	   	   	   	   	   	  	  
Table	  10.	  Performance	  of	  classifiers	  between	  the	  Carcinoma	  (n=49)	  and	  Healthy	  control	  (n=50)	  
groups	   with	   7	   prediction	   analysis	   methods	   at	   p<0.005	   significance	   level	   and	   with	   1.25	   fold	  





Figure	  37.	  ROC	  curve	  of	  cross	  validation	  with	  Bayesian	  Compound	  Covariate	  Predictor	  analysis	  
for	   carcinoma	   (n=49)	   against	   control	   (n=50)	   groups	   at	   significance	   level	   of	   p<0.005	   using	  
Quantiles	  normalized	  data.	  AUC=0.786.	  
	  
Figure	  38.	  ROC	  curve	  of	  cross	  validation	  with	  Bayesian	  Compound	  Covariate	  Predictor	  analysis	  
for	   carcinoma	   against	   control	   groups	   with	   25	   greedy-­‐pairs	   genes	   using	  Quantiles	   normalized	  
data.	  AUC=0.818.	  
When	  the	  25	  greedy-­‐pairs	  criteria	  was	  set	  for	  the	  prediction,	  again	  79%	  correct	  classification	  
between	  control	  and	  cancer	  groups	  could	  be	  achieved	  with	  1-­‐Nearest	  Neighbor	  method.	  AUC	  




38).	  With	   the	   50	   features	   Carcinoma	   and	   Healthy	   control	   groups	   can	   be	   classified	  with	   89%	  
sensitivity	   and	   68%	   specificity	   with	   1-­‐Nearest	   Neighbor	   Classifier	   method	   (Table	   11).	   An	  
exceptionally	  high,	  97%	  correct	  classification	  rate	  was	  achieved	  between	  healthy	  control	  (n=17)	  
and	  carcinoma	  (n=17)	  with	  1	  and	  3-­‐Nearest	  Neighbor	  method	  for	  samples	  in	  run	  1	  and	  an	  AUC	  
of	  0.99	  (table	  16).	  
Compound	  Covariate	  Predictor	  
	   	   	  
Diagonal	  Linear	  Discriminant	  Analysis	  Classifier	  
Class	   Sensitivity	   Specificity	   PPV	   NPV	  	  
	  
Class	   Sensitivity	   Specificity	   PPV	   NPV	  	  
Carcinoma	   0.816	   0.72	  
0.7
41	   0.8	  
	  
Carcinoma	   0.776	   0.66	   0.691	   0.75	  
Control	   0.72	   0.816	   0.8	   0.741	  
	  
Control	   0.66	   0.776	   0.75	   0.691	  
	   	   	   	   	   	   	   	   	   	   	  1-­‐Nearest	  Neighbor	  Classifier	  
	   	   	  
3-­‐Nearest	  Neighbors	  Classifier	  
	   	  Class	   Sensitivity	   Specificity	   PPV	   NPV	  	  
	  
Class	   Sensitivity	   Specificity	   PPV	   NPV	  	  
Carcinoma	   0.898	   0.68	  
0.7
33	   0.872	  
	  
Carcinoma	   0.898	   0.54	   0.657	   0.844	  
Control	   0.68	   0.898	  
0.8
72	   0.733	  
	  
Control	   0.54	   0.898	   0.844	   0.657	  
	   	   	   	   	   	   	   	   	   	   	  
Nearest	  Centroid	  Classifier	  
	   	   	  
Support	  Vector	  Machine	  
Classifier	  
	   	  Class	   Sensitivity	   Specificity	   PPV	   NPV	  	  
	  
Class	   Sensitivity	   Specificity	   PPV	   NPV	  	  
Carcinoma	   0.837	   0.72	  
0.7
45	   0.818	  
	  
Carcinoma	   0.796	   0.66	   0.696	   0.767	  
Control	   0.72	   0.837	  
0.8
18	   0.745	  
	  
Control	   0.66	   0.796	   0.767	   0.696	  
	   	   	   	   	   	   	   	   	   	   	  Bayesian	  Compound	  Covariate	  Classifier	  
	   	   	   	   	   	   	  Class	   Sensitivity	   Specificity	   PPV	   NPV	  	  
	   	   	   	   	   	  
Carcinoma	   0.653	   0.62	  
0.6
27	   0.646	  
	   	   	   	   	   	  
Control	   0.62	   0.653	  
0.6
46	   0.627	  
	   	   	   	   	   	  
Table	   11.	   Performance	   of	   50	   classifiers	   (25	   greedy-­‐pairs)	   between	   the	   Carcinoma	   (n=49)	   and	  
Healthy	  control	  (n=50)	  groups	  with	  7	  prediction	  analysis	  methods.	  
For	   the	  DWD	  adjusted	  expression	  data,	   the	  25	  greedy-­‐pairs	  genes	  were	  able	   to	   	   correctly	  
classify	  93%	  of	  control	  and	  carcinoma	  samples	  utilizing	  Bayesian	  Compound	  Covariate	  Predictor	  
method	  and	  89%	  using	  a	  Compound	  Covariate	  Predictor	  method	  with	  and	  AUC	  of	  0.927	  (Figure	  
39).	  The	  specificity	  and	  sensitivities	  of	  the	  methods	  applied	  are	  presented	   in	  table	  12.	  The	  40	  




classification	   rate	   of	   83%	   using	   Support	   Vector	   Machines	   method,	   showing	   an	   AUC	   of	   0.88	  
(Figure	  40).	  	  
Compound	  Covariate	  Predictor	  
	   	   	  
Diagonal	  Linear	  Discriminant	  Analysis	  Classifier	  
Class	   Sensitivity	   Specificity	   PPV	   NPV	  	  
	  
Class	   Sensitivity	   Specificity	   PPV	   NPV	  	  
Carcinoma	   0.837	   0.9	   0.891	   0.849	  
	  
Carcinoma	   0.857	   0.84	   0.84	   0.857	  
Control	   0.9	   0.837	   0.849	   0.891	  
	  
Control	   0.84	   0.857	   0.857	   0.84	  
	   	   	   	   	   	   	   	   	   	   	  1-­‐Nearest	  Neighbor	  Classifier	  
	   	   	  
3-­‐Nearest	  Neighbors	  Classifier	  
	   	  Class	   Sensitivity	   Specificity	   PPV	   NPV	  	  
	  
Class	   Sensitivity	   Specificity	   PPV	   NPV	  	  
Carcinoma	   0.898	   0.7	   0.746	   0.875	  
	  
Carcinoma	   0.918	   0.7	   0.75	   0.897	  
Control	   0.7	   0.898	   0.875	   0.746	  
	  
Control	   0.7	   0.918	   0.897	   0.75	  
	   	   	   	   	   	   	   	   	   	   	  
Nearest	  Centroid	  Classifier	  
	   	   	  
Support	  Vector	  Machine	  
Classifier	  
	   	  Class	   Sensitivity	   Specificity	   PPV	   NPV	  	  
	  
Class	   Sensitivity	   Specificity	   PPV	   NPV	  	  
Carcinoma	   0.857	   0.86	   0.857	   0.86	  
	  
Carcinoma	   0.857	   0.78	   0.792	   0.848	  
Control	   0.86	   0.857	   0.86	   0.857	  
	  
Control	   0.78	   0.857	   0.848	   0.792	  
	   	   	   	   	   	   	   	   	   	   	  Bayesian	  Compound	  Covariate	  Classifier	  
	   	   	   	   	   	   	  Class	   Sensitivity	   Specificity	   PPV	   NPV	  	  
	   	   	   	   	   	  Carcinoma	   0.796	   0.72	   0.736	   0.783	  
	   	   	   	   	   	  Control	   0.72	   0.796	   0.783	   0.736	  
	   	   	   	   	   	  
Table	   12.	   Performance	   of	   50	   classifiers	   (25	   greedy-­‐pairs)	   between	   the	   Carcinoma	   (n=49)	   and	  
Healthy	  control	  (n=50)	  groups	  with	  7	  prediction	  analysis	  methods.	  
	  
Figure	  39.	  ROC	  curve	  of	  cross	  validation	  with	  Bayesian	  Compound	  Covariate	  Predictor	  analysis	  





Compound	  Covariate	  Predictor	  
	   	   	  
Diagonal	  Linear	  Discriminant	  Analysis	  Classifier	  
Class	   Sensitivity	   Specificity	   PPV	   NPV	  	  
	  
Class	   Sensitivity	   Specificity	   PPV	   NPV	  	  
Carcinoma	   0.816	   0.78	   0.784	   0.812	  
	  
Carcinoma	   0.837	   0.74	   0.759	   0.822	  
Control	   0.78	   0.816	   0.812	   0.784	  
	  
Control	   0.74	   0.837	   0.822	   0.759	  
	   	   	   	   	   	   	   	   	   	   	  1-­‐Nearest	  Neighbor	  Classifier	  
	   	   	  
3-­‐Nearest	  Neighbors	  Classifier	  
	   	  Class	   Sensitivity	   Specificity	   PPV	   NPV	  	  
	  
Class	   Sensitivity	   Specificity	   PPV	   NPV	  	  
Carcinoma	   0.837	   0.8	   0.804	   0.833	  
	  
Carcinoma	   0.878	   0.74	   0.768	   0.86	  
Control	   0.8	   0.837	   0.833	   0.804	  
	  
Control	   0.74	   0.878	   0.86	   0.768	  
	   	   	   	   	   	   	   	   	   	   	  
Nearest	  Centroid	  Classifier	  
	   	   	  
Support	  Vector	  Machine	  
Classifier	  
	   	  Class	   Sensitivity	   Specificity	   PPV	   NPV	  	  
	  
Class	   Sensitivity	   Specificity	   PPV	   NPV	  	  
Carcinoma	   0.776	   0.82	   0.809	   0.788	  
	  
Carcinoma	   0.816	   0.84	   0.833	   0.824	  
Control	   0.82	   0.776	   0.788	   0.809	  
	  
Control	   0.84	   0.816	   0.824	   0.833	  
	   	   	   	   	   	   	   	   	   	   	  Bayesian	  Compound	  Covariate	  Classifier	  
	   	   	   	   	   	   	  Class	   Sensitivity	   Specificity	   PPV	   NPV	  	  
	   	   	   	   	   	  Carcinoma	   0.796	   0.78	   0.78	   0.796	  
	   	   	   	   	   	  Control	   0.78	   0.796	   0.796	   0.78	  
	   	   	   	   	   	  
Table	  13.	  Performance	  of	  40	   classifiers	   (40	   recursive	   features)	  between	   the	  Carcinoma	   (n=49)	  
and	  Healthy	  control	  (n=50)	  groups	  with	  7	  prediction	  analysis	  methods.	  
	  
Figure	  40.	  ROC	  curve	  of	  cross	  validation	  with	  Bayesian	  Compound	  Covariate	  Predictor	  analysis	  





7.3.2 Control	  vs	  Low	  risk	  vs	  High	  risk	  vs	  Carcinoma	  
Binary	  tree	  classification	  with	  Quantiles	  normalized	  data	  to	  classify	  all	  four	  classes,	  namely	  
control	  (n=50),	  low	  risk	  (n=18),	  high	  risk	  (n=18)	  and	  carcinoma	  (n=50)	  were	  performed	  and	  an	  
optimal	  binary	  search	   tree	  with	  3	  nodes	  was	  obtained	   (Figure	  41).	  A	  Support	  Vector	  Machine	  
was	  employed	  using	  features	  with	  a	  significance	  p	  value	  cut-­‐off	  <0.001.	  	  
	  
Figure	  41.	  An	  optimal	  binary	  tree	  prediction	  of	  all	  4	  groups	  with	  Quantiles	  normalized	  data.	  
Node	  	   Group	  1	  Classes	  	   Group	  2	  Classes	  
Mis-­‐classification	  
rate	  (%)	  	  
Number	  of	  
classifiers	  
1	   Carcinoma,	  Control,	  High	  Risk	   Low	  Risk	   15.7	   90	  
2	   Carcinoma,	  High	  Risk	   Control	   13.5	   342	  
3	   Carcinoma	   High	  Risk	   14.7	   16	  
Table	  14.	  Cross-­‐validation	  error	  rates	   for	   the	  optimal	  binary	   tree	  structure	  shown	   in	  Figure	  42	  
and	  the	  number	  of	  classifiers	  for	  classification	  of	  each	  nodes.	  
Node	   1	   of	   the	   optimal	   binary	   tree	  with	   3	   nodes	   consisted	   of	   low	   risk	   group	   as	   one	   class	  
against	  the	  other	  three	  groups	  in	  second	  class,	  predicted	  with	  mis-­‐classification	  rate	  of	  15.7%.	  
Second	   node	   contained	   control	   group	   as	   one	   class	   with	  mis-­‐classification	   rate	   of	   13.5%	   and	  
finally,	  the	  third	  node	  contained	  carcinoma	  and	  high	  risk	  groups	  as	  separate	  classes	  with	  correct	  
classification	  rate	  of	  85.3%.	  The	  numbers	  of	  predictor	  features	  for	  node	  1	  was	  90,	  node	  2	  was	  
342	  and	  for	  node	  3	  was	  16	  (Table	  14).	  	  There	  were	  8	  features	  overlapping	  between	  nodes	  1	  and	  




For	  DWD	  transformed	  data,	  an	  optimal	  binary	  search	  tree	  having	  two	  nodes	  was	  obtained	  
at	  p<0.001	  significance	  level	  with	  Support	  Vector	  Machines	  prediction	  method	  (Figure	  42).	  The	  
first	  node	  consisted	  of	  carcinoma	  (n=50),	   low	  risk	   (n=18)	  and	  high	  risk	   (n=18)	  groups	  and	  the	  
second	   node	   of	   control	   (n=50)	   group.	   Node	   1	   was	   predicted	   with	   287	   features	   with	   mis-­‐
classification	  rate	  of	  7.1%.	  Node	  	  1	  contained	  carcinoma	  and	  high	  risk	  groups	  as	  one	  class	  and	  
low	  risk	  as	  the	  second,	  predicted	  with	  150	  differentially	  expressed	  features	  with	  84.6%	  correct	  
classification	  rate	  (Table	  15).	  There	  are	  12	  features	  overlapping	  between	  the	  classifiers	  of	  nodes	  
1	  and	  2.	  	  
	  
Figure	  42.	  An	  optimal	  binary	  tree	  prediction	  of	  all	  4	  groups	  with	  DWD	  adjusted	  data.	  
	  
Node	  	   Group	  1	  Classes	  	   Group	  2	  Classes	  
Mis-­‐classification	  
rate	  (%)	  	  
Number	  of	  
classifiers	  
1	   Carcinoma,	  High	  Risk,	  Low	  Risk	   Control	   7.1	   287	  
2	   Carcinoma,	  High	  Risk	   Low	  Risk	   15.4	   150	  
Table	  15.	  Cross-­‐validation	  error	  rates	   for	   the	  optimal	  binary	   tree	  structure	  shown	   in	  Figure	  42	  





7.3.3 Summary	  of	  class	  prediction	  analyses	  and	  selection	  of	  Colon	  Cancer	  Candidate	  array	  
classifiers	  
Aside	   from	   the	   class	   prediction	   analyses	   of	   the	   contrasted	   control	   vs	   carcinoma	   and	  
between	   all	   sample	   groups,	   the	   analyses	   were	  made	   between	   predefined	   classes	   containing	  
different	   sample	  groups	  as	  described	   in	   table	  9.	  The	  below	  presented	   table	  16	   illustrates	   the	  
prediction	   success	   between	   the	   different	   classes,	   the	   algorithm	   used	   and	   the	   gene	   selection	  
criteria.	  	  
	  
Table	   16.	   	   Summary	   of	   class	   prediction	   analysis	   performed	   between	   the	   specified	   classes	  
containing	   different	   settings	   of	   sample	   groups.	   The	   algorithm,	   gene	   selection	   criteria	   and	  
prediction	   successes	   (sensitivity,	   specificity,	   percentage	   of	   correct	   classification	   and	   cross-­‐









Healthy	  Control	  vs	  Carcinoma 1-­‐Nearest	  
Neighbor
25	  greedy-­‐pairs 0.941 1 97 0.99
Healthy	  Control	  and	  Low	  risk	  polyps	  





0.806 0.836 82 	  0.852
Healthy	  Control	  vs	  Low	  risk	  polyps,	  





0.917 0.64 81 0.777





0.889 0.611 75 0.864
Low	  risk	  polyps	  vs	  High	  risk	  polyps
1-­‐Nearest	  
Neighbor
19	  greedy-­‐pairs 0.882 0.778 83 0.778
High	  risk	  polyps	  vs	  Carcinoma.
Support	  Vector	  
Machines









Healthy	  Control	  vs	  Carcinoma
Support	  Vector	  
Machines
25	  greedy-­‐pairs 0.941 0.941 94 	  0.969
Healthy	  Control	  and	  Low	  risk	  polyps	  




25	  greedy-­‐pairs 0.791 0.836 81 0.849
Healthy	  Control	  vs	  Low	  risk	  polyps,	  





0.976 0.56 82 0.839
Healthy	  Control	  vs	  Low	  risk	  polyps
3-­‐Nearest	  
Neighbor
25	  greedy-­‐pairs 0.833 0.944 89 0.948
Low	  risk	  polyps	  vs	  High	  risk	  polyps
Support	  Vector	  
Machines
25	  greedy-­‐pairs 0.882 0.833 86 0.807
High	  risk	  polyps	  vs	  Carcinoma.
1-­‐Nearest	  
Neighbor












































A	  total	  of	  632	  features	  differentially	  expressed	  between	  the	  4	  samples	  groups	  were	  chosen	  
for	  the	  Colon	  Cancer	  Candidate	  array	  after	  stringent	  prediction	  analyses.	  The	  prediction	  classes,	  
number	   of	   classifiers	   obtained	   and	   the	   corresponding	   criteria	   set	   for	   the	   analysis	   are	  
summarized	   in	   table	   17.	   The	   632	   selected	   features	   correspond	   to	   clones	   that	   represent	   593	  
genes.	  	  
Table	  17.	  Summary	  of	  classifier	  clones	  selected	  for	  the	  Colon	  Candidate	  Array	  production.	  
In	   addition	   to	   the	   above	  632	   selected	   clones,	   a	   review	  of	   research	   articles	   reporting	   TAA	  
biomarker	   screening	  and	  discovery	   in	  colon	  cancer	  using	  protein	  microarray	  was	  made	  and	  a	  
total	   of	   105	   genes	   have	   been	   selected	   to	   be	   incorporated	   into	   the	   Colon	   Cancer	   Candidate	  
array.	  Of	  those	  105	  genes,	  5	  were	  also	  found	  in	  the	  632	  selected	  clones	  from	  UniPEx	  library	  16K	  
array	  candidate	  marker	  screening	  experiments	  using	  a	  test	  set	  of	  colon	  cancer	  plasma	  samples.	  
As	  a	  result,	  732	  clones	  deduced,	  that	  will	  comprise	  the	  Colon	  Cancer	  Candidate	  array	  which	  will	  
be	  further	  validated	  using	  a	  larger	  set	  of	  Colon	  cancer	  plasma	  samples.	  	  
	  
	  
Quantil DWD Quantil+DWD Quantil DWD
1 Controls	  vs	  Carcinomas 307 119 371 314 25	  greedy-­‐pairs,	  grid	  of	  
alpha,	  1.25	  fold
15	  and	  25	  greedy-­‐pairs,	  
40	  recursive	  features
2
Control,	  Low	  risk	  vs	  
Carcinoma,	  High	  risk 82 50 110 104
25	  greedy	  pairs,	  40	  
recursive	  features 25	  greedy	  pairs
3
Carcinoma	  vs	  High	  risk	  vs	  
Low	  risk	  vs	  Control-­‐	  
“BinTree”	  nodes
125 125 116 Node	  1	  Car,HR,LR	  vs	  
Con
Node	  1	  Car,HR,	  LR	  vs	  
Con
4
Control	  vs	  Carcinoma,	  High	  
risk,	  Low	  risk 50 80 106 96 25	  greedy	  pairs
25	  greedy	  pairs,	  40	  
greedy	  pairs
5 Control	  vs	  Low	  risk 40 50 85 80 40	  recursive	  features 25	  greedy	  pairs
6 Low	  risk	  vs	  High	  risk 50 50 78 67 19	  and	  25	  greedy	  pairs 25	  greedy	  pairs
7 High	  risk	  vs	  Carcinoma 75 86 127 116
20	  greedy	  pairs,	  40	  
recursive	  features
25	  greedy	  pairs,	  40	  
recursive	  features
729 435 632 593





8 DISCUSSION	  	  
An	  evident	  need	  for	  improvements	  of	  technical	  aspects	  and	  reagents	  suited	  for	  the	  type	  of	  
protein	  microarray	  experiments	  performed	  for	  the	  current	  candidate	  cancer	  marker	  screening	  
experiment	  arose	  when	  the	  commonly	  used	  protocol	  for	  protein	  microarrays	  (Protocol	  1)	  was	  
utilized	   for	   the	   pilot	   screening	   experiment.	   The	   limited	   performance	   of	   the	   protocol	   in	  
distinguishing	   between	   the	   4	   groups	   of	   clinical	   samples	   was	   a	   clear	   indication.	   Therefore	   a	  
series	   of	   protein	   microarray	   protocol	   optimization	   experiments	   were	   carried	   out	   addressing	  
issues	  such	  as:	  surface	  chemistry,	  slide	  surface	  blocking	  reagents,	  experimental	  conditions	  with	  
respect	   to	  motion	   and	   duration,	   blocking	   components	   for	   reduction	   of	   non-­‐specific	   binding,	  
buffer	   detergents	   to	   reduce	   tension	   and	   increase	   penetration	   of	   the	   spotted	   proteins	   and	  
captured	  antibodies,	  and	  finally	  reduction	  of	  sample	  complexity	  by	  applying	  purified	  IgG	  from	  
serum	   samples.	   For	   the	   current	  UniPEx	  cDNA	   library	  derived	  proteins	  used	   for	   production	  of	  
16K	  arrays,	  epoxy	  treated	  surfaces	  clearly	  performed	  to	  our	  advantage	  with	  less	  technical	  flaws	  
and	   higher	   signal-­‐to-­‐noise	   ratio.	   An	   efficient	   blocking	   of	   the	   surface	   SU8	   epoxy	   could	   be	  
accomplished	  by	  the	  blocking	  solution	  DIG	  Easy	  Hyb.	  	  
The	  drawback	  of	  uneven	  distribution	  of	   samples	  or	  detection	  antibodies	  over	   arrays	  with	  
static	  conditions	  was	  overcome	  by	  carrying	  out	  probing	  with	  gasket	   rimmed	  cover	  slides	   that	  
give	   enough	   space	   for	   samples	   to	   move	   over	   the	   arrays	   while	   positioned	   in	   rotating	  
hybridization	   ovens	   with	   controlled	   temperature.	   This	   allows	   a	   closed	   environment	   during	  
target	   binding,	   with	   constant	   mixing,	   which	   is	   vital	   for	   protein	   microarrays.	   Additionally,	  
extending	   sample	   incubation	   time	   point	   to	   4	   hours	   increases	   the	   antibody	   capturing	   by	   the	  
proteins	  present	  on	  arrays.	  With	  both	   rotating	   conditions	  and	   longer	   incubations,	   the	  overall	  
signal	   intensities	   increased	   and	   due	   to	   the	   saturation	   of	   some	   features	   at	   16	   hours	   of	  
incubation,	   this	   option	   was	   excluded.	   As	   the	   4	   hours	   of	   sample	   incubation	   yielded	   higher	  
intensities	   than	  2	  hours	  of	   incubation	  and	  had	  comparable	   sample	   replicate	   correlations,	   the	  
option	  to	  extend	  to	  4	  hours	  was	  chosen.	  	  
In	  protein	  immunoassay	  procedures,	  the	  presence	  of	  a	  blocking	  component	  during	  sample	  




current	   optimizations,	  where	   buffers	   containing	   3%	  milk	   powder	   used	   to	   dilute	   samples	   and	  
detection	   antibodies	   distinctly	   increased	   specific	   binding.	   Dual	   color	   experiments	   clearly	  
demonstrated	   that	   appropriate	   dual	   fluorescence	   could	   be	   obtained	   with	   two	   detection	  
antibodies	   directed	   against	   human	   IgG	   and	   6xHis-­‐tag	   of	   spotted	   proteins	   when	   buffer	  
containing	  milk	  powder	  is	  used	  for	  their	  dilutions.	  Dual	  fluorescence	  could	  not	  be	  observed	  in	  
probing	  without	  milk	  powder,	  suggesting	  that	  binding	  of	  the	  second	  detection	  antibody	  applied	  
onto	  arrays	  are	  significantly	  enhanced	  with	  the	  blocking	  agent.	  It	  may	  also	  be	  due	  to	  binding	  of	  
detection	   antibodies	   instead	   onto	   the	   planar	   surface	   of	   the	   coverslips.	   Furthermore,	   buffer	  
detergents	  Tween20	  and	  Triton	  X-­‐100	  were	  tested	  for	  their	  compatibility	  with	  the	  current	  slide	  
surface	  chemistry,	  arrayed	  proteins	  and	  samples.	  Triton	  X-­‐100	  is	  observed	  as	  better	  suited,	  by	  
presenting	   higher	   signal	   intensities	   and	   enhanced	   reproducibility	   with	   regards	   to	   the	  
correlations	  between	  sample	  replicates.	  	  
Finally,	   the	   complexity	   of	   samples	   for	   autoantibody	   screening	   was	   addressed	   and	   a	  
possibility	   to	   eliminate	   predominant,	   competitive	   proteins	   in	   serum	   or	   plasma	  was	   pursued.	  
With	  the	  aim	  of	  screening	  for	  autoantibodies,	  it	  is	  reasonable	  to	  consider	  usage	  of	  IgG	  fractions	  
purified	   from	  serum	  or	  plasma	   in	   tumor	  autoantibody	  screening.	  Thus,	   IgG	  was	  purified	   from	  
serum	  samples	  were	  tested	  and	  results	  showed	  the	  anticipated	  outcome	  of	  lower	  numbers	  of	  
classifiers.	   Interestingly,	  very	   low	  number	  of	  classifiers	  could	  be	  seen	  to	  overlap	  between	  the	  
deduced	   classifiers	   of	   serum	   and	   IgG	   samples	   when	   class	   comparison	   analysis	   was	   done	  
between	   the	   two	   samples	   used.	   As	   the	   IgG	   and	   serum	   of	   samples	   have	   comparable	  
performance	   in	   sample	   discrimination	   and	   reproducibility,	   the	   application	   of	   purified	   IgG	   of	  
samples	  was	  speculated	  to	  have	  increased	  specificity	  for	  TAA	  profiling	  on	  protein	  microarrays.	  
An	   “amended”	   Standard	   Operating	   Procedure	   was	   established	   from	   the	   optimization	  
experiments	   and	   designated	   Protocol	   2,	   which	   was	   used	   for	   candidate	   marker	   screening	  
experiments.	   The	   second	   screening	  experiment	  using	   the	   same	   test	   set	   samples	  used	   for	   the	  
first	   screening	   attempt	   showed	   significantly	   improved	   performance	   in	   class	   predictions.	   The	  
healthy	   control	  and	  carcinoma	  groups	  were	  predicted	  with	  95%	  correct	   classification	  with	  an	  




samples	  groups	  into	  classes,	  a	  total	  of	  632	  reactive	  proteins	  were	  selected.	  To	  possibly	  improve	  
the	   performance	   of	   the	   candidate	   marker	   panel,	   similar	   studies	   performed	   for	   tumor	  
autoantibody	  discovery	  in	  colorectal	  cancer,	  100	  genes	  were	  obtained	  from	  already	  published	  
data	  and	  included	  in	  the	  list	  of	  clones	  for	  Colon	  Cancer	  Candidate	  array	  production.	  This	  array	  
will	   be	   further	  used	   to	   validate	   the	  732	   clones	   in	   tumor	  autoantibody	  discovery	  experiments	  
using	  a	  validation	  sample	  set	  already	  available,	  comprising	  of	  384	  clinical	  samples	  belonging	  to	  
the	  four	  groups.	  	  
Although	   several	   issues	   concerning	   improvements	   in	   protein	  microarray	  procedures	  were	  
dealt	  with	  here,	  due	  to	  the	  highly	  intricate	  nature	  of	  proteins,	  the	  problem	  with	  reproducibility	  
of	  experiments	  still	  persist.	  Aside	  from	  setting	  an	  optimized	  protocol	  for	  protein	  microarrays,	  it	  
is	   also	   important	   to	   develop	   bioinformatics	   tools	   that	   overcome	   the	   biases	   introduced	   by	  
factors	  such	  as	  processing	  runs,	  operators,	  stored	  samples,	  protein	  microarray	  printing	  batches	  
and	  many	  more	  batch	  effects.	  Here	  we	  successfully	  applied	  Distance	  Weighted	  Discrimination	  
(DWD)	   that	   specifically	   removes	   systematic	   bias	   from	   microarray	   data	   (“Distance	   Weighted	  
Discrimination	  (DWD)").	  	  
In	  comparison	  to	  published	  data	  on	  TAA	  classification	  of	  healthy	  control	  and	  colon	  cancer	  
samples	   using	   protein	  microarray	   screening	  methods,	   the	   50	   proteins	   deduced	   by	  1-­‐Nearest	  
Neighbor	   has	   a	   significantly	   improved	   performance	   of	   97%	   correct	   classification,	   94-­‐100%	  
sensitivity	  and	  specificity	  with	  and	  AUC	  of	  0.99	  (samples	  control	  n=17	  and	  carcinoma	  n=17).	  For	  
example,	  Kijanka	  et.al	  could	  identify	  22	  antigens	  able	  to	  distinguish	  between	  colorectal	  cancer	  
(training	   set	   n=20,	   training	   set	   n=43)	   and	   non	   cancer	   (training	   set	   n=20,	   training	   set	   n=40)	  
patients	   using	   a	   high-­‐density	   protein	   microarray	   containing	   37,830	   recombinant	   human	  
proteins.	   	   The	   deduced	   22	   antigens	   classified	   sample	   groups	  with	   83.7%	   sensitivity	   and	   87%	  
specificity	  (Kijanka	  et	  al.,	  2010).	  Further	  validation	  with	  a	  greater	  number	  of	  samples	  should	  be	  
carried	  out	  to	  confirm	  our	  findings.	  	  
	  





The	  following	  conclusions	  are	  drawn	  from	  the	  experiments	  carried	  out	  within	  the	  frame	  of	  this	  
thesis:	   epoxy	   surface	   is	   best	   suited	   for	   printing	   of	  UniPEx	   library	   derived	   proteins.	   Rotating	  
condition	  applied	   to	  protein	  microarray	  experiments	  plays	  a	   critical	   role	   in	  enhanced	   specific	  
binding	  of	  target	  and	  capture	  proteins.	  Upon	  testing	  different	  sample	  incubation	  time	  points,	  2	  
hours	  of	  sample	  incubation	  is	  not	  sufficient	  to	  reach	  binding	  plateau	  of	  antibodies	  to	  proteins	  
on	  16K	   array,	   rather	   4	   hours	   is	   a	   better	   alternative.	   It	   was	   concluded	   from	   the	   experiments	  
within	   the	   frame	   of	   the	   current	   thesis	   that	   Triton	   X-­‐100	   detergent	   increases	   binding	   of	  
antibodies	  on	  arrays	  compared	  to	  Tween20.	  Purified	  IgG	  could	  be	  used	  for	  TAA	  screening	  with	  
improved	  specificity	   than	  serum	  samples,	   resulting	   in	   improved	  performance,	  as	   indicated	  by	  
the	   TAA	   candidate	  marker	   screening	   experiment	   according	   to	   the	   Protocol	   2.	   Results	   of	   the	  
screening	  experiment	  with	  the	  new	  SOP,	  prediction	  success	  could	  be	  enhanced	  to	  95%	  correct	  
classification	   between	   control	   and	   colon	   carcinoma	   sample	   groups.	   Although	   the	   current	  
improvement	   of	   the	   protocol	   regarding	   the	   protein	   microarray	   experiment	   using	   the	  
recombinant	   proteins	   utilized	   within	   the	   frame	   of	   this	   thesis	   gives	   a	   promising	   result,	   other	  
technical	  aspect	  could	  still	  be	  improved.	  This	  includes	  optimal	  expression	  and	  purification	  of	  the	  
proteins	   used	   or	   even	   label-­‐free	   detection	   of	   binding	   experiments	   performed	   on	   protein	  
microarrays.	  The	  results	  presented	  herein	  are	  a	  very	  promising	  basis	  for	  further	  validation	  using	  
the	   discovered	   TAAs	   as	   biomarkers	   for	   colon	   cancer	   non-­‐invasive	   detection	   and	   studies	   that	  
follow	  with	  regards	  to	  elucidating	  their	  specific	  functions	  in	  colon	  carcinogenesis.	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